Johnson & Johnson (JNJ) 10-Q25 Jul 242024 Q2 Quarterly reportFinancial data

Company Profile

Cover

Cover - shares	6 Months Ended
Cover - shares	Jun. 30, 2024	Jul. 19, 2024
Entity Information [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2024
Document Transition Report	false
Entity File Number	1-3215
Entity Registrant Name	Johnson & Johnson
Entity Incorporation, State or Country Code	NJ
Entity Tax Identification Number	22-1024240
Entity Address, Address Line One	One Johnson & Johnson Plaza
Entity Address, City or Town	New Brunswick
Entity Address, State or Province	NJ
Entity Address, Postal Zip Code	08933
City Area Code	732
Local Phone Number	524-0400
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		2,407,243,667
Entity Central Index Key	0000200406
Current Fiscal Year End Date	--12-29
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q2
Amendment Flag	false
Common Stock, Par Value $1.00
Entity Information [Line Items]
Title of 12(b) Security	Common Stock, Par Value $1.00
Trading Symbol	JNJ
Security Exchange Name	NYSE
1.150% Notes Due November 2028
Entity Information [Line Items]
Title of 12(b) Security	5.50% Notes Due November 2024
Trading Symbol	JNJ24BP
Security Exchange Name	NYSE
1.150% Notes Due November 2028
Entity Information [Line Items]
Title of 12(b) Security	1.150% Notes Due November 2028
Trading Symbol	JNJ28
Security Exchange Name	NYSE
3.20% Notes Due November 2032
Entity Information [Line Items]
Title of 12(b) Security	3.20% Notes Due November 2032
Trading Symbol	JNJ32
Security Exchange Name	NYSE
1.650% Notes Due May 2035
Entity Information [Line Items]
Title of 12(b) Security	1.650% Notes Due May 2035
Trading Symbol	JNJ35
Security Exchange Name	NYSE
3.350% Notes Due November 2036
Entity Information [Line Items]
Title of 12(b) Security	3.350% Notes Due November 2036
Trading Symbol	JNJ36A
Security Exchange Name	NYSE
3.550% Notes Due November 2044
Entity Information [Line Items]
Title of 12(b) Security	3.550% Notes Due November 2044
Trading Symbol	JNJ44
Security Exchange Name	NYSE

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Millions	Jun. 30, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents (Note 4)	$ 24,878	$ 21,859
Marketable securities	597	1,068
Accounts receivable, trade, less allowances $161 (2023, $166)	15,794	14,873
Inventories (Note 2)	12,169	11,181
Prepaid expenses and other	4,379	4,514
Total current assets	57,817	53,495
Property, plant and equipment at cost	48,035	47,776
Less: accumulated depreciation	(28,287)	(27,878)
Property, plant and equipment, net	19,748	19,898
Intangible assets, net (Note 3)	39,725	34,175
Goodwill (Note 3)	44,250	36,558
Deferred taxes on income (Note 5)	9,004	9,279
Other assets	10,544	14,153
Total assets	181,088	167,558
Current liabilities:
Loans and notes payable	9,855	3,451
Accounts payable	8,848	9,632
Accrued liabilities	10,539	10,212
Accrued rebates, returns and promotions	17,539	16,001
Accrued compensation and employee related obligations	2,843	3,993
Accrued taxes on income (Note 5)	4,309	2,993
Total current liabilities	53,933	46,282
Long-term debt (Note 4)	31,636	25,881
Deferred taxes on income (Note 5)	2,635	3,193
Employee related obligations (Note 6)	6,919	7,149
Long-term taxes payable (Note 5)	341	2,881
Other liabilities	14,086	13,398
Total liabilities	109,550	98,784
Commitments and Contingencies (Note 11)
Shareholders’ equity:
Common stock — par value $1.00 per share (authorized 4,320,000,000 shares; issued 3,119,843,000 shares)	3,120	3,120
Accumulated other comprehensive income (loss) (Note 7)	(11,253)	(12,527)
Retained earnings and Additional paid-in capital	155,360	153,843
Less: common stock held in treasury, at cost (712,997,000 and 712,765,000 shares)	75,689	75,662
Total shareholders’ equity	71,538	68,774
Total shareholders’ equity	71,538	68,774
Total liabilities and shareholders’ equity	$ 181,088	$ 167,558

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Millions	Jun. 30, 2024	Dec. 31, 2023
Current assets:
Allowances for doubtful accounts	$ 161	$ 166
Shareholders' equity:
Common stock, par value per share (in usd per share)	$ 1	$ 1
Common stock, shares authorized (in shares)	4,320,000,000	4,320,000,000
Common stock, shares issued (in shares)	3,119,843,000	3,119,843,000
Treasury stock (in shares)	712,997,000	712,765,000

Consolidated Statements of Earn

Consolidated Statements of Earnings - USD ($) shares in Millions, $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jul. 02, 2023	Jun. 30, 2024	Jul. 02, 2023
Income Statement [Abstract]
Sales to customers (Note 9)	$ 22,447	$ 21,519	$ 43,830	$ 42,413
Sales to customers percent to sales	100%	100%	100%	100%
Cost of products sold	$ 6,869	$ 6,462	$ 13,380	$ 13,149
Cost of products sold percent to sales	30.60%	30%	30.50%	31%
Gross profit	$ 15,578	$ 15,057	$ 30,450	$ 29,264
Gross Profit Percent To Sales	69.40%	70%	69.50%	69%
Selling, marketing and administrative expenses	$ 5,681	$ 5,396	$ 10,938	$ 10,302
Selling marketing and administrative expenses percent to sales	25.30%	25.10%	25%	24.30%
Research and development expense	$ 3,440	$ 3,703	$ 6,982	$ 7,158
Research and development expense percent to sales	15.30%	17.20%	16%	16.90%
In-process research and development impairments	$ 194	$ 0	$ 194	$ 49
In-process research and development percent to sales	0.90%	0%	0.40%	0.10%
Interest income	$ (395)	$ (326)	$ (759)	$ (524)
Interest income percent to sales	(1.80%)	(1.50%)	(1.80%)	(1.20%)
Interest expense, net of portion capitalized	$ 270	$ 217	$ 425	$ 429
Interest expense, net of portion capitalized percent to sales	1.20%	1%	1%	1%
Other (income) expense, net	$ 653	$ (384)	$ 3,057	$ 6,556
Other (income) expense, net percent to sales	2.90%	(1.80%)	7%	15.50%
Restructuring (Note 12)	$ (13)	$ 145	$ 151	$ 275
Restructuring charge percent to sales	0%	0.70%	0.30%	0.60%
Earnings before provision for taxes on income	$ 5,748	$ 6,306	$ 9,462	$ 5,019
Earnings before provision for taxes on income percent to sales	25.60%	29.30%	21.60%	11.80%
Provision for taxes on income (Note 5)	$ 1,062	$ 930	$ 1,521	$ 134
Provision for taxes on income percent to sales	4.70%	4.30%	3.50%	0.30%
Net earnings from continuing operations	$ 4,686	$ 5,376	$ 7,941	$ 4,885
Net earnings from continuing operations percent of sales	20.90%	25%	18.10%	11.50%
Net earnings (loss) from discontinued operations, net of tax (Note 13)	$ 0	$ (232)	$ 0	$ 191
Net earnings	$ 4,686	$ 5,144	$ 7,941	$ 5,076
NET EARNINGS PER SHARE
Continuing operations - basic (in dollars per share)	$ 1.95	$ 2.07	$ 3.30	$ 1.88
Discontinued operations - basic (in dollars per share)	0	(0.09)	0	0.07
Total net earnings per share - basic (in dollars per share)	1.95	1.98	3.30	1.95
Continuing operations - diluted (in dollars per share)	1.93	2.05	3.27	1.86
Discontinued operations - diluted (in dollars per share)	0	(0.09)	0	0.07
Total net earnings per share - diluted (in dollars per share)	$ 1.93	$ 1.96	$ 3.27	$ 1.93
Avg. shares outstanding
Basic (shares)	2,406.8	2,598.4	2,407.5	2,601.9
Diluted (shares)	2,422	2,625.7	2,428.5	2,630.7

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jul. 02, 2023	Jun. 30, 2024	Jul. 02, 2023
Statement of Comprehensive Income [Abstract]
Net earnings	$ 4,686	$ 5,144	$ 7,941	$ 5,076
Other comprehensive income (loss), net of tax
Foreign currency translation	(389)	(715)	1,734	(896)
Securities:
Unrealized holding gain (loss) arising during period	(1)	4	1	21
Reclassifications to earnings	0	0	0	0
Net change	(1)	4	1	21
Employee benefit plans:
Prior service cost amortization during period	(34)	(36)	(272)	(71)
Gain (loss) amortization during period	43	(34)	333	(67)
Net change	9	(70)	61	(138)
Derivatives & hedges:
Unrealized gain (loss) arising during period	75	(137)	(92)	433
Reclassifications to earnings	(179)	(139)	(430)	(136)
Net change	(104)	(276)	(522)	297
Other comprehensive income (loss)	(485)	(1,057)	1,274	(716)
Comprehensive income	$ 4,201	$ 4,087	$ 9,215	$ 4,360

Consolidated Statements of Co_2

Consolidated Statements of Comprehensive Income (Parenthetical) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jul. 02, 2023	Jun. 30, 2024	Jul. 02, 2023
Statement of Comprehensive Income [Abstract]
Foreign currency translation adjustment income (loss)	$ 65	$ (32)	$ 684	$ (266)
Securities income (loss)	1	1		6
Employee benefit plans income (loss)	(1)	21	41	43
Derivatives & hedges income (loss)	$ (28)	$ (74)	$ (139)	$ 80

Consolidated Statements of Equi

Consolidated Statements of Equity - USD ($) $ in Millions	Total	Retained Earnings and Additional Paid-in Capital	Accumulated Other Comprehensive Income (AOCI)	Common Stock Issued Amount	Treasury Stock Amount	Non-Controlling interest (NCI)
Beginning balance at Jan. 01, 2023	$ 76,804	$ 128,345	$ (12,967)	$ 3,120	$ (41,694)	$ 0
Net earnings	5,076	5,076
Cash dividends paid	(6,034)	(6,034)
Employee compensation and stock option plans	944	(476)			1,420
Repurchase of common stock	(3,918)				(3,918)
Other	(25)				(25)
Kenvue IPO	4,278	2,470	548			1,260
Other comprehensive income (loss), net of tax	(716)		(716)
Ending balance at Jul. 02, 2023	76,409	129,381	(13,135)	3,120	(44,217)	1,260
Beginning balance at Apr. 02, 2023	70,869	124,558	(12,626)	3,120	(44,183)	0
Net earnings	5,144	5,144
Cash dividends paid	(3,092)	(3,092)
Employee compensation and stock option plans	649	301			348
Repurchase of common stock	(381)				(381)
Other	(1)	0			(1)
Kenvue IPO	4,278	2,470	548			1,260
Other comprehensive income (loss), net of tax	(1,057)		(1,057)
Ending balance at Jul. 02, 2023	76,409	129,381	(13,135)	3,120	(44,217)	$ 1,260
Beginning balance at Dec. 31, 2023	68,774	153,843	(12,527)	3,120	(75,662)
Net earnings	7,941	7,941
Cash dividends paid	(5,854)	(5,854)
Employee compensation and stock option plans	1,015	(570)			1,585
Repurchase of common stock	(1,611)				(1,611)
Other	(1)				(1)
Other comprehensive income (loss), net of tax	1,274		1,274
Ending balance at Jun. 30, 2024	71,538	155,360	(11,253)	3,120	(75,689)
Beginning balance at Mar. 31, 2024	70,020	153,378	(10,768)	3,120	(75,710)
Net earnings	4,686	4,686
Cash dividends paid	(2,985)	(2,985)
Employee compensation and stock option plans	438	281			157
Repurchase of common stock	(136)				(136)
Other comprehensive income (loss), net of tax	(485)		(485)
Ending balance at Jun. 30, 2024	$ 71,538	$ 155,360	$ (11,253)	$ 3,120	$ (75,689)

Consolidated Statements of Eq_2

Consolidated Statements of Equity (Parenthetical) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jul. 02, 2023	Jun. 30, 2024	Jul. 02, 2023
Statement of Stockholders' Equity [Abstract]
Cash dividends paid (in dollars per share)	$ 1.24	$ 1.19	$ 2.43	$ 2.32
Noncontrolling interest, ownership percentage				10.40%
Net earnings attributable to noncontrolling interest				$ 37

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Millions	6 Months Ended
	Jun. 30, 2024	Jul. 02, 2023
CASH FLOWS FROM OPERATING ACTIVITIES
Net earnings	$ 7,941	$ 5,076
Adjustments to reconcile net earnings to cash flows from operating activities:
Depreciation and amortization of property and intangibles	3,597	3,814
Stock based compensation	643	688
Asset write-downs	379	388
Net gain on sale of assets/businesses	(223)	(47)
Deferred tax provision	(2,257)	(2,342)
Credit losses and accounts receivable allowances	0	0
Changes in assets and liabilities, net of effects from acquisitions and divestitures:
Increase in accounts receivable	(1,163)	(599)
Increase in inventories	(739)	(741)
Increase/(Decrease) in accounts payable and accrued liabilities	449	(1,061)
Decrease/(Increase) in other current and non-current assets	3,731	(1,144)
(Decrease)/Increase in other current and non-current liabilities	(3,068)	3,407
Net cash flows from operating activities	9,290	7,439
Cash flows from investing activities
Additions to property, plant and equipment	(1,783)	(1,987)
Proceeds from the disposal of assets/businesses, net (Note 10)	573	116
Acquisitions, net of cash acquired (Note 10)	(14,807)	0
Purchases of investments	(1,184)	(9,688)
Sales of investments	1,706	11,877
Credit support agreements activity, net	1,430	(798)
Other (including capitalized licenses and milestones)	(86)	19
Net cash used by investing activities	(14,151)	(461)
Cash flows from financing activities
Dividends to shareholders	(5,854)	(6,034)
Repurchase of common stock	(1,611)	(3,918)
Proceeds from short-term debt	13,976	12,221
Repayment of short-term debt	(3,915)	(13,611)
Proceeds from long-term debt, net of issuance costs	6,659	7,674
Repayment of long-term debt	(803)	(501)
Proceeds from the exercise of stock options/employee withholding tax on stock awards, net	290	254
Credit support agreements activity, net	281	(126)
Settlement of convertible debt acquired from Shockwave	(970)	0
Proceeds from Kenvue initial public offering	0	4,241
Other	37	(53)
Net cash flows from financing activities	8,090	147
Effect of exchange rate changes on cash and cash equivalents	(210)	(69)
Increase in cash and cash equivalents	3,019	7,056
Cash and cash equivalents from continuing operations, beginning of period	21,859	12,889
Cash and cash equivalents from discontinued operations, beginning of period	0	1,238
Cash and Cash equivalents beginning of period	21,859	14,127
Cash and cash equivalents from continuing operations, end of period	24,878	19,958
Cash and cash equivalents from discontinued operations, end of period	0	1,225
Cash and cash equivalents, end of period	24,878	21,183
Acquisitions (Note 10)
Fair value of assets acquired	15,748	0
Fair value of liabilities assumed	(1,629)	0
Net cash paid for acquisitions	$ 14,119	$ 0

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
Summary of Significant Accounting Policies	Jun. 30, 2024
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	The accompanying unaudited interim consolidated financial statements and related notes should be read in conjunction with the audited Consolidated Financial Statements of Johnson & Johnson and its subsidiaries (the Company) and related notes as contained in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023. The unaudited interim financial statements include all adjustments (consisting only of normal recurring adjustments) and accruals necessary in the judgment of management for a fair statement of the results for the periods presented. Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures. New accounting standards The Company assesses the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board on the Company's financial statements as well as material updates to previous assessments, if any, from the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023. Recently adopted accounting standards There were no new material accounting standards adopted in the fiscal six months in 2024. Recently issued accounting standards Not adopted as of June 30, 2024 ASU 2023-07: Segment Reporting (Topic 280) – Improvements to Reportable Segment Disclosures This update requires expanded annual and interim disclosures for significant segment expenses that are regularly provided to the chief operating decision maker and included within each reported measure of segment profit or loss. This update will be effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. This standard is to be applied retrospectively to all periods presented in the financial statements. Early adoption is permitted. While this accounting standard will increase disclosures, it will not have a material impact on the Company’s Consolidated Financial Statement results. ASU 2023-09: Income Taxes (Topic 740) - Improvements to Income Tax Disclosures This update standardizes categories for the effective tax rate reconciliation, requires disaggregation of income taxes and additional income tax-related disclosures. This update is required to be effective for the Company for fiscal periods beginning after December 15, 2024. While this accounting standard will increase disclosures, it will not have a material impact on the Company’s Consolidated Financial Statement results. There were no new material accounting standards issued in the fiscal second quarter of 2024. Supplier finance program obligations The Company has agreements for supplier finance programs with third-party financial institutions. These programs provide participating suppliers the ability to finance payment obligations from the Company with the third-party financial institutions. The Company is not a party to the arrangements between the suppliers and the third-party financial institutions. The Company’s obligations to its suppliers, including amounts due, and scheduled payment dates (which have general payment terms of 90 days), are not affected by a participating supplier’s decision to participate in the program.

Inventories

Inventories	6 Months Ended
Inventories	Jun. 30, 2024
Inventory Disclosure [Abstract]
Inventories	Inventories (Dollars in Millions) June 30, 2024 December 31, 2023 Raw materials and supplies $2,407 2,355 Goods in process 2,556 1,952 Finished goods 7,206 6,874 Total inventories $12,169 11,181

Intangible Assets and Goodwill

Intangible Assets and Goodwill	6 Months Ended
Intangible Assets and Goodwill	Jun. 30, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets and Goodwill	Intangible assets and goodwill Intangible assets that have finite useful lives are amortized over their estimated useful lives. The latest annual impairment assessment of goodwill and indefinite lived intangible assets was completed in the fiscal fourth quarter of 2023. Future impairment tests for goodwill and indefinite lived intangible assets will be performed annually in the fiscal fourth quarter, or sooner, if warranted. (Dollars in Millions) June 30, 2024 December 31, 2023 Intangible assets with definite lives: Patents and trademarks — gross $43,438 40,417 Less accumulated amortization (24,835) (24,808) Patents and trademarks — net 18,603 15,609 Customer relationships and other intangibles — gross 20,176 20,322 Less accumulated amortization (13,018) (12,685) Customer relationships and other intangibles — net (1) 7,158 7,637 Intangible assets with indefinite lives: Trademarks 1,655 1,714 Purchased in-process research and development 12,309 9,215 Total intangible assets with indefinite lives 13,964 10,929 Total intangible assets — net $39,725 34,175 (1) The majority is comprised of customer relationships Goodwill as of June 30, 2024 was allocated by segment of business as follows: (Dollars in Millions) Innovative Medicine MedTech Total Goodwill at December 31, 2023 $10,407 26,151 36,558 Goodwill, related to acquisitions 563 7,494 8,057 Goodwill, related to divestitures — (56) (56) Currency translation/Other (202) (107) (309) Goodwill at June 30, 2024 $10,768 33,482 44,250 The weighted average amortization period for patents and trademarks is approximately 12 years. The weighted average amortization period for customer relationships and other intangible assets is approximately 18 years. The amortization expense of amortizable intangible assets included in the cost of products sold was $1.1 billion and $1.1 billion for the fiscal second quarters ended June 30, 2024 and July 2, 2023, respectively. The amortization expense of amortizable intangible assets included in the cost of products sold was $2.2 billion and $2.2 billion for the fiscal six months ended June 30, 2024 and July 2, 2023, respectively. Intangible asset write-downs are included in Other (income) expense, net. The estimated amortization expense for approved products, before tax, for the five succeeding years is approximately: (Dollars in Millions) 2024 2025 2026 2027 2028 $4,500 3,900 3,300 2,700 2,000 See Note 10 to the Consolidated Financial Statements for additional details related to acquisitions and divestitures.

Fair Value Measurements

Fair Value Measurements	6 Months Ended
Fair Value Measurements	Jun. 30, 2024
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair value measurements The Company uses forward foreign exchange contracts to manage its exposure to the variability of cash flows, primarily related to the foreign exchange rate changes of future intercompany product and third-party purchases of materials denominated in a foreign currency. The Company uses cross currency interest rate swaps to manage currency risk primarily related to borrowings. Both types of derivatives are designated as cash flow hedges. Additionally, the Company uses interest rate swaps as an instrument to manage interest rate risk related to fixed rate borrowings. These derivatives are designated as fair value hedges. The Company uses cross currency interest rate swaps and forward foreign exchange contracts designated as net investment hedges. Additionally, the Company uses forward foreign exchange contracts to offset its exposure to certain foreign currency assets and liabilities. These forward foreign exchange contracts are not designated as hedges, and therefore, changes in the fair values of these derivatives are recognized in earnings, thereby offsetting the current earnings effect of the related foreign currency assets and liabilities. The Company does not enter into derivative financial instruments for trading or speculative purposes, or that contain credit risk related contingent features. The Company maintains credit support agreements (CSA) with certain derivative counterparties establishing collateral thresholds based on respective credit ratings and netting agreements. As of June 30, 2024, the cumulative amount of cash collateral paid by the Company under the CSA amounted to $2.3 billion net, related to net investment and cash flow hedges. On an ongoing basis, the Company monitors counter-party credit ratings. The Company considers credit non-performance risk to be low because the Company primarily enters into agreements with commercial institutions that have at least an investment grade credit rating. Refer to the table on significant financial assets and liabilities measured at fair value contained in this footnote for receivables and payables with these commercial institutions. As of June 30, 2024, the Company had notional amounts outstanding for forward foreign exchange contracts, cross currency interest rate swaps and interest rate swaps of $44.5 billion, $41.0 billion and $10.0 billion, respectively. As of December 31, 2023, the Company had notional amounts outstanding for forward foreign exchange contracts, cross currency interest rate swaps and interest rate swaps of $42.9 billion, $39.7 billion and $10.0 billion, respectively. All derivative instruments are recorded on the balance sheet at fair value. Changes in the fair value of derivatives are recorded each period in current earnings or other comprehensive income, depending on whether the derivative is designated as part of a hedge transaction, and if so, the type of hedge transaction. The designation as a cash flow hedge is made at the entrance date of the derivative contract. At inception, all derivatives are expected to be highly effective. Foreign exchange contracts designated as cash flow hedges are accounted for under the forward method and all gains/losses associated with these contracts will be recognized in the income statement when the hedged item impacts earnings. Changes in the fair value of these derivatives are recorded in accumulated other comprehensive income until the underlying transaction affects earnings and are then reclassified to earnings in the same account as the hedged transaction. Gains and losses associated with interest rate swaps and changes in fair value of hedged debt attributable to changes in interest rates are recorded to interest expense in the period in which they occur. Gains and losses on net investment hedges are accounted for through the currency translation account within accumulated other comprehensive income. The portion excluded from effectiveness testing is recorded through interest (income) expense using the spot method. On an ongoing basis, the Company assesses whether each derivative continues to be highly effective in offsetting changes of hedged items. If and when a derivative is no longer expected to be highly effective, hedge accounting is discontinued. The Company designated its Euro denominated notes with due dates ranging from 2024 to 2044 as a net investment hedge of the Company's investments in certain of its international subsidiaries that use the Euro as their functional currency in order to reduce the volatility caused by changes in exchange rates. As of June 30, 2024, the balance of deferred net loss on derivatives included in accumulated other comprehensive income was $899 million after-tax. For additional information, see the Consolidated Statements of Comprehensive Income and Note 7. The Company expects that substantially all of the amounts related to forward foreign exchange contracts will be reclassified into earnings over the next 12 months as a result of transactions that are expected to occur over that period. The maximum length of time over which the Company is hedging transaction exposure is 18 months, excluding interest rate contracts and net investment hedge contracts. The amount ultimately realized in earnings may differ as foreign exchange rates change. Realized gains and losses are ultimately determined by actual exchange rates at maturity of the derivative. The following table is a summary of the activity related to derivatives and hedges for the fiscal second quarters ended June 30, 2024 and July 2, 2023, net of tax: June 30, 2024 July 2, 2023 (Dollars in Millions) Sales Cost of Products Sold R&D Expense Interest (Income) Expense Other (Income) Expense Sales Cost of Products Sold R&D Expense Interest (Income) Expense Other (Income) Expense The effects of fair value, net investment and cash flow hedging: Gain (Loss) on fair value hedging relationship: Interest rate swaps contracts: Hedged items $— — — (53) — — — — (175) — Derivatives designated as hedging instruments — — — 53 — — — — 175 — Gain (Loss) on net investment hedging relationship: Cross currency interest rate swaps contracts: Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing — — — 33 — — — — 33 — Amount of gain or (loss) recognized in AOCI — — — 33 — — — — 33 — Gain (Loss) on cash flow hedging relationship: Forward foreign exchange contracts: Amount of gain or (loss) reclassified from AOCI into income (1) 94 8 — 3 (15) 56 (12) — 3 Amount of gain or (loss) recognized in AOCI 2 66 11 — 1 (14) 251 7 — 18 Cross currency interest rate swaps contracts: Amount of gain or (loss) reclassified from AOCI into income — — — 42 — — — — 74 — Amount of gain or (loss) recognized in AOCI $— — — (38) — — — — (432) — The following table is a summary of the activity related to derivatives and hedges for the fiscal six months ended June 30, 2024 and July 2, 2023, net of tax: June 30, 2024 July 2, 2023 (Dollars in Millions) Sales Cost of Products Sold R&D Expense Interest (Income) Expense Other (Income) Expense Sales Cost of Products Sold R&D Expense Interest (Income) Expense Other (Income) Expense The effects of fair value, net investment and cash flow hedging: Gain (Loss) on fair value hedging relationship: Interest rate swaps contracts: Hedged items $— — — (45) — — — — (6) — Derivatives designated as hedging instruments — — — 45 — — — — 6 — Gain (Loss) on net investment hedging relationship: Cross currency interest rate swaps contracts: Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing — — — 67 — — — — 67 — Amount of gain or (loss) recognized in AOCI — — — 67 — — — — 67 — Gain (Loss) on cash flow hedging relationship: Forward foreign exchange contracts: Amount of gain or (loss) reclassified from AOCI into income — 259 12 — 1 (3) (90) (25) — 5 Amount of gain or (loss) recognized in AOCI (1) 47 33 — 5 10 396 (29) — 4 Cross currency interest rate swaps contracts: Amount of gain or (loss) reclassified from AOCI into income — — — 91 — — — — 182 — Amount of gain or (loss) recognized in AOCI $— — — (243) — — — — (15) — As of June 30, 2024, and December 31, 2023, the following amounts were recorded on the Consolidated Balance Sheet related to cumulative basis adjustment for fair value hedges: Line item in the Consolidated Balance Sheet in which the hedged item is included Carrying Amount of the Hedged Liability Cumulative Amount of Fair Value Hedging Gain/ (Loss) Included in the Carrying Amount of the Hedged Liability (Dollars in Millions) June 30, 2024 December 31, 2023 June 30, 2024 December 31, 2023 Long-term Debt $8,812 8,862 (1,274) (1,216) The following table is the effect of derivatives not designated as hedging instruments for the fiscal second quarters ended 2024 and 2023: Gain/(Loss) Gain/(Loss) (Dollars in Millions) Location of Gain /(Loss) Recognized in Income on Derivative Fiscal Second Quarter Ended Fiscal Six Months Ended Derivatives Not Designated as Hedging Instruments June 30, 2024 July 2, 2023 June 30, 2024 July 2, 2023 Foreign Exchange Contracts Other (income) expense $20 33 45 2 The following table is the effect of net investment hedges for the fiscal second quarters ended in 2024 and 2023: Gain/(Loss) Recognized In Accumulated OCI Location of Gain or (Loss) Reclassified from Accumulated Other Comprehensive Income Into Income Gain/(Loss) Reclassified From (Dollars in Millions) June 30, 2024 July 2, 2023 June 30, 2024 July 2, 2023 Debt $46 11 Interest (income) expense — — Cross Currency interest rate swaps $92 (24) Interest (income) expense — — The following table is the effect of net investment hedges for the fiscal six months ended in 2024 and 2023: Gain/(Loss) Location of Gain or (Loss) Reclassified from Accumulated Other Comprehensive Income Into Income Gain/(Loss) Reclassified From (Dollars in Millions) June 30, 2024 July 2, 2023 June 30, 2024 July 2, 2023 Debt $130 (66) Interest (income) expense — — Cross Currency interest rate swaps $820 666 Interest (income) expense — — The Company holds equity investments with readily determinable fair values and equity investments without readily determinable fair values. The Company has elected to measure equity investments that do not have readily determinable fair values at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. The following table is a summary of the activity related to equity investments: December 31, 2023 June 30, 2024 (Dollars in Millions) Carrying Value Changes in Fair Value Reflected in Net Income (1) (Sales)/ Purchases/Other (2) Carrying Value Non Current Other Assets Equity Investments with readily determinable value* $4,473 (4) (3,999) 470 470 Equity Investments without readily determinable value $696 (15) (8) 673 673 (1) Recorded in Other (income)/expense, net (2) Other includes impact of currency * The December 31, 2023 balance includes the 9.5% remaining stake in Kenvue. A debt to equity exchange was completed in the fiscal second quarter of 2024. On May 15, 2024, the Company issued $3.6 billion aggregate principal amount of commercial paper and received $3.6 billion of net cash proceeds to be used for general corporate purposes. On May 17, 2024, the Company completed a Debt-for-Equity Exchange of its remaining 182,329,550 shares of Kenvue Common Stock for the outstanding Commercial Paper. Upon completion of the Debt-for-Equity Exchange, the Commercial Paper was satisfied and discharged and the Company no longer owns any shares of Kenvue Common Stock. This exchange resulted in a loss of approximately $0.4 billion recorded in Other (income) expense. Fair value is the exit price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement determined using assumptions that market participants would use in pricing an asset or liability. In accordance with ASC 820, a three-level hierarchy was established to prioritize the inputs used in measuring fair value. The levels within the hierarchy are described below with Level 1 inputs having the highest priority and Level 3 inputs having the lowest. The fair value of a derivative financial instrument (i.e., forward foreign exchange contracts, interest rate contracts) is the aggregation by currency of all future cash flows discounted to its present value at the prevailing market interest rates and subsequently converted to the U.S. Dollar at the current spot foreign exchange rate. The Company does not believe that fair values of these derivative instruments materially differ from the amounts that could be realized upon settlement or maturity, or that the changes in fair value will have a material effect on the Company’s results of operations, cash flows or financial position. The Company also holds equity investments which are classified as Level 1 and debt securities which are classified as Level 2. The Company holds acquisition related contingent liabilities based upon certain regulatory and commercial events, which are classified as Level 3, whose values are determined using discounted cash flow methodologies or similar techniques for which the determination of fair value requires significant judgment or estimations. The following three levels of inputs are used to measure fair value: Level 1 — Quoted prices in active markets for identical assets and liabilities. Level 2 — Significant other observable inputs. Level 3 — Significant unobservable inputs. The Company’s significant financial assets and liabilities measured at fair value as of June 30, 2024 and December 31, 2023 were as follows: June 30, 2024 December 31, 2023 (Dollars in Millions) Level 1 Level 2 Level 3 Total Total (1) Derivatives designated as hedging instruments: Assets: Forward foreign exchange contracts $— 523 — 523 539 Interest rate contracts (2) — 1,392 — 1,392 988 Total — 1,915 — 1,915 1,527 Liabilities: Forward foreign exchange contracts — 512 — 512 624 Interest rate contracts (2) — 3,874 — 3,874 5,338 Total — 4,386 — 4,386 5,962 Derivatives not designated as hedging instruments: Assets: Forward foreign exchange contracts — 27 — 27 64 Liabilities: Forward foreign exchange contracts — 19 — 19 75 Other Investments: Equity investments (3) 470 — — 470 4,473 Debt securities (4) — 6,840 — 6,840 8,874 Other Liabilities Contingent consideration (5) $— — 1,248 1,248 1,092 Gross to Net Derivative Reconciliation June 30, 2024 December 31, 2023 (Dollars in Millions) Total Gross Assets $1,942 1,591 Credit Support Agreement (CSA) (1,911) (1,575) Total Net Asset 31 16 Total Gross Liabilities 4,405 6,037 Credit Support Agreement (CSA) (4,229) (5,604) Total Net Liabilities $176 433 Summarized information about changes in liabilities for contingent consideration for the fiscal second quarters ended June 30, 2024 and July 2, 2023 is as follows: June 30, 2024 July 2, 2023 (Dollars in Millions) Beginning Balance $1,092 1,120 Changes in estimated fair value (6) 44 25 Additions 112 — Payments — (3) Ending Balance $1,248 1,142 (1) 2023 assets and liabilities are all classified as Level 2 with the exception of equity investments of $4,473 million, which are classified as Level 1 and contingent consideration of $1,092 million, classified as Level 3. (2) Includes cross currency interest rate swaps and interest rate swaps. (3) Classified as non-current other assets. (4) Classified within cash equivalents and current marketable securities. (5) Classified as non-current other liabilities as of June 30, 2024 and December 31, 2023, respectively. (6) Ongoing fair value adjustment amounts are primarily recorded in Research and Development expense. The Company's cash, cash equivalents and current marketable securities as of June 30, 2024 comprised: (Dollars in Millions) Carrying Amount Unrealized Gain Estimated Fair Value Cash & Cash Equivalents Current Marketable Securities Cash $4,247 — 4,247 4,247 — U.S. Gov't securities — — — — — Non-U.S. sovereign securities 150 — 150 150 — U.S. reverse repurchase agreements 8,496 — 8,496 8,496 — Corporate debt securities (1) — — — — — Money market funds 4,883 — 4,883 4,883 — Time deposits (1) 859 — 859 859 — Subtotal 18,635 — 18,635 18,635 — U.S. Gov’t securities 6,585 — 6,585 6,182 403 U.S. Gov’t Agencies 11 — 11 — 11 Other sovereign securities 2 — 2 — 2 Corporate debt securities 242 — 242 61 181 Subtotal available for sale debt (2) $6,840 — 6,840 6,243 597 Total cash, cash equivalents and current marketable securities $25,475 — 25,475 24,878 597 (1) Held to maturity investments are reported at amortized cost and gains or losses are reported in earnings. (2) Available for sale debt securities are reported at fair value with unrealized gains and losses reported net of taxes in other comprehensive income. As of the fiscal year ended December 31, 2023, the carrying amount was approximately the same as the estimated fair value. Fair value of government securities and obligations and corporate debt securities was estimated using quoted broker prices and significant other observable inputs. The Company classifies all highly liquid investments with stated maturities of three months or less from date of purchase as cash equivalents and all highly liquid investments with stated maturities of greater than three months from the date of purchase as current marketable securities. Available for sale securities with stated maturities of greater than one year from the date of purchase are available to fund current operations and are classified as either cash equivalents or current marketable securities. The contractual maturities of the available for sale securities as of June 30, 2024 are as follows: (Dollars in Millions) Cost Basis Fair Value Due within one year $6,821 6,821 Due after one year through five years 19 19 Due after five years through ten years — — Total debt securities $6,840 6,840 Financial instruments not measured at fair value The following financial liabilities are held at carrying amount on the consolidated balance sheet as of June 30, 2024: (Dollars in Millions) Carrying Amount Estimated Fair Value Financial Liabilities Current Debt $9,855 9,835 Non-Current Debt 0.55% Notes due 2025 973 950 2.46% Notes due 2026 1,998 1,921 2.95% Notes due 2027 902 955 0.95% Notes due 2027 1,430 1,334 2.90% Notes due 2028 1,497 1,418 1.150% Notes due 2028 (750MM Euro 1.0721) 801 744 4.80% Notes due 2029 (1) 1,145 1,161 6.95% Notes due 2029 298 332 1.30% Notes due 2030 1,626 1,445 4.90% Notes due 2031 (1) 1,145 1,161 3.20% Notes due 2032 (700MM Euro 1.0721) (1) 747 750 4.95% Notes due 2033 499 513 4.375% Notes due 2033 854 835 4.95% Notes due 2034 (1) 846 860 1.650% Notes due 2035 (1.5B Euro 1.0721) 1,597 1,384 3.35% Notes due 2036 (800MM Euro 1.0721) (1) 852 853 3.587% Notes due 2036 855 876 5.95% Notes due 2037 994 1,089 3.625% Notes due 2037 1,346 1,310 3.40% Notes due 2038 993 839 5.85% Notes due 2038 697 756 4.50% Notes due 2040 541 521 2.10% Notes due 2040 836 670 4.85% Notes due 2041 297 293 4.50% Notes due 2043 496 470 3.55% Notes due 2044 (1.0B Euro 1.0721) (1) 1,062 1,062 3.73% Notes due 2046 1,978 1,609 3.75% Notes due 2047 816 805 3.50% Notes due 2048 743 579 2.25% Notes due 2050 807 593 5.25% Notes due 2054 (1) 843 854 2.45% Notes due 2060 1,055 707 Other 67 67 Total Non-Current Debt $31,636 29,716 (1) In the fiscal second quarter of 2024, the Company issued senior unsecured notes for a total of $6.7 billion. The net proceeds from this offering were used to fund the Shockwave acquisition which closed on May 31, 2024, and for general corporate purposes. The weighted average effective interest rate on non-current debt is 3.28%. The excess of the carrying value over the estimated fair value of debt was $1.0 billion at December 31, 2023. Fair value of the non-current debt was estimated using market prices, which were corroborated by quoted broker prices and significant other observable inputs.

Income Taxes

Income Taxes	6 Months Ended
Income Taxes	Jun. 30, 2024
Income Tax Disclosure [Abstract]
Income Taxes	Income taxes The worldwide effective income tax rates for the fiscal six months of 2024 and 2023 were 16.1% and 2.7%, respectively. The change in the consolidated tax rate as compared to the prior year is primarily due to a charge of $7.0 billion in the fiscal six months of 2023 and a charge of $3.0 billion in the fiscal six months of 2024, both related to talc matters. Both charges were recorded at an effective U.S. federal and state tax rate of approximately 23% (for further information see Note 11 to the Consolidated Financial Statements). Additionally in the fiscal six months of 2024, the effective tax rate was unfavorably impacted by legislative changes that went into effect for Pillar Two in some of the Company's foreign jurisdictions as well as tax audit expenses incurred in the fiscal second quarter of 2024 related to multi-year transfer pricing agreements with the IRS and certain other foreign jurisdictions. As of June 30, 2024, the Company had approximately $2.5 billion of liabilities from unrecognized tax benefits. The Company conducts business and files tax returns in numerous countries and currently has tax audits in progress in a number of jurisdictions. With respect to the United States, the Internal Revenue Service (IRS) has completed its audit for the tax years through 2016 and in the fiscal first quarter of 2024 has commenced the audit for tax years 2017 through 2020. The Company currently expects completion of multi-year transfer pricing agreements with the IRS and certain other foreign jurisdictions in the next 12 months. As a result, the Company has classified approximately $0.4 billion of unrecognized tax benefits and associated interest as a current liability on the “Accrued taxes on Income” line of the Consolidated Balance Sheet as of the end of the second fiscal quarter of 2024 in anticipation of final settlement. In other major jurisdictions where the Company conducts business, the years that remain open to tax audit go back to the year 2013. The Company believes it is possible that tax audits may be completed over the next twelve months by taxing authorities in some jurisdictions outside of the United States. However, the Company is not able to provide a reasonably reliable estimate of the timing of any other future tax payments relating to uncertain tax positions.

Pensions and Other Benefit Plan

Pensions and Other Benefit Plans	6 Months Ended
Pensions and Other Benefit Plans	Jun. 30, 2024
Retirement Benefits [Abstract]
Pensions and Other Benefit Plans	Pensions and other benefit plans Components of net periodic benefit cost Net periodic benefit costs for the Company’s defined benefit retirement plans and other benefit plans include the following components: Fiscal Second Quarter Ended Fiscal Six Months Ended Retirement Plans Other Benefit Plans Retirement Plans Other Benefit Plans (Dollars in Millions) June 30, 2024 July 2, 2023 June 30, 2024 July 2, 2023 June 30, 2024 July 2, 2023 June 30, 2024 July 2, 2023 Service cost $222 215 69 69 446 425 138 137 Interest cost 351 371 52 55 703 723 104 109 Expected return on plan assets (639) (694) (1) (2) (1,281) (1,362) (3) (3) Amortization of prior service cost/(credit) (46) (46) (1) (1) (92) (92) (1) (1) Recognized actuarial (gains)/losses 44 (50) 13 7 87 (100) 26 13 Curtailments and settlements (8) — — — (8) — — — Net periodic benefit cost/(credit) $(76) (204) 132 128 (145) (406) 264 255 The service cost component of net periodic benefit cost is presented in the same line items on the Consolidated Statement of Earnings where other employee compensation costs are reported, including Cost of products sold, Research and development expense, Selling, marketing and administrative expenses, and in the fiscal second quarter and fiscal six months of 2023, Net earnings from discontinued operations, net of taxes if related to the separation of Kenvue. All other components of net periodic benefit cost are presented as part of Other (income) expense, net on the Consolidated Statement of Earnings. Company contributions For the fiscal six months ended June 30, 2024, the Company contributed $61 million and $7 million to its U.S. and international retirement plans, respectively. The Company plans to continue to fund its U.S. defined benefit plans to comply with the Pension Protection Act of 2006. International plans are funded in accordance with local regulations.

Accumulated Other Comprehensive

Accumulated Other Comprehensive Income	6 Months Ended
Accumulated Other Comprehensive Income	Jun. 30, 2024
Equity [Abstract]
Accumulated Other Comprehensive Income	Accumulated other comprehensive income Components of other comprehensive income/(loss) consist of the following: (Dollars in Millions) Foreign Currency Translation Gain/ (Loss) On Securities Employee Benefit Plans Gain/ (Loss) On Derivatives & Hedges Total Accumulated Other Comprehensive Income/(Loss) December 31, 2023 $(10,149) (1) (2,000) (377) (12,527) Net change 1,734 1 61 (522) 1,274 June 30, 2024 (8,415) 0 (1,939) (899) (11,253) Amounts in accumulated other comprehensive income are presented net of the related tax impact. Foreign currency translation is not adjusted for income taxes where it relates to permanent investments in international subsidiaries. For additional details on comprehensive income see the Consolidated Statements of Comprehensive Income. Details on reclassifications out of Accumulated Other Comprehensive Income: Gain/(Loss) On Securities - reclassifications released to Other (income) expense, net. Employee Benefit Plans - reclassifications are included in net periodic benefit cost. See Note 6 for additional details.

Earnings Per Share

Earnings Per Share	6 Months Ended
Earnings Per Share	Jun. 30, 2024
Earnings Per Share [Abstract]
Earnings Per Share	Earnings per share The following is a reconciliation of basic net earnings per share to diluted net earnings per share: Fiscal Second Quarter Ended Fiscal Six Months Ended (Shares in Millions) June 30, 2024 July 2, 2023 June 30, 2024 July 2, 2023 Basic net earnings per share from continuing operations $1.95 2.07 3.30 1.88 Basic net earnings (loss) per share from discontinued operations — (0.09) — 0.07 Total net earnings per share - basic 1.95 1.98 3.30 1.95 Average shares outstanding — basic 2,406.8 2,598.4 2,407.5 2,601.9 Potential shares exercisable under stock option plans 62.6 95.2 79.3 96.9 Less: shares which could be repurchased under treasury stock method (47.4) (67.9) (58.3) (68.1) Average shares outstanding — diluted 2,422.0 2,625.7 2,428.5 2,630.7 Diluted net earnings per share from continuing operations 1.93 2.05 3.27 1.86 Diluted net earnings (loss) per share from discontinuing operations — (0.09) — 0.07 Total net earnings per share - diluted $1.93 1.96 3.27 1.93 (Shares in Millions) The diluted net earnings per share calculation excluded the following number of shares related to stock options, as the exercise price of these options was greater than the average market value of the Company’s stock. 72.2 50.8 53.8 46.8

Segments of Business and Geogra

Segments of Business and Geographic Areas	6 Months Ended
Segments of Business and Geographic Areas	Jun. 30, 2024
Segment Reporting [Abstract]
Segments of Business and Geographic Areas	Segments of business and geographic areas Following the separation of the Consumer Health business in the fiscal third quarter of 2023, the Company is now organized into two business segments: Innovative Medicine and MedTech. The segment results have been recast for all periods to reflect the continuing operations of the Company. Sales by segment of business Fiscal Second Quarter Ended Fiscal Six Months Ended (Dollars in Millions) June 30, July 2, Percent June 30, July 2, Percent Change INNOVATIVE MEDICINE Immunology U.S. $2,978 2,865 4.0 % $5,431 5,313 2.2 % International 1,744 1,631 6.9 3,538 3,295 7.4 Worldwide 4,722 4,496 5.0 8,969 8,608 4.2 REMICADE U.S. 231 277 (16.7) 497 553 (10.1) U.S. Exports 35 33 7.9 62 74 (15.4) International 127 152 (16.6) 268 322 (16.9) Worldwide 393 462 (14.9) 827 949 (12.9) SIMPONI / SIMPONI ARIA U.S. 267 285 (6.3) 521 556 (6.2) International 270 244 10.9 569 510 11.7 Worldwide 537 529 1.6 1,091 1,066 2.3 STELARA U.S. 1,855 1,817 2.1 3,251 3,268 (0.5) International 1,030 981 5.0 2,085 1,974 5.6 Worldwide 2,885 2,797 3.1 5,336 5,241 1.8 TREMFYA U.S. 589 450 30.8 1,098 856 28.2 International 317 255 23.9 616 489 25.8 Worldwide 906 706 28.3 1,714 1,346 27.3 OTHER IMMUNOLOGY U.S. 2 4 (51.5) 2 7 (75.4) International 0 0 — 0 0 — Worldwide 2 4 (51.5) 2 7 (75.4) Infectious Diseases U.S. 334 395 (15.4) 658 787 (16.4) International 631 727 (13.1) 1,128 1,920 (41.3) Worldwide 965 1,121 (13.9) 1,786 2,707 (34.0) COVID-19 VACCINE U.S. 0 0 — 0 0 — International 172 285 (39.7) 197 1,032 (80.9) Worldwide 172 285 (39.7) 197 1,032 (80.9) Fiscal Second Quarter Ended Fiscal Six Months Ended (Dollars in Millions) June 30, July 2, Percent June 30, July 2, Percent Change EDURANT / rilpivirine U.S. 8 8 (2.8) 16 17 (7.0) International 288 258 11.5 603 529 14.1 Worldwide 297 266 11.0 620 546 13.4 PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA U.S. 321 382 (16.0) 635 760 (16.5) International 117 109 6.5 221 208 6.0 Worldwide 438 491 (11.0) 856 968 (11.6) OTHER INFECTIOUS DISEASES U.S. 5 5 18.5 7 10 (29.4) International 55 74 (25.6) 107 151 (29.3) Worldwide 61 79 (23.1) 114 161 (29.3) Neuroscience U.S. 1,102 1,029 7.1 2,156 2,007 7.4 International 679 764 (11.1) 1,428 1,590 (10.2) Worldwide 1,782 1,793 (0.6) 3,585 3,597 (0.3) CONCERTA / methylphenidate U.S. 34 64 (47.7) 75 134 (44.3) International 129 143 (9.8) 265 279 (5.1) Worldwide 163 208 (21.5) 340 414 (17.8) INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA U.S. 784 721 8.8 1,549 1,434 8.0 International 269 310 (13.1) 561 641 (12.4) Worldwide 1,054 1,031 2.2 2,110 2,075 1.7 SPRAVATO U.S. 226 144 57.9 417 255 63.9 International 44 25 73.5 78 45 74.6 Worldwide 271 169 60.2 496 300 65.5 OTHER NEUROSCIENCE U.S. 57 100 (42.5) 115 184 (37.3) International 237 286 (17.0) 524 625 (16.2) Fiscal Second Quarter Ended Fiscal Six Months Ended (Dollars in Millions) June 30, July 2, Percent June 30, July 2, Percent Change Worldwide 294 386 (23.7) 639 809 (21.0) Oncology U.S. 2,636 2,069 27.4 5,019 3,958 26.8 International 2,455 2,329 5.4 4,885 4,552 7.3 Worldwide 5,090 4,398 15.7 9,904 8,510 16.4 CARVYKTI U.S. 167 114 46.5 307 184 66.8 International 20 3 * 36 5 * Worldwide 186 117 59.8 343 189 81.5 DARZALEX U.S. 1,641 1,322 24.2 3,105 2,513 23.6 International 1,237 1,110 11.5 2,465 2,182 12.9 Worldwide 2,878 2,431 18.4 5,570 4,695 18.6 ERLEADA U.S. 318 241 32.2 603 490 23.0 International 418 326 28.0 822 619 32.8 Worldwide 736 567 29.8 1,425 1,109 28.4 IMBRUVICA U.S. 246 262 (6.4) 511 532 (3.9) International 525 579 (9.4) 1,043 1,136 (8.3) Worldwide 770 841 (8.5) 1,554 1,668 (6.9) TECVAYLI U.S. 104 82 27.5 205 139 47.7 International 30 12 * 63 18 * Worldwide 135 94 42.9 268 157 70.2 ZYTIGA / abiraterone acetate U.S. 11 9 21.6 20 25 (19.7) International 154 218 (29.6) 326 447 (27.2) Worldwide 165 227 (27.7) 346 472 (26.8) OTHER ONCOLOGY U.S. 148 40 * 267 75 * International 71 80 (10.4) 131 144 (8.5) Worldwide 221 120 84.2 399 219 82.4 Pulmonary Hypertension U.S. 743 684 8.7 1,509 1,284 17.5 International 296 289 2.6 579 561 3.4 Worldwide 1,039 972 6.9 2,088 1,844 13.2 OPSUMIT U.S. 373 328 13.7 729 601 21.3 International 170 179 (5.0) 339 346 (2.2) Worldwide 544 507 7.1 1,068 947 12.7 UPTRAVI Fiscal Second Quarter Ended Fiscal Six Months Ended (Dollars in Millions) June 30, July 2, Percent June 30, July 2, Percent Change U.S. 349 338 3.3 741 642 15.5 International 76 61 24.6 152 119 27.6 Worldwide 426 399 6.6 894 761 17.4 OTHER PULMONARY HYPERTENSION U.S. 20 18 18.8 38 41 (6.1) International 50 48 3.1 89 95 (6.7) Worldwide 71 66 7.2 127 136 (6.5) Cardiovascular / Metabolism / Other U.S. 717 776 (7.7) 1,348 1,491 (9.6) International 176 174 0.6 373 386 (3.6) Worldwide 892 950 (6.2) 1,721 1,877 (8.3) XARELTO U.S. 587 637 (7.9) 1,105 1,215 (9.1) International — — — — — — Worldwide 587 637 (7.9) 1,105 1,215 (9.1) OTHER U.S. 129 138 (6.4) 243 275 (11.8) International 176 174 0.6 373 386 (3.6) Worldwide 305 313 (2.5) 616 662 (7.0) TOTAL INNOVATIVE MEDICINE U.S. 8,510 7,818 8.9 16,122 14,841 8.6 International 5,980 5,913 1.1 11,930 12,303 (3.0) Worldwide 14,490 13,731 5.5 28,052 27,144 3.3 MEDTECH Cardiovascular (1) U.S. 1,119 908 23.3 2,144 1,771 21.1 International 753 712 5.7 1,534 1,352 13.4 Worldwide 1,873 1,620 15.6 3,679 3,123 17.8 ELECTROPHYSIOLOGY U.S. 705 609 15.7 1,397 1,180 18.4 International 618 587 5.4 1,270 1,109 14.6 Worldwide 1,323 1,196 10.6 2,667 2,288 16.5 ABIOMED U.S. 309 272 13.2 612 536 14.1 International 72 59 20.7 139 119 16.5 Worldwide 379 331 14.5 750 655 14.5 SHOCKWAVE (2) U.S. 77 — * 77 — * International 0 — — 0 — — Worldwide 77 — * 77 — * OTHER CARDIOVASCULAR (1) U.S. 29 27 12.5 59 55 7.7 Fiscal Second Quarter Ended Fiscal Six Months Ended (Dollars in Millions) June 30, July 2, Percent June 30, July 2, Percent Change International 64 67 (4.5) 126 125 0.8 Worldwide 93 93 0.3 185 180 2.9 Orthopaedics U.S. 1,422 1,388 2.5 2,870 2,751 4.3 International 890 878 1.4 1,782 1,759 1.3 Worldwide 2,312 2,265 2.1 4,652 4,510 3.2 HIPS U.S. 265 250 5.8 535 491 8.9 International 152 147 3.4 304 296 2.6 Worldwide 417 397 4.9 839 787 6.5 KNEES U.S. 230 221 4.2 472 447 5.5 International 163 142 14.9 323 284 13.6 Worldwide 394 363 8.4 795 731 8.7 TRAUMA U.S. 498 483 3.0 1,002 974 2.9 International 260 255 2.4 521 522 0.0 Worldwide 759 739 2.8 1,524 1,496 1.9 SPINE, SPORTS & OTHER U.S. 430 433 (0.8) 862 839 2.7 International 314 334 (6.1) 634 657 (3.5) Worldwide 743 766 (3.1) 1,495 1,495 0.0 Surgery U.S. 995 1,015 (2.0) 1,982 1,990 (0.4) International 1,493 1,580 (5.5) 2,922 3,039 (3.8) Worldwide 2,488 2,594 (4.1) 4,904 5,028 (2.5) ADVANCED U.S. 466 466 0.1 912 910 0.2 International 675 757 (10.8) 1,316 1,430 (8.0) Worldwide 1,141 1,222 (6.7) 2,228 2,340 (4.8) GENERAL U.S. 528 548 (3.7) 1,070 1,079 (0.9) International 818 823 (0.7) 1,606 1,608 (0.2) Worldwide 1,346 1,372 (1.9) 2,676 2,688 (0.5) Vision U.S. 523 529 (1.2) 1,070 1,087 (1.5) International 763 778 (2.0) 1,473 1,521 (3.2) Worldwide 1,285 1,308 (1.7) 2,543 2,608 (2.5) CONTACT LENSES / OTHER U.S. 409 409 0.2 847 853 (0.6) Fiscal Second Quarter Ended Fiscal Six Months Ended (Dollars in Millions) June 30, July 2, Percent June 30, July 2, Percent Change International 509 530 (4.0) 981 1,039 (5.6) Worldwide 918 939 (2.2) 1,828 1,892 (3.4) SURGICAL U.S. 113 120 (5.8) 223 234 (4.8) International 254 249 2.1 492 482 2.1 Worldwide 367 369 (0.5) 715 716 (0.1) TOTAL MEDTECH U.S. 4,059 3,839 5.7 8,067 7,598 6.2 International 3,898 3,949 (1.3) 7,711 7,671 0.5 Worldwide 7,957 7,788 2.2 15,778 15,269 3.3 WORLDWIDE U.S. 12,569 11,657 7.8 24,189 22,439 7.8 International 9,878 9,862 0.2 19,641 19,974 (1.7) Worldwide $22,447 21,519 4.3 % $43,830 42,413 3.3 % * Percentage greater than 100% or not meaningful (1) Previously referred to as Interventional (2) Acquired on May 31, 2024 Earnings before provision for taxes by segment Fiscal Second Quarter Ended Fiscal Six Months Ended (Dollars in Millions) June 30, July 2, Percent June 30, July 2, Percent Innovative Medicine (1) $5,459 4,812 13.4 % $10,428 9,214 13.2 % MedTech (2) 1,089 1,671 (34.8) 2,609 3,080 (15.3) Segment earnings before provision for taxes 6,548 6,483 1.0 13,037 12,294 6.0 Less: Expense not allocated to segments (3) 800 177 3,575 7,275 Worldwide income (loss) before tax $5,748 6,306 (8.8) % $9,462 5,019 88.5 % (1) Innovative Medicine includes: • Intangible amortization expense of $0.7 billion in both the fiscal second quarter of 2024 and 2023. Intangible amortization expense of $1.4 billion and $1.5 billion in the fiscal six months of 2024 and 2023, respectively. • One-time COVID-19 Vaccine related exit costs of $0.1 billion in both the fiscal second quarter and fiscal six months of 2024. One-time COVID-19 Vaccine related exit costs of $0.2 billion and $0.6 billion in the fiscal second quarter and fiscal six months of 2023, respectively. • Restructuring income of $0.1 billion in the fiscal second quarter of 2024 and a restructuring related charge of $0.1 billion in the fiscal six months of 2024. A restructuring related charge of $0.1 billion and $0.3 billion in the fiscal second quarter and fiscal six months of 2023, respectively. Refer to Note 12 for additional details. • An In-process research and development impairment of $0.2 billion in the fiscal second quarter and fiscal six months of 2024 associated with the M710 (biosimilar) asset acquired from Momenta in 2020. (2) MedTech includes: • Intangible amortization expense of $0.4 billion in both the fiscal second quarter of 2024 and 2023. Intangible amortization expense of $0.8 billion in both the fiscal six months of 2024 and 2023. • Favorable intellectual property litigation settlements of $0.3 billion in both the fiscal second quarter and fiscal six months of 2023 • Acquisition and integration related expense of $0.6 billion and $0.6 billion, primarily driven by the Shockwave acquisition, in the fiscal second quarter and fiscal six months of 2024, respectively. Acquisition and integration related expense of $0.1 billion in the fiscal six months of 2023. • A gain of $0.2 billion related to the Acclarent divestiture recorded in Other (income) expense in the fiscal second quarter and fiscal six months of 2024 • Restructuring related charge of $0.1 billion in the fiscal second quarter and fiscal six months of 2024 (3 ) Amounts not allocated to segments include interest (income)/expense and general corporate (income)/expense. The fiscal second quarters of 2024 and 2023 include charges for talc matters of $0.3 billion and $0.2 billion, respectively. The fiscal six months of 2024 and 2023 include charges for talc matters of $3.0 billion and $7.1 billion, respectively (See Note 11, Legal Proceedings, for additional details). The fiscal second quarter and six months of 2024 includes a loss of approximately $0.4 billion related to the debt to equity exchange of the Company's remaining shares of Kenvue Common Stock Sales by geographic area Fiscal Second Quarter Ended Fiscal Six Months Ended (Dollars in Millions) June 30, 2024 July 2, 2023 Percent June 30, 2024 July 2, 2023 Percent Change United States $12,569 11,657 7.8 % $24,189 22,439 7.8 % Europe 5,214 5,131 1.6 10,377 10,721 (3.2) Western Hemisphere, excluding U.S. 1,212 1,136 6.7 2,406 2,212 8.8 Asia-Pacific, Africa 3,452 3,595 (4.0) 6,858 7,041 (2.6) Total $22,447 21,519 4.3 % $43,830 42,413 3.3 %

Acquisitions and Divestitures

Acquisitions and Divestitures	6 Months Ended
Acquisitions and Divestitures	Jun. 30, 2024
Business Combinations [Abstract]
Acquisitions and Divestitures	Acquisitions and divestitures Subsequent to the quarter, on July 11, 2024, the Company completed the acquisition of Yellow Jersey Therapeutics (Yellow Jersey), a demerged subsidiary of Numab Therapeutics, to secure the global rights to NM26, a novel, investigational first-in-class bispecific antibody targeting two clinically proven pathways in atopic dermatitis (AD), in an all-cash transaction for approximately $1.25 billion. The transaction is being accounted for as an asset acquisition, resulting in an in-process research and development (IPR&D) charge of approximately $1.25 billion recorded as part of research and development expense and the results of operations will be included in the Innovative Medicine segment as of the acquisition date. The acquisition is not expected to be deductible for tax purposes. On June 20, 2024, the Company completed the acquisition of Proteologix, Inc., a privately held biotechnology company focused on bispecific antibodies for immune-mediated diseases, for approximately $0.8 billion net of cash acquired, with potential for an additional milestone payment. The transaction was accounted for as a business combination and the results of operations were included in the Innovative Medicine segment as of the acquisition date. The fair value of the acquisition was allocated to assets acquired of $1.2 billion, primarily non-amortizable intangible assets, inclusive of purchased IPR&D, for $0.9 billion, goodwill for $0.3 billion, and $0.3 billion of liabilities acquired which included $0.1 billion related to a contingent consideration. The preliminary purchase price allocation is subject to any subsequent valuation adjustments within the measurement period. A probability of success factor ranging from 30% to 45% was used in the fair value calculation to reflect inherent regulatory and commercial risk of the IPR&D. The discount rate applied was approximately 16%. The goodwill is primarily attributable to synergies expected to arise from the business acquisition and is not expected to be deductible for tax purposes. Acquisition related costs before tax for the fiscal second quarter of 2024 were not material. On May 31, 2024, the Company completed the acquisition of Shockwave Medical Inc. (SWAV)(Shockwave), a leading, first-to-market provider of innovative intravascular lithotripsy (IVL) technology for the treatment of calcified coronary artery disease (CAD) and peripheral artery disease (PAD) in an all-cash merger transaction. The Company acquired all the outstanding shares of Shockwave’s common stock for $335.00 per share through a merger of Shockwave with a subsidiary of the Company. The transaction was accounted for as a business combination and the results of operations were included in the MedTech segment as of the acquisition date. Details of the fair value amounts recognized for assets acquired and liabilities assumed as of the acquisition date: (Dollars in Billions) Assets acquired: Cash $1.1 Goodwill 7.5 Amortizable intangibles 5.3 IPR&D 0.6 Inventory 0.5 Other assets 0.5 Total assets acquired $15.5 Liabilities assumed: Deferred taxes $1.5 Notes payable* 1.0 Accrued liabilities** 0.4 Total liabilities assumed $2.9 Net assets acquired $12.6 Net assets acquired as of May 31, 2024 $12.6 Less: Cash acquired 1.1 Equity awards settled 0.6 Settlement of Note payable* 1.0 Total enterprise value as of June 30, 2024 $13.1 • Represents the convertible debt which was subsequently paid in the fiscal second quarter of 2024. ** Includes $0.2 billion of equity awards The preliminary purchase price allocation is subject to any subsequent valuation adjustments within the measurement period. The goodwill is primarily attributable to synergies expected to arise from the business acquisition and is not expected to be deductible for tax purposes. Acquisition related costs before tax for the fiscal second quarter were $0.5 billion of which $0.4 billion related to equity awards and was recorded in Other (income) expense. The amortizable intangible assets were primarily comprised of already in-market CAD and PAD IVL products with the average weighted lives of 14 years. The IPR&D assets were valued for technology programs for unapproved products. The value of the IPR&D was calculated using a probability-adjusted cash flow projection discounted for the risk inherent in such projects with the weighted average probability of success factors of approximately 50%. The discount rate applied was 9.0%. During the fiscal first quarter of 2024, the Company completed the acquisition of Ambrx Biopharma, Inc., (Ambrx), a clinical-stage biopharmaceutical company with a proprietary synthetic biology technology platform to design and develop next-generation antibody drug conjugates (ADCs), in an all-cash merger transaction for a total equity value of approximately $2.0 billion, or $1.8 billion net of cash acquired. The Company acquired all of the outstanding shares of Ambrx’s common stock for $28.00 per share through a merger of Ambrx with a subsidiary of the Company. The transaction was accounted for as a business combination and the results of operations were included in the Innovative Medicine segment as of the acquisition date. The fair value of the acquisition was allocated to assets acquired of $2.3 billion, primarily non-amortizable intangible assets, inclusive of purchased IPR&D, for $1.9 billion, goodwill for $0.3 billion and liabilities assumed of $0.5 billion, which includes deferred taxes of $0.4 billion. The preliminary purchase price allocation is subject to any subsequent valuation adjustments within the measurement period. A probability of success factor ranging from 40% to 70% was used in the fair value calculation to reflect inherent regulatory and commercial risk of the IPR&D. The discount rate applied was approximately 17%. The goodwill is primarily attributable to synergies expected to arise from the business acquisition and is not expected to be deductible for tax purposes. Acquisition related costs before tax for the fiscal six months of 2024 were not material. Divestitures In the fiscal second quarter of 2024, the Company completed the divestiture of Acclarent resulting in approximately $0.3 billion in proceeds. In the fiscal first quarter of 2024, the Company completed the divestiture of Ponvory outside of the U.S. resulting in approximately $0.2 billion in proceeds. There were no material acquisitions or divestitures in the fiscal first quarter or fiscal second quarter of 2023.

Legal Proceedings

Legal Proceedings	6 Months Ended
Legal Proceedings	Jun. 30, 2024
Commitments and Contingencies Disclosure [Abstract]
Legal Proceedings	Legal Proceedings Johnson & Johnson and certain of its subsidiaries are involved in various lawsuits and claims regarding product liability; intellectual property; commercial; indemnification and other matters; governmental investigations; and other legal proceedings that arise from time to time in the ordinary course of their business. The Company records accruals for loss contingencies associated with these legal matters when it is probable that a liability will be incurred, and the amount of the loss can be reasonably estimated. As of June 30, 2024, the Company has determined that the liabilities associated with certain litigation matters are probable and can be reasonably estimated. The Company has accrued for these matters and will continue to monitor each related legal issue and adjust accruals as might be warranted based on new information and further developments in accordance with ASC 450-20-25. For these and other litigation and regulatory matters discussed below for which a loss is probable or reasonably possible, the Company is unable to estimate the possible loss or range of loss beyond the amounts accrued. Amounts accrued for legal contingencies often result from a complex series of judgments about future events and uncertainties that rely heavily on estimates and assumptions including timing of related payments. The ability to make such estimates and judgments can be affected by various factors including, among other things, whether damages sought in the proceedings are unsubstantiated or indeterminate; scientific and legal discovery has not commenced or is not complete; proceedings are in early stages; matters present legal uncertainties; there are significant facts in dispute; procedural or jurisdictional issues; the uncertainty and unpredictability of the number of potential claims; ability to achieve comprehensive multi-party settlements; complexity of related cross-claims and counterclaims; and/or there are numerous parties involved. To the extent adverse awards, judgments or verdicts have been rendered against the Company, the Company does not record an accrual until a loss is determined to be probable and can be reasonably estimated. In the Company’s opinion, based on its examination of these matters, its experience to date and discussions with counsel, the ultimate outcome of legal proceedings, net of liabilities accrued in the Company’s balance sheet, is not expected to have a material adverse effect on the Company’s financial position. However, the resolution of, or increase in accruals for, one or more of these matters in any reporting period may have a material adverse effect on the Company’s results of operations and cash flows for that period. Matters concerning talc A significant number of personal injury claims alleging that talc causes cancer have been asserted against Johnson & Johnson Consumer Inc., its successor LLT Management LLC (previously known as LTL Management LLC) and the Company arising out of the use of body powders containing talc, primarily JOHNSON’S Baby Powder. In talc cases that have gone to trial, the Company has obtained a number of defense verdicts, but there also have been verdicts against the Company, many of which have been reversed on appeal. In June 2020, the Missouri Court of Appeals reversed in part and affirmed in part a July 2018 verdict of $4.7 billion in Ingham v. Johnson & Johnson, et al., No. ED 207476 (Mo. App.), reducing the overall award to $2.1 billion. An application for transfer of the case to the Missouri Supreme Court was subsequently denied, and in June 2021, a petition for certiorari, seeking a review of the Ingham decision by the United States Supreme Court, was denied. In June 2021, the Company paid the award, which, including interest, totaled approximately $2.5 billion. The facts and circumstances, including the terms of the award, were unique to the Ingham decision and not representative of other claims brought against the Company. The Company continues to believe that it has strong legal grounds to contest the other talc verdicts that it has appealed. Notwithstanding the Company’s confidence in the safety of its talc products, in certain circumstances the Company has settled cases. In June 2014, the Mississippi Attorney General filed a complaint against the Company alleging violation of the Mississippi Consumer Protection Act by failing to disclose alleged health risks associated with female consumers’ use of talc contained in JOHNSON’S Baby Powder and JOHNSON’S Shower to Shower (a product divested in 2012). The Company has reached an agreement to resolve this matter. In January 2020, the State of New Mexico filed a consumer protection case alleging that the Company deceptively marketed and sold its talcum powder products by making misrepresentations about the safety of the products and the presence of carcinogens, including asbestos. The Company has reached an agreement to resolve this matter. Forty-two states and the District of Columbia commenced a joint investigation into the Company’s marketing of its talcum powder products. In January 2024, the Company reached an agreement in principle with the multi-state group of state Attorneys General, subject to ongoing negotiation of non-monetary terms. In June 2024, the settlements were finalized. In October 2021, Johnson & Johnson Consumer Inc. (Old JJCI) implemented a corporate restructuring (the 2021 Corporate Restructuring). As a result of that restructuring, Old JJCI ceased to exist and three new entities were created: (a) LTL Management LLC, a North Carolina limited liability company (LTL or Debtor); (b) Royalty A&M LLC, a North Carolina limited liability company and a direct subsidiary of LTL (RAM); and (c) the Debtor’s direct parent, Johnson & Johnson Consumer Inc., a New Jersey company (New JJCI). The Debtor received certain of Old JJCI’s assets and became solely responsible for the talc-related liabilities of Old JJCI, including all liabilities related in any way to injury or damage, or alleged injury or damage, sustained or incurred in the purchase or use of, or exposure to, talc, including talc contained in any product, or to the risk of, or responsibility for, any such damage or injury, except for any liabilities for which the exclusive remedy is provided under a workers’ compensation statute or act (the Talc-Related Liabilities). In October 2021, notwithstanding the Company’s confidence in the safety of its talc products, the Debtor filed a voluntary petition with the United States Bankruptcy Court for the Western District of North Carolina, Charlotte Division, seeking relief under chapter 11 of the Bankruptcy Code (the LTL Bankruptcy Case). All litigation against LTL, Old JJCI, New JJCI, the Company, other of their corporate affiliates, identified retailers, insurance companies, and certain other parties (the Protected Parties) was stayed. The LTL Bankruptcy Case was transferred to the United States Bankruptcy Court for the District of New Jersey. Claimants filed motions to dismiss the LTL Bankruptcy Case and, following a multiple day hearing, the New Jersey Bankruptcy Court denied those motions in March 2022. The claimants subsequently filed notices of appeal as to the denial of the motions to dismiss the LTL Bankruptcy Case and the extension of the stay to the Protected Parties. On January 30, 2023, the Third Circuit reversed the Bankruptcy Court’s ruling and remanded to the Bankruptcy Court to dismiss the LTL bankruptcy. In April 2023, the New Jersey Bankruptcy Court dismissed the LTL Bankruptcy Case, effectively lifting the stay as to all parties and returning the talc litigation to the tort system. LTL re-filed in the United States Bankruptcy Court for the District of New Jersey seeking relief under chapter 11 of the Bankruptcy Code (the LTL 2 Bankruptcy Case). As a result of the new filing, all talc claims against LTL were again automatically stayed pursuant to section 362 of the Bankruptcy Code. Additionally, the New Jersey Bankruptcy Court issued a temporary restraining order staying all litigation as to LTL, Old JJCI, New JJCI, the Company, identified retailers, and certain other parties (the New Protected Parties). Also in April 2023, the New Jersey Bankruptcy Court issued a decision that granted limited injunctive relief to the Company and the New Protected Parties (the LTL 2 Preliminary Injunction). The LTL 2 Preliminary Injunction remained in force until late August 2023, following the Bankruptcy Court’s extension of the initial LTL 2 Preliminary Injunction in June 2023. Under the LTL 2 Preliminary Injunction, except for in those cases filed in the federal court ovarian cancer multi-district litigation, discovery in all personal injury and wrongful death matters was permitted to proceed. Furthermore, in April 2023, the Talc Claimants' Committee filed a motion to dismiss the LTL 2 Bankruptcy followed by similar motions from other claimants. Hearings on the motions to dismiss occurred in June 2023. In July 2023, the court dismissed the LTL 2 Bankruptcy case and, the same day, the Company stated its intent to appeal the decision and to continue its efforts to obtain a resolution of the talc claims. In September 2023, the Bankruptcy Court entered an order granting LTL leave to seek a direct appeal to the Third Circuit Court of Appeals. In October 2023, the Third Circuit granted LTL’s petition for a direct appeal. Briefing is ongoing. In October 2023, the Company stated that it was pursuing the following four parallel and alternative pathways to achieve a comprehensive and final resolution of the talc claims: (i) the appeal of the LTL 2 dismissal decision; (ii) pursuing a consensual “prepackaged” bankruptcy case, as “strongly encouraged” by the Bankruptcy Court in its dismissal decision; (iii) aggressively litigating the talc claims in the tort system; and (iv) pursuing affirmative claims against experts for false and defamatory narratives regarding the Company’s talc powder products. Following the dismissal of LTL 2, new lawsuits were filed, cases across the country that had been stayed were reactivated, and trials have commenced. The majority of the cases are pending in federal court, organized in a multi-district litigation (MDL) in the United States District Court for the District of New Jersey. In the MDL, case-specific discovery is proceeding and a trial is scheduled to occur in December 2024. In March 2024, the court granted the Company's motion for a renewed Daubert hearing prior to the trial. On May 1, 2024, the Company commenced a three-month solicitation period of its proposed consensual “prepackaged” chapter 11 bankruptcy plan (the “Proposed Plan”) for the comprehensive and final resolution of all current and future claims related to cosmetic talc in the United States, excluding claims related to mesothelioma or State consumer protection claims, in exchange for the payment by the Company of present value of approximately $6.475 billion payable over 25 years (nominal value of approximately $8.0 billion, discounted at a rate of 4.4%). The claims encompassed by the Proposed Plan constitute 99.75% of pending lawsuits against the Company relating to its talc powder products. Mesothelioma and State consumer protection claims are being addressed outside the Proposed Plan. The Company separately has resolved 95% of the mesothelioma lawsuits filed to date and has resolved the State claims. To account for these settlements and the contemplated comprehensive resolution through the Proposed Plan, the Company recorded an incremental charge of approximately $3.0 billion, through the second fiscal quarter 2024. As of June 30, 2024, the total present value of the reserve is approximately $10.6 billion (or nominal value of approximately $12.8 billion), net of payments made in fiscal 2024. Approximately one-third of the reserve is recorded as a current liability. The recorded amount remains the Company's best estimate of probable loss. During the pendency of the solicitation period, the Company will continue to pursue in parallel the other three previously-announced pathways to resolve the talc claims, including proceeding with the Daubert motions in the MDL. In February 2019, the Company’s talc supplier, Imerys Talc America, Inc. and two of its affiliates, Imerys Talc Vermont, Inc. and Imerys Talc Canada, Inc. (collectively, Imerys) filed a voluntary petition for relief under chapter 11 of the United States Code (the Bankruptcy Code) in the United States Bankruptcy Court for the District of Delaware (Imerys Bankruptcy). The Imerys Bankruptcy relates to Imerys’s potential liability for personal injury from exposure to talcum powder sold by Imerys. In its bankruptcy, Imerys alleges it has claims against the Company for indemnification and rights to joint insurance proceeds. In its bankruptcy, Imerys proposed a chapter 11 plan (the Imerys Plan) that contemplated all talc-related claims against it being channeled to a trust along with its alleged indemnification rights against the Company. Following confirmation and consummation of the plan, the trust would pay talc claims pursuant to proposed trust distribution procedures (the TDP) and then seek indemnification from the Company. In February 2021, Cyprus Mines Corporation (Cyprus), which had owned certain Imerys talc mines, filed a voluntary petition for relief under chapter 11 of the Bankruptcy Code and filed its Disclosure Statement and Plan (the Cyprus Plan). The Cyprus Plan contemplates a settlement with Imerys and talc claimants where Cyprus would make a monetary contribution to a trust established under the Imerys Plan in exchange for an injunction against talc claims asserted against it and certain affiliated parties. In September 2023, Imerys and Cyprus filed amended plans of reorganization. The amended plans contemplate a similar construct as the prior Imerys and Cyprus Plans, including all talc claims against Imerys and Cyprus (and certain other protected parties) being channeled to a trust along with Imerys’s and Cyprus’s alleged indemnification rights against the Company. In January 2024, Imerys and Cyprus each filed a disclosure statement for its respective Chapter 11 plans. On April 29, 2024, the Company, Imerys and Cyprus reached an agreement in principle on monetary and non-monetary terms to resolve their ongoing disputes, including disputes raised in the Imerys and Cyprus bankruptcies. The parties have finalized the agreement, which will be submitted to the Bankruptcy Court for approval on August 15, 2024. Imerys and Cyprus have adjourned the hearing on their respective disclosure statements pending submission of the agreement to the court. In February 2018, a securities class action lawsuit was filed against the Company and certain named officers in the United States District Court for the District of New Jersey, alleging that the Company violated the federal securities laws by failing to disclose alleged asbestos contamination in body powders containing talc, primarily JOHNSON’S Baby Powder, and that purchasers of the Company’s shares suffered losses as a result. In April 2019, the Company moved to dismiss the complaint. In December 2019, the Court denied, in part, the motion to dismiss. In April 2021, briefing on Plaintiff’s motion for class certification was completed. The case was stayed in May 2022 pursuant to the LTL Bankruptcy Case and was reopened in May 2023. In December 2023, the Court granted Plaintiff’s motion for class certification. In January 2024, Defendants filed a petition with the Third Circuit under Federal Rule of Civil Procedure 23(f) for permission to appeal the Court’s order granting class certification, and in February 2024, the Third Circuit granted Defendants' petition. In February 2024, fact discovery closed, the Court ordered the parties to mediate, and stayed the case pending mediation. In May 2024, the parties participated in an unsuccessful mediation. In June 2024, the parties requested that the case remain stayed, except for certain limited discovery, pending a decision from the Third Circuit on the 23(f) petition. A lawsuit was brought against the Company in the Superior Court of California for the County of San Diego alleging violations of California’s Consumer Legal Remedies Act (CLRA) relating to JOHNSON’S Baby Powder. In that lawsuit, the plaintiffs allege that the Company violated the CLRA by failing to provide required Proposition 65 warnings. The Company removed the lawsuit to the United States District Court for the Southern District of California. In January 2021, the court granted the Company's motion to dismiss plaintiffs' Fifth Amended Complaint with prejudice. On April 29, 2024, the Ninth Circuit affirmed the District Court's order dismissing the case with prejudice. In addition, the Company has received inquiries, subpoenas, and requests to produce documents regarding talc matters and the LTL Bankruptcy Case from various governmental authorities. The Company has produced documents and responded to inquiries, and will continue to cooperate with government inquiries. Matters concerning opioids Beginning in 2014 and continuing to the present, the Company and Janssen Pharmaceuticals, Inc. (JPI), along with other pharmaceutical companies, have been named in close to 3,500 lawsuits related to the marketing of opioids, including DURAGESIC, NUCYNTA and NUCYNTA ER. The majority of the cases were filed by state and local governments, which were subject to a final settlement in 2021. As of January 2024, the Company and JPI have settled or otherwise resolved the opioid claims advanced by all government entity claimants except the City of Baltimore, a number of school districts, and other claimants. Similar lawsuits have also been filed by private plaintiffs and organizations, including but not limited to the following: individual plaintiffs on behalf of children born with Neonatal Abstinence Syndrome (NAS); hospitals; and health insurers/payors. To date, the Company and JPI have litigated two of the cases to judgment and have prevailed in both, either at trial or on appeal. In July 2021, the Company announced finalization of an agreement to settle all remaining state and subdivision claims for up to $5.0 billion. Approximately 70% of the all-in settlement was paid by the end of fiscal second quarter 2024. The Company and JPI continue to defend the cases brought by the remaining government entity litigants as well as the cases brought by private litigants, including NAS claimants, and health insurers/payors. Counting the private litigant cases, there are approximately 20 remaining opioid cases against the Company and JPI in various state courts, 420 remaining cases in the Ohio MDL, and 3 additional cases in other federal courts. Some of these cases have been dismissed and are being appealed by the plaintiffs and certain others are scheduled for trial in 2024, 2025, or 2026. In addition, the Province of British Columbia filed suit against the Company and its Canadian affiliate Janssen Inc., and many other industry members, in Canada, and is seeking to have that action certified as an opt in class action on behalf of other provincial/territorial and the federal governments in Canada. Additional proposed class actions have been filed in Canada against the Company and Janssen Inc., and many other industry members, by and on behalf of people who used opioids (for personal injuries), municipalities and First Nations bands. The proposed class action in Quebec on behalf of residents diagnosed with opioid use disorder was authorized to proceed against Janssen Inc. and other industry members in April 2024; leave to appeal has been sought. These actions allege a variety of claims related to opioid marketing practices, including false advertising, unfair competition, public nuisance, consumer fraud violations, deceptive acts and practices, false claims and unjust enrichment. An adverse judgment in any of these lawsuits could result in the imposition of large monetary penalties and significant damages including, punitive damages, cost of abatement, substantial fines, equitable remedies and other sanctions. In November 2019, a shareholder filed a derivative complaint against the Company as the nominal defendant and certain current and former directors and officers as defendants in the Superior Court of New Jersey. The complaint alleges breaches of fiduciary duties related to the marketing of opioids, and that the Company has suffered damages as a result of those alleged breaches. A series of additional derivative complaints making similar allegations against the same and similar defendants were filed in New Jersey state and federal courts in 2019 and 2020. By 2022, all but two state court cases had been voluntarily dismissed. In February 2022, the state court granted the Company’s motion to dismiss one of the two cases, and the shareholder that brought the second case filed a notice of dismissal. The shareholder whose complaint was dismissed appealed the state court’s dismissal order, and briefing on the appeal concluded in October 2022. In February 2024, the appellate court affirmed the dismissal of the shareholder's amended complaint. In March 2024, the shareholder filed a notice of petition for certification with the Supreme Court of New Jersey seeking review of the appellate court's decision. In May 2024, briefing on the shareholder's petition for certification concluded. Product liability The Company and certain of its subsidiaries are involved in numerous product liability claims and lawsuits involving multiple products. Claimants in these cases seek substantial compensatory and, where available, punitive damages. While the Company believes it has substantial defenses, it is not feasible to predict the ultimate outcome of litigation. From time to time, even if it has substantial defenses, the Company considers isolated settlements based on a variety of circumstances. The Company has accrued for these matters and will continue to monitor each related legal issue and adjust accruals as might be warranted based on new information and further developments in accordance with ASC 450-20-25, Contingencies. The Company accrues an estimate of the legal defense costs needed to defend each matter when those costs are probable and can be reasonably estimated. For certain of these matters, the Company has accrued additional amounts such as estimated costs associated with settlements, damages and other losses. Product liability accruals can represent projected product liability for thousands of claims around the world, each in different litigation environments and with different fact patterns. Changes to the accruals may be required in the future as additional information becomes available. The table below contains the most significant of these cases and provides the approximate number of plaintiffs in the United States with direct claims in pending lawsuits regarding injuries allegedly due to the relevant product or product category as of June 30, 2024: Product or product category Number of plaintiffs Body powders containing talc, primarily JOHNSON’S Baby Powder 62,370 DePuy ASR XL Acetabular System and DePuy ASR Hip Resurfacing System 160 PINNACLE Acetabular Cup System 910 Pelvic meshes 6,230 ETHICON PHYSIOMESH Flexible Composite Mesh 170 RISPERDAL 20 ELMIRON 2,170 The number of pending lawsuits is expected to fluctuate as certain lawsuits are settled or dismissed and additional lawsuits are filed. There may be additional claims that have not yet been filed. MedTech DePuy ASR XL acetabular system and ASR Hip resurfacing system In August 2010, DePuy Orthopaedics, Inc. (DePuy) announced a worldwide voluntary recall of its ASR XL Acetabular System and DePuy ASR Hip Resurfacing System (ASR Hip) used in hip replacement surgery. Claims for personal injury have been made against DePuy and the Company. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Ohio. Litigation has also been filed in countries outside of the United States, primarily in the United Kingdom, Canada, Australia, Ireland, Germany, India and Italy. In November 2013, DePuy reached an agreement with a Court-appointed committee of lawyers representing ASR Hip plaintiffs to establish a program to settle claims with eligible ASR Hip patients in the United States who had surgery to replace their ASR Hips, known as revision surgery, as of August 2013. DePuy reached additional agreements in February 2015 and March 2017, which further extended the settlement program to include ASR Hip patients who had revision surgeries after August 2013 and prior to February 15, 2017. This settlement program has resolved more than 10,000 claims, thereby bringing to resolution significant ASR Hip litigation activity in the United States. However, lawsuits in the United States remain, and the settlement program does not address litigation outside of the United States. In Australia, a class action settlement was reached that resolved the claims of the majority of ASR Hip patients in that country. In Canada, the Company has reached agreements to settle the class actions filed in that country. The Company continues to receive information with respect to potential additional costs associated with this recall on a worldwide basis. The Company has established accruals for the costs associated with the United States settlement program and ASR Hip-related product liability litigation. DePuy PINNACLE Acetabular Cup System Claims for personal injury have also been made against DePuy Orthopaedics, Inc. and the Company (collectively, DePuy) relating to the PINNACLE Acetabular Cup System used in hip replacement surgery. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. Most cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Texas (Texas MDL). Beginning on June 1, 2022, the Judicial Panel on Multidistrict Litigation ceased transfer of new cases into the Texas MDL, and there are now cases pending in federal court outside the Texas MDL. Litigation also has been filed in state courts and in countries outside of the United States. During the first quarter of 2019, DePuy established a United States settlement program to resolve these cases. As part of the settlement program, adverse verdicts have been settled. The Company has established an accrual for product liability litigation associated with the PINNACLE Acetabular Cup System and the related settlement program. Ethicon Pelvic Mesh Claims for personal injury have been made against Ethicon, Inc. (Ethicon) and the Company arising out of Ethicon’s pelvic mesh devices used to treat stress urinary incontinence and pelvic organ prolapse. The Company continues to receive information with respect to potential costs and additional cases. Cases filed in federal courts in the United States had been organized as a multi-district litigation (MDL) in the United States District Court for the Southern District of West Virginia. In March 2021, the MDL Court entered an order closing the MDL. The MDL Court has remanded cases for trial to the jurisdictions where the case was originally filed and additional pelvic mesh lawsuits have been filed, and remain, outside of the MDL. The Company has settled or otherwise resolved the majority of the United States cases and the estimated costs associated with these settlements and the remaining cases are reflected in the Company’s accruals. In addition, class actions and individual personal injury cases or claims seeking damages for alleged injury resulting from Ethicon’s pelvic mesh devices have been commenced in various countries outside of the United States, including claims and cases in the United Kingdom, the Netherlands, and Ireland, and class actions in Israel, Australia, Canada and South Africa. The vast majority of these actions are now resolved. The Company has established accruals with respect to product liability litigation associated with Ethicon’s pelvic mesh products. Ethicon Physiomesh Following a June 2016 worldwide market withdrawal of Ethicon Physiomesh Flexible Composite Mesh (Physiomesh), claims for personal injury have been made against Ethicon, Inc. (Ethicon) and the Company alleging personal injury arising out of the use of this hernia mesh device. Cases filed in federal courts in the United States have been organized as a multi-district litigation (MDL) in the United States District Court for the Northern District of Georgia. A multi-county litigation (MCL) also has been formed in New Jersey state court and assigned to Atlantic County for cases pending in New Jersey. In addition to the matters in the MDL and MCL, there are additional lawsuits pending in the United States District Court for the Southern District of Ohio, which are part of the MDL for polypropylene mesh devices manufactured by C.R. Bard, Inc., and lawsuits pending in two New Jersey MCLs formed for Proceed/Proceed Ventral Patch and Prolene Hernia systems, and lawsuits pending outside the United States. In May 2021, Ethicon and lead counsel for the plaintiffs entered into a term sheet to resolve approximately 3,600 Physiomesh cases (covering approximately 4,300 plaintiffs) pending in the MDL and MCL at that time. A master settlement agreement (MSA) was entered into in September 2021 and includes 3,729 cases in the MDL and MCL. Other than a small number of cases still pending in the MDL, all Physiomesh matters in the United States have been resolved or are undergoing formal review for purposes of settlement. Claims have also been filed against Ethicon and the Company alleging personal injuries arising from the PROCEED Mesh and PROCEED Ventral Patch hernia mesh products. In March 2019, the New Jersey Supreme Court entered an order consolidating these cases pending in New Jersey as an MCL in Atlantic County Superior Court. Additional cases have been filed in various federal and state courts in the United States, and in jurisdictions outside the United States. Ethicon and the Company also have been subject to claims for personal injuries arising from the PROLENE Polypropylene Hernia System. In January 2020, the New Jersey Supreme Court created an MCL in Atlantic County Superior Court to handle such cases. Cases involving this product have also been filed in other federal and state courts in the United States. In October 2022, an agreement in principle, subject to various conditions, was reached to settle the majority of the pending cases involving Proceed, Proceed Ventral Patch, Prolene Hernia System and related multi-layered mesh products, as well as a number of unfiled claims. All litigation activities in the two New Jersey MCLs are stayed pending effectuation of the proposed settlement. Future cases that are filed in the New Jersey MCLs will be subject to docket control orders requiring early expert reports and discovery requirements. The Company has established accruals with respect to product liability litigation associated with Ethicon Physiomesh Flexible Composite Mesh, PROCEED Mesh and PROCEED Ventral Patch, and PROLENE Polypropylene Hernia System products. Innovative Medicine RISPERDAL Claims for personal injury have been made against Janssen Pharmaceuticals, Inc. and the Company arising out of the use of RISPERDAL, and related compounds, indicated for the treatment of schizophrenia, acute manic or mixed episodes associated with bipolar I disorder and irritability associated with autism. Lawsuits primarily have been filed in state courts in Pennsylvania, California, and Missouri. Other actions are pending in various courts in the United States and Canada. The Company continues to defend RISPERDAL product liability lawsuits, and continues to evaluate potential costs related to those claims. The Company has successfully defended a number of these cases but there have been verdicts against the Company, including a verdict in October 2019 of $8.0 billion of punitive damages related to one plaintiff, which the trial judge reduced to $6.8 million in January 2020. In September 2021, the Company entered into a settlement in principle with the counsel representing plaintiffs in this matter and in substantially all of the outstanding cases in the United States. The costs associated with this and other settlements are reflected in the Company’s accruals. ELMIRON Claims for personal injury have be

Kenvue Separation

Kenvue Separation	6 Months Ended
Kenvue Separation	Jun. 30, 2024
Discontinued Operations and Disposal Groups [Abstract]
Kenvue Separation	Kenvue separation The results of the Consumer Health business (previously reported as a separate business segment) have been reflected as discontinued operations in the Company’s consolidated statements of earnings as Net earnings from discontinued operations, net of taxes through August 23, 2023, the date of the exchange offer. Prior periods have been recast to reflect this presentation. Details of Net Earnings from Discontinued Operations, net of taxes are as follows: Fiscal Second Quarter Ended Fiscal Six Months Ended (Dollars in Millions) July 2, 2023 July 2, 2023 Sales to customers $4,011 $7,863 Cost of products sold 1,750 3,458 Gross profit 2,261 4,405 Selling, marketing and administrative expenses 1,269 2,501 Research and development expense 126 234 Interest Income (42) (79) Interest expense, net of portion capitalized 128 131 Other (income) expense, net 324 612 Earnings from Discontinued Operations Before Provision for Taxes on Income 456 1,006 Provision for taxes on income 688 815 Net (loss)/earnings from Discontinued Operations $(232) $191 The following table presents depreciation, amortization and capital expenditures of the discontinued operations related to Kenvue: Fiscal Second Quarter Ended Fiscal Six Months Ended (Dollars in Millions) July 2, 2023 July 2, 2023 Depreciation and Amortization $149 $302 Capital expenditures $92 $139

Restructuring

Restructuring	6 Months Ended
Restructuring	Jun. 30, 2024
Restructuring and Related Activities [Abstract]
Restructuring	Restructuring In fiscal 2023, the Company completed a prioritization of its research and development (R&D) investment within its Innovative Medicine segment to focus on the most promising medicines with the greatest benefit to patients. This resulted in the exit of certain programs within certain therapeutic areas. The R&D program exits are primarily in infectious diseases and vaccines including the discontinuation of its respiratory syncytial virus (RSV) adult vaccine program, hepatitis and HIV development. Pre-tax Restructuring income of $0.1 billion in the fiscal second quarter of 2024 and $0.1 billion of expense in the fiscal six months of 2024, included asset divestments, the termination of partnered and non-partnered development program costs and asset impairments. The pre-tax restructuring charge of approximately $0.1 billion and $0.3 billion in the fiscal second quarter and fiscal six months of 2023, respectively, included the termination of partnered and non-partnered program costs and asset impairments. Total project costs of approximately $0.6 billion have been recorded since the restructuring was announced. The majority of this restructuring program is completed, with minor charges expected in the remainder of year. In fiscal 2023, the Company initiated a restructuring program of its Orthopaedics franchise within its MedTech segment to streamline operations by exiting certain markets, product lines and distribution network arrangements. The pre-tax restructuring expense of $0.1 billion and $0.1 billion in the fiscal second quarter and fiscal six months of 2024, respectively, primarily included costs related to market and product exits. Total project costs of approximately $0.4 billion have been recorded since the restructuring was announced. The estimated costs of the total program are between $0.7 billion - $0.8 billion and is expected to be completed by the end of fiscal year 2025. The following table summarizes the restructuring (income) expenses for 2024: (Pre-tax Dollars in Millions) Fiscal Second Quarter Ended Fiscal Six Months Ended Innovative Medicine Segment (1) $(63) 81 MedTech Segment (2) 52 79 Total Programs $(11) 160 (1) Included in Restructuring on the Consolidated Statement of Earnings (2) The fiscal second quarter of 2024 included $50 million in Restructuring and $2 million in Cost of products sold on the Consolidated Statement of Earnings. The fiscal six months of 2024 included $70 million in Restructuring and $9 million in Cost of products sold on the Consolidated Statement of Earnings. Restructuring reserves as of June 30, 2024 and December 31, 2023 were insignificant.

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Millions	3 Months Ended		6 Months Ended
Pay vs Performance Disclosure - USD ($) $ in Millions	Jun. 30, 2024	Jul. 02, 2023	Jun. 30, 2024	Jul. 02, 2023
Pay vs Performance Disclosure
Net earnings	$ 4,686	$ 5,144	$ 7,941	$ 5,076

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
Insider Trading Arrangements	Jun. 30, 2024
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	6 Months Ended
Summary of Significant Accounting Policies (Policies)	Jun. 30, 2024
Accounting Policies [Abstract]
New and Recently Adopted Accounting Standards	New accounting standards The Company assesses the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board on the Company's financial statements as well as material updates to previous assessments, if any, from the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023. Recently adopted accounting standards There were no new material accounting standards adopted in the fiscal six months in 2024. Recently issued accounting standards Not adopted as of June 30, 2024 ASU 2023-07: Segment Reporting (Topic 280) – Improvements to Reportable Segment Disclosures This update requires expanded annual and interim disclosures for significant segment expenses that are regularly provided to the chief operating decision maker and included within each reported measure of segment profit or loss. This update will be effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. This standard is to be applied retrospectively to all periods presented in the financial statements. Early adoption is permitted. While this accounting standard will increase disclosures, it will not have a material impact on the Company’s Consolidated Financial Statement results. ASU 2023-09: Income Taxes (Topic 740) - Improvements to Income Tax Disclosures This update standardizes categories for the effective tax rate reconciliation, requires disaggregation of income taxes and additional income tax-related disclosures. This update is required to be effective for the Company for fiscal periods beginning after December 15, 2024. While this accounting standard will increase disclosures, it will not have a material impact on the Company’s Consolidated Financial Statement results. There were no new material accounting standards issued in the fiscal second quarter of 2024.
Cash and Cash Equivalents	The Company classifies all highly liquid investments with stated maturities of three months or less from date of purchase as cash equivalents and all highly liquid investments with stated maturities of greater than three months from the date of purchase as current marketable securities. Available for sale securities with stated maturities of greater than one year from the date of purchase are available to fund current operations and are classified as either cash equivalents or current marketable securities.

Inventories (Tables)

Inventories (Tables)	6 Months Ended
Inventories (Tables)	Jun. 30, 2024
Inventory Disclosure [Abstract]
Summary of Inventories	(Dollars in Millions) June 30, 2024 December 31, 2023 Raw materials and supplies $2,407 2,355 Goods in process 2,556 1,952 Finished goods 7,206 6,874 Total inventories $12,169 11,181

Intangible Assets and Goodwill

Intangible Assets and Goodwill (Tables)	6 Months Ended
Intangible Assets and Goodwill (Tables)	Jun. 30, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets and Goodwill	(Dollars in Millions) June 30, 2024 December 31, 2023 Intangible assets with definite lives: Patents and trademarks — gross $43,438 40,417 Less accumulated amortization (24,835) (24,808) Patents and trademarks — net 18,603 15,609 Customer relationships and other intangibles — gross 20,176 20,322 Less accumulated amortization (13,018) (12,685) Customer relationships and other intangibles — net (1) 7,158 7,637 Intangible assets with indefinite lives: Trademarks 1,655 1,714 Purchased in-process research and development 12,309 9,215 Total intangible assets with indefinite lives 13,964 10,929 Total intangible assets — net $39,725 34,175 (1) The majority is comprised of customer relationships
Goodwill	Goodwill as of June 30, 2024 was allocated by segment of business as follows: (Dollars in Millions) Innovative Medicine MedTech Total Goodwill at December 31, 2023 $10,407 26,151 36,558 Goodwill, related to acquisitions 563 7,494 8,057 Goodwill, related to divestitures — (56) (56) Currency translation/Other (202) (107) (309) Goodwill at June 30, 2024 $10,768 33,482 44,250
Intangible Asset Amortization Expense	The estimated amortization expense for approved products, before tax, for the five succeeding years is approximately: (Dollars in Millions) 2024 2025 2026 2027 2028 $4,500 3,900 3,300 2,700 2,000

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	6 Months Ended
Fair Value Measurements (Tables)	Jun. 30, 2024
Fair Value Disclosures [Abstract]
Summary of Derivative Activity	The following table is a summary of the activity related to derivatives and hedges for the fiscal second quarters ended June 30, 2024 and July 2, 2023, net of tax: June 30, 2024 July 2, 2023 (Dollars in Millions) Sales Cost of Products Sold R&D Expense Interest (Income) Expense Other (Income) Expense Sales Cost of Products Sold R&D Expense Interest (Income) Expense Other (Income) Expense The effects of fair value, net investment and cash flow hedging: Gain (Loss) on fair value hedging relationship: Interest rate swaps contracts: Hedged items $— — — (53) — — — — (175) — Derivatives designated as hedging instruments — — — 53 — — — — 175 — Gain (Loss) on net investment hedging relationship: Cross currency interest rate swaps contracts: Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing — — — 33 — — — — 33 — Amount of gain or (loss) recognized in AOCI — — — 33 — — — — 33 — Gain (Loss) on cash flow hedging relationship: Forward foreign exchange contracts: Amount of gain or (loss) reclassified from AOCI into income (1) 94 8 — 3 (15) 56 (12) — 3 Amount of gain or (loss) recognized in AOCI 2 66 11 — 1 (14) 251 7 — 18 Cross currency interest rate swaps contracts: Amount of gain or (loss) reclassified from AOCI into income — — — 42 — — — — 74 — Amount of gain or (loss) recognized in AOCI $— — — (38) — — — — (432) — The following table is a summary of the activity related to derivatives and hedges for the fiscal six months ended June 30, 2024 and July 2, 2023, net of tax: June 30, 2024 July 2, 2023 (Dollars in Millions) Sales Cost of Products Sold R&D Expense Interest (Income) Expense Other (Income) Expense Sales Cost of Products Sold R&D Expense Interest (Income) Expense Other (Income) Expense The effects of fair value, net investment and cash flow hedging: Gain (Loss) on fair value hedging relationship: Interest rate swaps contracts: Hedged items $— — — (45) — — — — (6) — Derivatives designated as hedging instruments — — — 45 — — — — 6 — Gain (Loss) on net investment hedging relationship: Cross currency interest rate swaps contracts: Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing — — — 67 — — — — 67 — Amount of gain or (loss) recognized in AOCI — — — 67 — — — — 67 — Gain (Loss) on cash flow hedging relationship: Forward foreign exchange contracts: Amount of gain or (loss) reclassified from AOCI into income — 259 12 — 1 (3) (90) (25) — 5 Amount of gain or (loss) recognized in AOCI (1) 47 33 — 5 10 396 (29) — 4 Cross currency interest rate swaps contracts: Amount of gain or (loss) reclassified from AOCI into income — — — 91 — — — — 182 — Amount of gain or (loss) recognized in AOCI $— — — (243) — — — — (15) — The following table is the effect of net investment hedges for the fiscal second quarters ended in 2024 and 2023: Gain/(Loss) Recognized In Accumulated OCI Location of Gain or (Loss) Reclassified from Accumulated Other Comprehensive Income Into Income Gain/(Loss) Reclassified From (Dollars in Millions) June 30, 2024 July 2, 2023 June 30, 2024 July 2, 2023 Debt $46 11 Interest (income) expense — — Cross Currency interest rate swaps $92 (24) Interest (income) expense — — The following table is the effect of net investment hedges for the fiscal six months ended in 2024 and 2023: Gain/(Loss) Location of Gain or (Loss) Reclassified from Accumulated Other Comprehensive Income Into Income Gain/(Loss) Reclassified From (Dollars in Millions) June 30, 2024 July 2, 2023 June 30, 2024 July 2, 2023 Debt $130 (66) Interest (income) expense — — Cross Currency interest rate swaps $820 666 Interest (income) expense — —
Schedule of Derivative Financial Instruments and Classification on Consolidated Balance Sheet	As of June 30, 2024, and December 31, 2023, the following amounts were recorded on the Consolidated Balance Sheet related to cumulative basis adjustment for fair value hedges: Line item in the Consolidated Balance Sheet in which the hedged item is included Carrying Amount of the Hedged Liability Cumulative Amount of Fair Value Hedging Gain/ (Loss) Included in the Carrying Amount of the Hedged Liability (Dollars in Millions) June 30, 2024 December 31, 2023 June 30, 2024 December 31, 2023 Long-term Debt $8,812 8,862 (1,274) (1,216)
Schedule of Effect of Derivatives not Designated as Hedging Instruments	The following table is the effect of derivatives not designated as hedging instruments for the fiscal second quarters ended 2024 and 2023: Gain/(Loss) Gain/(Loss) (Dollars in Millions) Location of Gain /(Loss) Recognized in Income on Derivative Fiscal Second Quarter Ended Fiscal Six Months Ended Derivatives Not Designated as Hedging Instruments June 30, 2024 July 2, 2023 June 30, 2024 July 2, 2023 Foreign Exchange Contracts Other (income) expense $20 33 45 2
Summary of Activity Related to Equity Investments	The following table is a summary of the activity related to equity investments: December 31, 2023 June 30, 2024 (Dollars in Millions) Carrying Value Changes in Fair Value Reflected in Net Income (1) (Sales)/ Purchases/Other (2) Carrying Value Non Current Other Assets Equity Investments with readily determinable value* $4,473 (4) (3,999) 470 470 Equity Investments without readily determinable value $696 (15) (8) 673 673 (1) Recorded in Other (income)/expense, net (2) Other includes impact of currency
Financial Assets and Liabilities at Fair Value	The Company’s significant financial assets and liabilities measured at fair value as of June 30, 2024 and December 31, 2023 were as follows: June 30, 2024 December 31, 2023 (Dollars in Millions) Level 1 Level 2 Level 3 Total Total (1) Derivatives designated as hedging instruments: Assets: Forward foreign exchange contracts $— 523 — 523 539 Interest rate contracts (2) — 1,392 — 1,392 988 Total — 1,915 — 1,915 1,527 Liabilities: Forward foreign exchange contracts — 512 — 512 624 Interest rate contracts (2) — 3,874 — 3,874 5,338 Total — 4,386 — 4,386 5,962 Derivatives not designated as hedging instruments: Assets: Forward foreign exchange contracts — 27 — 27 64 Liabilities: Forward foreign exchange contracts — 19 — 19 75 Other Investments: Equity investments (3) 470 — — 470 4,473 Debt securities (4) — 6,840 — 6,840 8,874 Other Liabilities Contingent consideration (5) $— — 1,248 1,248 1,092 Gross to Net Derivative Reconciliation June 30, 2024 December 31, 2023 (Dollars in Millions) Total Gross Assets $1,942 1,591 Credit Support Agreement (CSA) (1,911) (1,575) Total Net Asset 31 16 Total Gross Liabilities 4,405 6,037 Credit Support Agreement (CSA) (4,229) (5,604) Total Net Liabilities $176 433 Summarized information about changes in liabilities for contingent consideration for the fiscal second quarters ended June 30, 2024 and July 2, 2023 is as follows: June 30, 2024 July 2, 2023 (Dollars in Millions) Beginning Balance $1,092 1,120 Changes in estimated fair value (6) 44 25 Additions 112 — Payments — (3) Ending Balance $1,248 1,142 (1) 2023 assets and liabilities are all classified as Level 2 with the exception of equity investments of $4,473 million, which are classified as Level 1 and contingent consideration of $1,092 million, classified as Level 3. (2) Includes cross currency interest rate swaps and interest rate swaps. (3) Classified as non-current other assets. (4) Classified within cash equivalents and current marketable securities. (5) Classified as non-current other liabilities as of June 30, 2024 and December 31, 2023, respectively. (6)
Marketable Securities	The Company's cash, cash equivalents and current marketable securities as of June 30, 2024 comprised: (Dollars in Millions) Carrying Amount Unrealized Gain Estimated Fair Value Cash & Cash Equivalents Current Marketable Securities Cash $4,247 — 4,247 4,247 — U.S. Gov't securities — — — — — Non-U.S. sovereign securities 150 — 150 150 — U.S. reverse repurchase agreements 8,496 — 8,496 8,496 — Corporate debt securities (1) — — — — — Money market funds 4,883 — 4,883 4,883 — Time deposits (1) 859 — 859 859 — Subtotal 18,635 — 18,635 18,635 — U.S. Gov’t securities 6,585 — 6,585 6,182 403 U.S. Gov’t Agencies 11 — 11 — 11 Other sovereign securities 2 — 2 — 2 Corporate debt securities 242 — 242 61 181 Subtotal available for sale debt (2) $6,840 — 6,840 6,243 597 Total cash, cash equivalents and current marketable securities $25,475 — 25,475 24,878 597 (1) Held to maturity investments are reported at amortized cost and gains or losses are reported in earnings. (2) Available for sale debt securities are reported at fair value with unrealized gains and losses reported net of taxes in other comprehensive income.
Schedule of Available for Sale Securities Maturities	The contractual maturities of the available for sale securities as of June 30, 2024 are as follows: (Dollars in Millions) Cost Basis Fair Value Due within one year $6,821 6,821 Due after one year through five years 19 19 Due after five years through ten years — — Total debt securities $6,840 6,840
Financial Liabilities not Measured at Fair Value	Financial instruments not measured at fair value The following financial liabilities are held at carrying amount on the consolidated balance sheet as of June 30, 2024: (Dollars in Millions) Carrying Amount Estimated Fair Value Financial Liabilities Current Debt $9,855 9,835 Non-Current Debt 0.55% Notes due 2025 973 950 2.46% Notes due 2026 1,998 1,921 2.95% Notes due 2027 902 955 0.95% Notes due 2027 1,430 1,334 2.90% Notes due 2028 1,497 1,418 1.150% Notes due 2028 (750MM Euro 1.0721) 801 744 4.80% Notes due 2029 (1) 1,145 1,161 6.95% Notes due 2029 298 332 1.30% Notes due 2030 1,626 1,445 4.90% Notes due 2031 (1) 1,145 1,161 3.20% Notes due 2032 (700MM Euro 1.0721) (1) 747 750 4.95% Notes due 2033 499 513 4.375% Notes due 2033 854 835 4.95% Notes due 2034 (1) 846 860 1.650% Notes due 2035 (1.5B Euro 1.0721) 1,597 1,384 3.35% Notes due 2036 (800MM Euro 1.0721) (1) 852 853 3.587% Notes due 2036 855 876 5.95% Notes due 2037 994 1,089 3.625% Notes due 2037 1,346 1,310 3.40% Notes due 2038 993 839 5.85% Notes due 2038 697 756 4.50% Notes due 2040 541 521 2.10% Notes due 2040 836 670 4.85% Notes due 2041 297 293 4.50% Notes due 2043 496 470 3.55% Notes due 2044 (1.0B Euro 1.0721) (1) 1,062 1,062 3.73% Notes due 2046 1,978 1,609 3.75% Notes due 2047 816 805 3.50% Notes due 2048 743 579 2.25% Notes due 2050 807 593 5.25% Notes due 2054 (1) 843 854 2.45% Notes due 2060 1,055 707 Other 67 67 Total Non-Current Debt $31,636 29,716 (1)

Pensions and Other Benefit Pl_2

Pensions and Other Benefit Plans (Tables)	6 Months Ended
Pensions and Other Benefit Plans (Tables)	Jun. 30, 2024
Retirement Benefits [Abstract]
Components of Net Periodic Benefit Cost	Components of net periodic benefit cost Net periodic benefit costs for the Company’s defined benefit retirement plans and other benefit plans include the following components: Fiscal Second Quarter Ended Fiscal Six Months Ended Retirement Plans Other Benefit Plans Retirement Plans Other Benefit Plans (Dollars in Millions) June 30, 2024 July 2, 2023 June 30, 2024 July 2, 2023 June 30, 2024 July 2, 2023 June 30, 2024 July 2, 2023 Service cost $222 215 69 69 446 425 138 137 Interest cost 351 371 52 55 703 723 104 109 Expected return on plan assets (639) (694) (1) (2) (1,281) (1,362) (3) (3) Amortization of prior service cost/(credit) (46) (46) (1) (1) (92) (92) (1) (1) Recognized actuarial (gains)/losses 44 (50) 13 7 87 (100) 26 13 Curtailments and settlements (8) — — — (8) — — — Net periodic benefit cost/(credit) $(76) (204) 132 128 (145) (406) 264 255

Accumulated Other Comprehensi_2

Accumulated Other Comprehensive Income (Tables)	6 Months Ended
Accumulated Other Comprehensive Income (Tables)	Jun. 30, 2024
Equity [Abstract]
Components of Accumulated Other Comprehensive Income	Components of other comprehensive income/(loss) consist of the following: (Dollars in Millions) Foreign Currency Translation Gain/ (Loss) On Securities Employee Benefit Plans Gain/ (Loss) On Derivatives & Hedges Total Accumulated Other Comprehensive Income/(Loss) December 31, 2023 $(10,149) (1) (2,000) (377) (12,527) Net change 1,734 1 61 (522) 1,274 June 30, 2024 (8,415) 0 (1,939) (899) (11,253)

Earnings Per Share (Tables)

Earnings Per Share (Tables)	6 Months Ended
Earnings Per Share (Tables)	Jun. 30, 2024
Earnings Per Share [Abstract]
Reconciliation of Basic Net Earnings per Share to Diluted Net Earnings per Share	The following is a reconciliation of basic net earnings per share to diluted net earnings per share: Fiscal Second Quarter Ended Fiscal Six Months Ended (Shares in Millions) June 30, 2024 July 2, 2023 June 30, 2024 July 2, 2023 Basic net earnings per share from continuing operations $1.95 2.07 3.30 1.88 Basic net earnings (loss) per share from discontinued operations — (0.09) — 0.07 Total net earnings per share - basic 1.95 1.98 3.30 1.95 Average shares outstanding — basic 2,406.8 2,598.4 2,407.5 2,601.9 Potential shares exercisable under stock option plans 62.6 95.2 79.3 96.9 Less: shares which could be repurchased under treasury stock method (47.4) (67.9) (58.3) (68.1) Average shares outstanding — diluted 2,422.0 2,625.7 2,428.5 2,630.7 Diluted net earnings per share from continuing operations 1.93 2.05 3.27 1.86 Diluted net earnings (loss) per share from discontinuing operations — (0.09) — 0.07 Total net earnings per share - diluted $1.93 1.96 3.27 1.93 (Shares in Millions) The diluted net earnings per share calculation excluded the following number of shares related to stock options, as the exercise price of these options was greater than the average market value of the Company’s stock. 72.2 50.8 53.8 46.8

Segments of Business and Geog_2

Segments of Business and Geographic Areas (Tables)	6 Months Ended
Segments of Business and Geographic Areas (Tables)	Jun. 30, 2024
Segment Reporting [Abstract]
Sales By Segment Of Business	Fiscal Second Quarter Ended Fiscal Six Months Ended (Dollars in Millions) June 30, July 2, Percent June 30, July 2, Percent Change INNOVATIVE MEDICINE Immunology U.S. $2,978 2,865 4.0 % $5,431 5,313 2.2 % International 1,744 1,631 6.9 3,538 3,295 7.4 Worldwide 4,722 4,496 5.0 8,969 8,608 4.2 REMICADE U.S. 231 277 (16.7) 497 553 (10.1) U.S. Exports 35 33 7.9 62 74 (15.4) International 127 152 (16.6) 268 322 (16.9) Worldwide 393 462 (14.9) 827 949 (12.9) SIMPONI / SIMPONI ARIA U.S. 267 285 (6.3) 521 556 (6.2) International 270 244 10.9 569 510 11.7 Worldwide 537 529 1.6 1,091 1,066 2.3 STELARA U.S. 1,855 1,817 2.1 3,251 3,268 (0.5) International 1,030 981 5.0 2,085 1,974 5.6 Worldwide 2,885 2,797 3.1 5,336 5,241 1.8 TREMFYA U.S. 589 450 30.8 1,098 856 28.2 International 317 255 23.9 616 489 25.8 Worldwide 906 706 28.3 1,714 1,346 27.3 OTHER IMMUNOLOGY U.S. 2 4 (51.5) 2 7 (75.4) International 0 0 — 0 0 — Worldwide 2 4 (51.5) 2 7 (75.4) Infectious Diseases U.S. 334 395 (15.4) 658 787 (16.4) International 631 727 (13.1) 1,128 1,920 (41.3) Worldwide 965 1,121 (13.9) 1,786 2,707 (34.0) COVID-19 VACCINE U.S. 0 0 — 0 0 — International 172 285 (39.7) 197 1,032 (80.9) Worldwide 172 285 (39.7) 197 1,032 (80.9) Fiscal Second Quarter Ended Fiscal Six Months Ended (Dollars in Millions) June 30, July 2, Percent June 30, July 2, Percent Change EDURANT / rilpivirine U.S. 8 8 (2.8) 16 17 (7.0) International 288 258 11.5 603 529 14.1 Worldwide 297 266 11.0 620 546 13.4 PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA U.S. 321 382 (16.0) 635 760 (16.5) International 117 109 6.5 221 208 6.0 Worldwide 438 491 (11.0) 856 968 (11.6) OTHER INFECTIOUS DISEASES U.S. 5 5 18.5 7 10 (29.4) International 55 74 (25.6) 107 151 (29.3) Worldwide 61 79 (23.1) 114 161 (29.3) Neuroscience U.S. 1,102 1,029 7.1 2,156 2,007 7.4 International 679 764 (11.1) 1,428 1,590 (10.2) Worldwide 1,782 1,793 (0.6) 3,585 3,597 (0.3) CONCERTA / methylphenidate U.S. 34 64 (47.7) 75 134 (44.3) International 129 143 (9.8) 265 279 (5.1) Worldwide 163 208 (21.5) 340 414 (17.8) INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA U.S. 784 721 8.8 1,549 1,434 8.0 International 269 310 (13.1) 561 641 (12.4) Worldwide 1,054 1,031 2.2 2,110 2,075 1.7 SPRAVATO U.S. 226 144 57.9 417 255 63.9 International 44 25 73.5 78 45 74.6 Worldwide 271 169 60.2 496 300 65.5 OTHER NEUROSCIENCE U.S. 57 100 (42.5) 115 184 (37.3) International 237 286 (17.0) 524 625 (16.2) Fiscal Second Quarter Ended Fiscal Six Months Ended (Dollars in Millions) June 30, July 2, Percent June 30, July 2, Percent Change Worldwide 294 386 (23.7) 639 809 (21.0) Oncology U.S. 2,636 2,069 27.4 5,019 3,958 26.8 International 2,455 2,329 5.4 4,885 4,552 7.3 Worldwide 5,090 4,398 15.7 9,904 8,510 16.4 CARVYKTI U.S. 167 114 46.5 307 184 66.8 International 20 3 * 36 5 * Worldwide 186 117 59.8 343 189 81.5 DARZALEX U.S. 1,641 1,322 24.2 3,105 2,513 23.6 International 1,237 1,110 11.5 2,465 2,182 12.9 Worldwide 2,878 2,431 18.4 5,570 4,695 18.6 ERLEADA U.S. 318 241 32.2 603 490 23.0 International 418 326 28.0 822 619 32.8 Worldwide 736 567 29.8 1,425 1,109 28.4 IMBRUVICA U.S. 246 262 (6.4) 511 532 (3.9) International 525 579 (9.4) 1,043 1,136 (8.3) Worldwide 770 841 (8.5) 1,554 1,668 (6.9) TECVAYLI U.S. 104 82 27.5 205 139 47.7 International 30 12 * 63 18 * Worldwide 135 94 42.9 268 157 70.2 ZYTIGA / abiraterone acetate U.S. 11 9 21.6 20 25 (19.7) International 154 218 (29.6) 326 447 (27.2) Worldwide 165 227 (27.7) 346 472 (26.8) OTHER ONCOLOGY U.S. 148 40 * 267 75 * International 71 80 (10.4) 131 144 (8.5) Worldwide 221 120 84.2 399 219 82.4 Pulmonary Hypertension U.S. 743 684 8.7 1,509 1,284 17.5 International 296 289 2.6 579 561 3.4 Worldwide 1,039 972 6.9 2,088 1,844 13.2 OPSUMIT U.S. 373 328 13.7 729 601 21.3 International 170 179 (5.0) 339 346 (2.2) Worldwide 544 507 7.1 1,068 947 12.7 UPTRAVI Fiscal Second Quarter Ended Fiscal Six Months Ended (Dollars in Millions) June 30, July 2, Percent June 30, July 2, Percent Change U.S. 349 338 3.3 741 642 15.5 International 76 61 24.6 152 119 27.6 Worldwide 426 399 6.6 894 761 17.4 OTHER PULMONARY HYPERTENSION U.S. 20 18 18.8 38 41 (6.1) International 50 48 3.1 89 95 (6.7) Worldwide 71 66 7.2 127 136 (6.5) Cardiovascular / Metabolism / Other U.S. 717 776 (7.7) 1,348 1,491 (9.6) International 176 174 0.6 373 386 (3.6) Worldwide 892 950 (6.2) 1,721 1,877 (8.3) XARELTO U.S. 587 637 (7.9) 1,105 1,215 (9.1) International — — — — — — Worldwide 587 637 (7.9) 1,105 1,215 (9.1) OTHER U.S. 129 138 (6.4) 243 275 (11.8) International 176 174 0.6 373 386 (3.6) Worldwide 305 313 (2.5) 616 662 (7.0) TOTAL INNOVATIVE MEDICINE U.S. 8,510 7,818 8.9 16,122 14,841 8.6 International 5,980 5,913 1.1 11,930 12,303 (3.0) Worldwide 14,490 13,731 5.5 28,052 27,144 3.3 MEDTECH Cardiovascular (1) U.S. 1,119 908 23.3 2,144 1,771 21.1 International 753 712 5.7 1,534 1,352 13.4 Worldwide 1,873 1,620 15.6 3,679 3,123 17.8 ELECTROPHYSIOLOGY U.S. 705 609 15.7 1,397 1,180 18.4 International 618 587 5.4 1,270 1,109 14.6 Worldwide 1,323 1,196 10.6 2,667 2,288 16.5 ABIOMED U.S. 309 272 13.2 612 536 14.1 International 72 59 20.7 139 119 16.5 Worldwide 379 331 14.5 750 655 14.5 SHOCKWAVE (2) U.S. 77 — * 77 — * International 0 — — 0 — — Worldwide 77 — * 77 — * OTHER CARDIOVASCULAR (1) U.S. 29 27 12.5 59 55 7.7 Fiscal Second Quarter Ended Fiscal Six Months Ended (Dollars in Millions) June 30, July 2, Percent June 30, July 2, Percent Change International 64 67 (4.5) 126 125 0.8 Worldwide 93 93 0.3 185 180 2.9 Orthopaedics U.S. 1,422 1,388 2.5 2,870 2,751 4.3 International 890 878 1.4 1,782 1,759 1.3 Worldwide 2,312 2,265 2.1 4,652 4,510 3.2 HIPS U.S. 265 250 5.8 535 491 8.9 International 152 147 3.4 304 296 2.6 Worldwide 417 397 4.9 839 787 6.5 KNEES U.S. 230 221 4.2 472 447 5.5 International 163 142 14.9 323 284 13.6 Worldwide 394 363 8.4 795 731 8.7 TRAUMA U.S. 498 483 3.0 1,002 974 2.9 International 260 255 2.4 521 522 0.0 Worldwide 759 739 2.8 1,524 1,496 1.9 SPINE, SPORTS & OTHER U.S. 430 433 (0.8) 862 839 2.7 International 314 334 (6.1) 634 657 (3.5) Worldwide 743 766 (3.1) 1,495 1,495 0.0 Surgery U.S. 995 1,015 (2.0) 1,982 1,990 (0.4) International 1,493 1,580 (5.5) 2,922 3,039 (3.8) Worldwide 2,488 2,594 (4.1) 4,904 5,028 (2.5) ADVANCED U.S. 466 466 0.1 912 910 0.2 International 675 757 (10.8) 1,316 1,430 (8.0) Worldwide 1,141 1,222 (6.7) 2,228 2,340 (4.8) GENERAL U.S. 528 548 (3.7) 1,070 1,079 (0.9) International 818 823 (0.7) 1,606 1,608 (0.2) Worldwide 1,346 1,372 (1.9) 2,676 2,688 (0.5) Vision U.S. 523 529 (1.2) 1,070 1,087 (1.5) International 763 778 (2.0) 1,473 1,521 (3.2) Worldwide 1,285 1,308 (1.7) 2,543 2,608 (2.5) CONTACT LENSES / OTHER U.S. 409 409 0.2 847 853 (0.6) Fiscal Second Quarter Ended Fiscal Six Months Ended (Dollars in Millions) June 30, July 2, Percent June 30, July 2, Percent Change International 509 530 (4.0) 981 1,039 (5.6) Worldwide 918 939 (2.2) 1,828 1,892 (3.4) SURGICAL U.S. 113 120 (5.8) 223 234 (4.8) International 254 249 2.1 492 482 2.1 Worldwide 367 369 (0.5) 715 716 (0.1) TOTAL MEDTECH U.S. 4,059 3,839 5.7 8,067 7,598 6.2 International 3,898 3,949 (1.3) 7,711 7,671 0.5 Worldwide 7,957 7,788 2.2 15,778 15,269 3.3 WORLDWIDE U.S. 12,569 11,657 7.8 24,189 22,439 7.8 International 9,878 9,862 0.2 19,641 19,974 (1.7) Worldwide $22,447 21,519 4.3 % $43,830 42,413 3.3 % * Percentage greater than 100% or not meaningful (1) Previously referred to as Interventional (2) Acquired on May 31, 2024
Operating Profit by Segment of Business	Fiscal Second Quarter Ended Fiscal Six Months Ended (Dollars in Millions) June 30, July 2, Percent June 30, July 2, Percent Innovative Medicine (1) $5,459 4,812 13.4 % $10,428 9,214 13.2 % MedTech (2) 1,089 1,671 (34.8) 2,609 3,080 (15.3) Segment earnings before provision for taxes 6,548 6,483 1.0 13,037 12,294 6.0 Less: Expense not allocated to segments (3) 800 177 3,575 7,275 Worldwide income (loss) before tax $5,748 6,306 (8.8) % $9,462 5,019 88.5 % (1) Innovative Medicine includes: • Intangible amortization expense of $0.7 billion in both the fiscal second quarter of 2024 and 2023. Intangible amortization expense of $1.4 billion and $1.5 billion in the fiscal six months of 2024 and 2023, respectively. • One-time COVID-19 Vaccine related exit costs of $0.1 billion in both the fiscal second quarter and fiscal six months of 2024. One-time COVID-19 Vaccine related exit costs of $0.2 billion and $0.6 billion in the fiscal second quarter and fiscal six months of 2023, respectively. • Restructuring income of $0.1 billion in the fiscal second quarter of 2024 and a restructuring related charge of $0.1 billion in the fiscal six months of 2024. A restructuring related charge of $0.1 billion and $0.3 billion in the fiscal second quarter and fiscal six months of 2023, respectively. Refer to Note 12 for additional details. • An In-process research and development impairment of $0.2 billion in the fiscal second quarter and fiscal six months of 2024 associated with the M710 (biosimilar) asset acquired from Momenta in 2020. (2) MedTech includes: • Intangible amortization expense of $0.4 billion in both the fiscal second quarter of 2024 and 2023. Intangible amortization expense of $0.8 billion in both the fiscal six months of 2024 and 2023. • Favorable intellectual property litigation settlements of $0.3 billion in both the fiscal second quarter and fiscal six months of 2023 • Acquisition and integration related expense of $0.6 billion and $0.6 billion, primarily driven by the Shockwave acquisition, in the fiscal second quarter and fiscal six months of 2024, respectively. Acquisition and integration related expense of $0.1 billion in the fiscal six months of 2023. • A gain of $0.2 billion related to the Acclarent divestiture recorded in Other (income) expense in the fiscal second quarter and fiscal six months of 2024 • Restructuring related charge of $0.1 billion in the fiscal second quarter and fiscal six months of 2024 (3 ) Amounts not allocated to segments include interest (income)/expense and general corporate (income)/expense. The fiscal second quarters of 2024 and 2023 include charges for talc matters of $0.3 billion and $0.2 billion, respectively. The fiscal six months of 2024 and 2023 include charges for talc matters of $3.0 billion and $7.1 billion, respectively (See Note 11, Legal Proceedings, for additional details). The fiscal second quarter and six months of 2024 includes a loss of approximately $0.4 billion related to the debt to equity exchange of the Company's remaining shares of Kenvue Common Stock
Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas	Fiscal Second Quarter Ended Fiscal Six Months Ended (Dollars in Millions) June 30, 2024 July 2, 2023 Percent June 30, 2024 July 2, 2023 Percent Change United States $12,569 11,657 7.8 % $24,189 22,439 7.8 % Europe 5,214 5,131 1.6 10,377 10,721 (3.2) Western Hemisphere, excluding U.S. 1,212 1,136 6.7 2,406 2,212 8.8 Asia-Pacific, Africa 3,452 3,595 (4.0) 6,858 7,041 (2.6) Total $22,447 21,519 4.3 % $43,830 42,413 3.3 %

Acquisitions and Divestitures (

Acquisitions and Divestitures (Tables)	6 Months Ended
Acquisitions and Divestitures (Tables)	Jun. 30, 2024
Business Combinations [Abstract]
Schedule of Preliminary Amounts Recognized for Assets Acquired and Liabilities Assumed	Details of the fair value amounts recognized for assets acquired and liabilities assumed as of the acquisition date: (Dollars in Billions) Assets acquired: Cash $1.1 Goodwill 7.5 Amortizable intangibles 5.3 IPR&D 0.6 Inventory 0.5 Other assets 0.5 Total assets acquired $15.5 Liabilities assumed: Deferred taxes $1.5 Notes payable* 1.0 Accrued liabilities** 0.4 Total liabilities assumed $2.9 Net assets acquired $12.6 Net assets acquired as of May 31, 2024 $12.6 Less: Cash acquired 1.1 Equity awards settled 0.6 Settlement of Note payable* 1.0 Total enterprise value as of June 30, 2024 $13.1 • Represents the convertible debt which was subsequently paid in the fiscal second quarter of 2024. ** Includes $0.2 billion of equity awards

Legal Proceedings (Tables)

Legal Proceedings (Tables)	6 Months Ended
Legal Proceedings (Tables)	Jun. 30, 2024
Commitments and Contingencies Disclosure [Abstract]
Summary Of Claims In Pending Lawsuits	The table below contains the most significant of these cases and provides the approximate number of plaintiffs in the United States with direct claims in pending lawsuits regarding injuries allegedly due to the relevant product or product category as of June 30, 2024: Product or product category Number of plaintiffs Body powders containing talc, primarily JOHNSON’S Baby Powder 62,370 DePuy ASR XL Acetabular System and DePuy ASR Hip Resurfacing System 160 PINNACLE Acetabular Cup System 910 Pelvic meshes 6,230 ETHICON PHYSIOMESH Flexible Composite Mesh 170 RISPERDAL 20 ELMIRON 2,170

Kenvue Separation (Tables)

Kenvue Separation (Tables)	6 Months Ended
Kenvue Separation (Tables)	Jun. 30, 2024
Discontinued Operations and Disposal Groups [Abstract]
Disposal Groups, Including Discontinued Operations	Details of Net Earnings from Discontinued Operations, net of taxes are as follows: Fiscal Second Quarter Ended Fiscal Six Months Ended (Dollars in Millions) July 2, 2023 July 2, 2023 Sales to customers $4,011 $7,863 Cost of products sold 1,750 3,458 Gross profit 2,261 4,405 Selling, marketing and administrative expenses 1,269 2,501 Research and development expense 126 234 Interest Income (42) (79) Interest expense, net of portion capitalized 128 131 Other (income) expense, net 324 612 Earnings from Discontinued Operations Before Provision for Taxes on Income 456 1,006 Provision for taxes on income 688 815 Net (loss)/earnings from Discontinued Operations $(232) $191 The following table presents depreciation, amortization and capital expenditures of the discontinued operations related to Kenvue: Fiscal Second Quarter Ended Fiscal Six Months Ended (Dollars in Millions) July 2, 2023 July 2, 2023 Depreciation and Amortization $149 $302 Capital expenditures $92 $139

Restructuring (Tables)

Restructuring (Tables)	6 Months Ended
Restructuring (Tables)	Jun. 30, 2024
Restructuring and Related Activities [Abstract]
Schedule of Restructuring Reserve	The following table summarizes the restructuring (income) expenses for 2024: (Pre-tax Dollars in Millions) Fiscal Second Quarter Ended Fiscal Six Months Ended Innovative Medicine Segment (1) $(63) 81 MedTech Segment (2) 52 79 Total Programs $(11) 160 (1) Included in Restructuring on the Consolidated Statement of Earnings (2) The fiscal second quarter of 2024 included $50 million in Restructuring and $2 million in Cost of products sold on the Consolidated Statement of Earnings. The fiscal six months of 2024 included $70 million in Restructuring and $9 million in Cost of products sold on the Consolidated Statement of Earnings.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Details) - USD ($) $ in Millions	Jun. 30, 2024	Dec. 31, 2023
Accounting Policies [Abstract]
Supplier finance program, payment timing, period	90 days
Supplier finance program, obligation	$ 600	$ 700

Inventories (Details)

Inventories (Details) - USD ($) $ in Millions	Jun. 30, 2024	Dec. 31, 2023
Inventory Disclosure [Abstract]
Raw materials and supplies	$ 2,407	$ 2,355
Goods in process	2,556	1,952
Finished goods	7,206	6,874
Total inventories	$ 12,169	$ 11,181

Intangible Assets and Goodwil_2

Intangible Assets and Goodwill (Details) - USD ($) $ in Millions	Jun. 30, 2024	Dec. 31, 2023
Intangible assets with indefinite lives:
Total intangible assets with indefinite lives	$ 13,964	$ 10,929
Total intangible assets — net	39,725	34,175
Trademarks
Intangible assets with indefinite lives:
Total intangible assets with indefinite lives	1,655	1,714
Purchased In-Process Research And Development
Intangible assets with indefinite lives:
Total intangible assets with indefinite lives	12,309	9,215
Patents And Trademarks
Intangible assets with definite lives:
Finite-lived intangible assets, gross	43,438	40,417
Less accumulated amortization	(24,835)	(24,808)
Finite-lived intangible assets, net	18,603	15,609
Customer relationships and other intangible assets
Intangible assets with definite lives:
Finite-lived intangible assets, gross	20,176	20,322
Less accumulated amortization	(13,018)	(12,685)
Finite-lived intangible assets, net	$ 7,158	$ 7,637

Intangible Assets and Goodwil_3

Intangible Assets and Goodwill - Goodwill By Segment (Details) $ in Millions	6 Months Ended
	Jun. 30, 2024 USD ($)
Goodwill [Roll Forward]
Goodwill Beginning of Period	$ 36,558
Goodwill, related to acquisitions	8,057
Goodwill, related to divestitures	(56)
Currency translation/Other	(309)
Goodwill End of Period	44,250
Innovative Medicine
Goodwill [Roll Forward]
Goodwill Beginning of Period	10,407
Goodwill, related to acquisitions	563
Goodwill, related to divestitures	0
Currency translation/Other	(202)
Goodwill End of Period	10,768
MedTech
Goodwill [Roll Forward]
Goodwill Beginning of Period	26,151
Goodwill, related to acquisitions	7,494
Goodwill, related to divestitures	(56)
Currency translation/Other	(107)
Goodwill End of Period	$ 33,482

Intangible Assets and Goodwil_4

Intangible Assets and Goodwill - Narrative (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jul. 02, 2023	Jun. 30, 2024	Jul. 02, 2023
Finite-Lived Intangible Assets [Line Items]
Amortization expense of amortizable intangible assets	$ 1,100	$ 1,100	$ 2,200	$ 2,200
Patents And Trademarks
Finite-Lived Intangible Assets [Line Items]
Useful life (in years)	12 years		12 years
Customer relationships and other intangible assets
Finite-Lived Intangible Assets [Line Items]
Useful life (in years)	18 years		18 years

Intangible Assets and Goodwil_5

Intangible Assets and Goodwill - Intangible Asset Amortization Expense (Details) $ in Millions	Jun. 30, 2024 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
2024	$ 4,500
2025	3,900
2026	3,300
2027	2,700
2028	$ 2,000

Fair Value Measurements - Narra

Fair Value Measurements - Narrative (Details) - USD ($) $ in Millions			6 Months Ended	12 Months Ended
	May 17, 2024	May 15, 2024	Jun. 30, 2024	Dec. 31, 2023
Derivative [Line Items]
Accumulated other comprehensive income on derivatives, after tax			$ 899
Hedging exposure			18 months
Commercial paper		$ 3,600
Proceeds from issuance of commercial paper		$ 3,600
Debt for equity exchange, shares exchanged (in shares)	182,329,550
Debt for equity exchange, loss on shares exchanged	$ 400
Weighted average interest rate on non-current debt			3.28%
Excess of carrying value over fair value of debt				$ 1,000
Current Debt			$ 9,855	3,451
Commercial Paper
Derivative [Line Items]
Current Debt			$ 8,500
Weighted average interest rate			5.28%
Term			1 month
Forward foreign exchange contracts
Derivative [Line Items]
Collateral already posted, aggregate fair value			$ 2,300
Derivative, notional amount			44,500	42,900
Cross currency interest rate swaps
Derivative [Line Items]
Derivative, notional amount			41,000	39,700
Interest Rate Swap
Derivative [Line Items]
Derivative, notional amount			$ 10,000	$ 10,000

Fair Value Measurements - Summa

Fair Value Measurements - Summary of Derivative Activity (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jul. 02, 2023	Jun. 30, 2024	Jul. 02, 2023
Other (income) expense
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) reclassified from AOCI into income	$ 0	$ 0	$ 0	$ 0
Cross currency interest rate swaps \| Other (income) expense
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) reclassified from AOCI into income	0	0	0	0
Fair Value Hedging \| Interest Rate Swap \| Sales to customers
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing	0	0	0	0
Amount of gain or (loss) recognized in AOCI	0	0	0	0
Fair Value Hedging \| Interest Rate Swap \| Cost of products sold
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing	0	0	0	0
Amount of gain or (loss) recognized in AOCI	0	0	0	0
Fair Value Hedging \| Interest Rate Swap \| Research and Development Expense
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing	0	0	0	0
Amount of gain or (loss) recognized in AOCI	0	0	0	0
Fair Value Hedging \| Interest Rate Swap \| Interest (income)/Interest expense, net
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing	(53)	(175)	(45)	(6)
Amount of gain or (loss) recognized in AOCI	53	175	45	6
Fair Value Hedging \| Interest Rate Swap \| Other (income) expense
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing	0	0	0	0
Amount of gain or (loss) recognized in AOCI	0	0	0	0
Fair Value Hedging \| Cross currency interest rate swaps \| Sales to customers
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing			0	0
Amount of gain or (loss) recognized in AOCI			0	0
Fair Value Hedging \| Cross currency interest rate swaps \| Cost of products sold
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing			0	0
Amount of gain or (loss) recognized in AOCI			0	0
Fair Value Hedging \| Cross currency interest rate swaps \| Research and Development Expense
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing			0	0
Amount of gain or (loss) recognized in AOCI			0	0
Fair Value Hedging \| Cross currency interest rate swaps \| Interest (income)/Interest expense, net
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing			67	67
Amount of gain or (loss) recognized in AOCI			67	67
Fair Value Hedging \| Cross currency interest rate swaps \| Other (income) expense
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing			0	0
Amount of gain or (loss) recognized in AOCI			0	0
Net Investment Hedging \| Net Investment Hedging \| Sales to customers
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing	0	0
Amount of gain or (loss) recognized in AOCI	0	0
Net Investment Hedging \| Net Investment Hedging \| Cost of products sold
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing	0	0
Amount of gain or (loss) recognized in AOCI	0	0
Net Investment Hedging \| Net Investment Hedging \| Research and Development Expense
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing	0	0
Amount of gain or (loss) recognized in AOCI	0	0
Net Investment Hedging \| Net Investment Hedging \| Interest (income)/Interest expense, net
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing	33	33
Amount of gain or (loss) recognized in AOCI	33	33
Net Investment Hedging \| Net Investment Hedging \| Other (income) expense
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing	0	0
Amount of gain or (loss) recognized in AOCI	0	0
Cash Flow Hedging \| Forward foreign exchange contracts \| Sales to customers
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) recognized in AOCI	2	(14)	(1)	10
Amount of gain or (loss) reclassified from AOCI into income	(1)	(15)	0	(3)
Cash Flow Hedging \| Forward foreign exchange contracts \| Cost of products sold
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) recognized in AOCI	66	251	47	396
Amount of gain or (loss) reclassified from AOCI into income	94	56	259	(90)
Cash Flow Hedging \| Forward foreign exchange contracts \| Research and Development Expense
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) recognized in AOCI	11	7	33	(29)
Amount of gain or (loss) reclassified from AOCI into income	8	(12)	12	(25)
Cash Flow Hedging \| Forward foreign exchange contracts \| Interest (income)/Interest expense, net
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) recognized in AOCI	0	0	0	0
Amount of gain or (loss) reclassified from AOCI into income	0	0	0	0
Cash Flow Hedging \| Forward foreign exchange contracts \| Other (income) expense
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) recognized in AOCI	1	18	5	4
Amount of gain or (loss) reclassified from AOCI into income	3	3	1	5
Cash Flow Hedging \| Cross currency interest rate swaps \| Sales to customers
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) recognized in AOCI	0	0	0	0
Amount of gain or (loss) reclassified from AOCI into income	0	0	0	0
Cash Flow Hedging \| Cross currency interest rate swaps \| Cost of products sold
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) recognized in AOCI	0	0	0	0
Amount of gain or (loss) reclassified from AOCI into income	0	0	0	0
Cash Flow Hedging \| Cross currency interest rate swaps \| Research and Development Expense
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) recognized in AOCI	0	0	0	0
Amount of gain or (loss) reclassified from AOCI into income	0	0	0	0
Cash Flow Hedging \| Cross currency interest rate swaps \| Interest (income)/Interest expense, net
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) recognized in AOCI	(38)	(432)	(243)	(15)
Amount of gain or (loss) reclassified from AOCI into income	42	74	91	182
Cash Flow Hedging \| Cross currency interest rate swaps \| Other (income) expense
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) recognized in AOCI	0	0	0	0
Amount of gain or (loss) reclassified from AOCI into income	$ 0	$ 0	$ 0	$ 0

Fair Value Measurements - Deriv

Fair Value Measurements - Derivatives, Balance Sheet Location (Details) - USD ($) $ in Millions	Jun. 30, 2024	Dec. 31, 2023
Derivative [Line Items]
Carrying Amount of the Hedged Liability	$ 4,405	$ 6,037
Designated as Hedging Instrument
Derivative [Line Items]
Carrying Amount of the Hedged Liability	8,812	8,862
Cumulative Amount of Fair Value Hedging Gain/ (Loss) Included in the Carrying Amount of the Hedged Liability	$ (1,274)	$ (1,216)

Fair Value Measurements - Sched

Fair Value Measurements - Schedule of Effect of Derivatives not Designated as Hedging Instruments (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jul. 02, 2023	Jun. 30, 2024	Jul. 02, 2023
Not Designated as Hedging Instrument \| Forward foreign exchange contracts
Derivative Instruments, Gain (Loss) [Line Items]
Gain/(Loss) Recognized In Income on Derivative	$ 20	$ 33	$ 45	$ 2

Fair Value Measurements - Sch_2

Fair Value Measurements - Schedule of Effect of Net Investment Hedges (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jul. 02, 2023	Jun. 30, 2024	Jul. 02, 2023
Derivative Instruments, Gain (Loss) [Line Items]
Gain/(Loss) Recognized In Accumulated OCI	$ 46	$ 11	$ 130	$ (66)
Other Income Expense Net
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) reclassified from AOCI into income	0	0	0	0
Cross Currency Interest Rate Contract
Derivative Instruments, Gain (Loss) [Line Items]
Gain/(Loss) Recognized In Accumulated OCI	92	(24)	820	666
Cross Currency Interest Rate Contract \| Other Income Expense Net
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) reclassified from AOCI into income	$ 0	$ 0	$ 0	$ 0

Fair Value Measurements - Sum_2

Fair Value Measurements - Summary of Activity Related to Equity Investments (Details) - USD ($) $ in Millions		6 Months Ended
	Aug. 23, 2023	Jun. 30, 2024	Dec. 31, 2023
Equity Investment [Roll Forward]
Non Current Other Assets		$ 10,544	$ 14,153
Kenvue Inc. \| Johnson & Johnson
Equity Investment [Roll Forward]
Percentage ownership after transaction	9.50%
Equity Securities \| Equity Investments with readily determinable value*
Equity Investment [Roll Forward]
Carrying value, beginning of period		4,473
Equity, Fair Value Adjustment		(4)
Sales/ Purchases/Other		(3,999)
Carrying value, end of period		470
Non Current Other Assets		470
Equity Securities \| Equity Investments without readily determinable value
Equity Investment [Roll Forward]
Carrying value, beginning of period		696
Equity, Fair Value Adjustment		(15)
Sales/ Purchases/Other		(8)
Carrying value, end of period		673
Non Current Other Assets		$ 673

Fair Value Measurements - Finan

Fair Value Measurements - Financial Assets and Liabilities at Fair Value (Details) - USD ($) $ in Millions	6 Months Ended
	Jun. 30, 2024	Jul. 02, 2023	Dec. 31, 2023
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	$ 1,915
Derivatives designated as hedging instruments : Liabilities	4,386
Available-for-sale Securities, Equity Securities	470		$ 4,473
Available-for-sale Securities	6,840		8,874
Contingent consideration	1,248		1,092
Total Gross Assets	1,942		1,591
Credit Support Agreement (CSA)	(1,911)		(1,575)
Total Net Asset	31		16
Total Gross Liabilities	4,405		6,037
Credit Support Agreement (CSA)	(4,229)		(5,604)
Total Net Liabilities	176		433
Beginning Balance	1,092	$ 1,120
Changes in estimated fair value(6)	44	25
Additions	112	0
Payments	0	(3)
Ending Balance	1,248	$ 1,142
Quoted prices in active markets for identical assets and liabilities Level 1
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	0
Derivatives designated as hedging instruments : Liabilities	0
Available-for-sale Securities, Equity Securities	470		4,473
Available-for-sale Securities	0
Contingent consideration	0
Significant other observable inputs Level 2
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	1,915		1,527
Derivatives designated as hedging instruments : Liabilities	4,386		5,962
Available-for-sale Securities, Equity Securities	0
Available-for-sale Securities	6,840
Contingent consideration	0
Significant unobservable inputs Level 3
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	0
Derivatives designated as hedging instruments : Liabilities	0
Available-for-sale Securities, Equity Securities	0
Available-for-sale Securities	0
Contingent consideration	1,248		1,092
Interest Rate Contract
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	1,392
Derivatives designated as hedging instruments : Liabilities	3,874
Interest Rate Contract \| Quoted prices in active markets for identical assets and liabilities Level 1
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	0
Derivatives designated as hedging instruments : Liabilities	0
Interest Rate Contract \| Significant other observable inputs Level 2
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	1,392		988
Derivatives designated as hedging instruments : Liabilities	3,874		5,338
Interest Rate Contract \| Significant unobservable inputs Level 3
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	0
Derivatives designated as hedging instruments : Liabilities	0
Forward foreign exchange contracts
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	523
Derivatives designated as hedging instruments : Liabilities	512
Derivatives not designated as hedging instruments : Assets	27
Derivatives not designated as hedging instruments : Liabilities	19
Forward foreign exchange contracts \| Quoted prices in active markets for identical assets and liabilities Level 1
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	0
Derivatives designated as hedging instruments : Liabilities	0
Derivatives not designated as hedging instruments : Assets	0
Derivatives not designated as hedging instruments : Liabilities	0
Forward foreign exchange contracts \| Significant other observable inputs Level 2
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	523		539
Derivatives designated as hedging instruments : Liabilities	512		624
Derivatives not designated as hedging instruments : Assets	27		64
Derivatives not designated as hedging instruments : Liabilities	19		$ 75
Forward foreign exchange contracts \| Significant unobservable inputs Level 3
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	0
Derivatives designated as hedging instruments : Liabilities	0
Derivatives not designated as hedging instruments : Assets	0
Derivatives not designated as hedging instruments : Liabilities	$ 0

Fair Value Measurements - Cash,

Fair Value Measurements - Cash, Cash Equivalents and Marketable Securities (Details) - USD ($) $ in Millions	Jun. 30, 2024	Dec. 31, 2023
Debt Securities, Available-for-sale [Abstract]
Available-for-sale Securities - Estimated Fair Value	$ 6,840	$ 8,874
Debt Securities, Available-for-sale and Held-to-maturity [Abstract]
Cash and Cash Equivalents	24,878	21,859
Marketable securities	597	$ 1,068
Total cash, cash equivalents and current marketable securities, Carrying Amount	25,475
Total cash, cash equivalents and current marketable securities, Unrealized Gain	0
Total cash, cash equivalents and current marketable securities, Estimated Fair Value	25,475
Held-to-maturity Securities
Debt Securities, Held-to-maturity [Abstract]
Held-to-maturity Securities - Carrying Amount	18,635
Held-to-maturity Securities, Unrecognized Gain	0
Held-to-maturity Securities - Estimated Fair Value	18,635
Debt Securities, Available-for-sale and Held-to-maturity [Abstract]
Cash and Cash Equivalents	18,635
Marketable securities	0
Held-to-maturity Securities \| Cash
Debt Securities, Held-to-maturity [Abstract]
Held-to-maturity Securities - Carrying Amount	4,247
Held-to-maturity Securities, Unrecognized Gain	0
Held-to-maturity Securities - Estimated Fair Value	4,247
Debt Securities, Available-for-sale and Held-to-maturity [Abstract]
Cash and Cash Equivalents	4,247
Marketable securities	0
Held-to-maturity Securities \| U.S. Gov't securities
Debt Securities, Held-to-maturity [Abstract]
Held-to-maturity Securities - Carrying Amount	0
Held-to-maturity Securities, Unrecognized Gain	0
Held-to-maturity Securities - Estimated Fair Value	0
Debt Securities, Available-for-sale and Held-to-maturity [Abstract]
Cash and Cash Equivalents	0
Marketable securities	0
Held-to-maturity Securities \| Non-U.S. sovereign securities
Debt Securities, Held-to-maturity [Abstract]
Held-to-maturity Securities - Carrying Amount	150
Held-to-maturity Securities, Unrecognized Gain	0
Held-to-maturity Securities - Estimated Fair Value	150
Debt Securities, Available-for-sale and Held-to-maturity [Abstract]
Cash and Cash Equivalents	150
Marketable securities	0
Held-to-maturity Securities \| U.S. reverse repurchase agreements
Debt Securities, Held-to-maturity [Abstract]
Held-to-maturity Securities - Carrying Amount	8,496
Held-to-maturity Securities, Unrecognized Gain	0
Held-to-maturity Securities - Estimated Fair Value	8,496
Debt Securities, Available-for-sale and Held-to-maturity [Abstract]
Cash and Cash Equivalents	8,496
Marketable securities	0
Held-to-maturity Securities \| Corporate debt securities(1)
Debt Securities, Held-to-maturity [Abstract]
Held-to-maturity Securities - Carrying Amount	0
Held-to-maturity Securities, Unrecognized Gain	0
Held-to-maturity Securities - Estimated Fair Value	0
Debt Securities, Available-for-sale and Held-to-maturity [Abstract]
Cash and Cash Equivalents	0
Marketable securities	0
Held-to-maturity Securities \| Money market funds
Debt Securities, Held-to-maturity [Abstract]
Held-to-maturity Securities - Carrying Amount	4,883
Held-to-maturity Securities, Unrecognized Gain	0
Held-to-maturity Securities - Estimated Fair Value	4,883
Debt Securities, Available-for-sale and Held-to-maturity [Abstract]
Cash and Cash Equivalents	4,883
Marketable securities	0
Held-to-maturity Securities \| Time deposits(1)
Debt Securities, Held-to-maturity [Abstract]
Held-to-maturity Securities - Carrying Amount	859
Held-to-maturity Securities, Unrecognized Gain	0
Held-to-maturity Securities - Estimated Fair Value	859
Debt Securities, Available-for-sale and Held-to-maturity [Abstract]
Cash and Cash Equivalents	859
Marketable securities	0
Available-for-sale Securities
Debt Securities, Available-for-sale [Abstract]
Available-for-sale Securities - Carrying Amount	6,840
Available-for-sale Securities, Unrecognized Gain	0
Available-for-sale Securities - Estimated Fair Value	6,840
Debt Securities, Available-for-sale and Held-to-maturity [Abstract]
Cash and Cash Equivalents	6,243
Marketable securities	597
Available-for-sale Securities \| U.S. Gov’t securities
Debt Securities, Available-for-sale [Abstract]
Available-for-sale Securities - Carrying Amount	6,585
Available-for-sale Securities - Estimated Fair Value	6,585
Available-for-sale Securities \| U.S. Gov’t Agencies
Debt Securities, Available-for-sale [Abstract]
Available-for-sale Securities - Carrying Amount	11
Available-for-sale Securities - Estimated Fair Value	11
Available-for-sale Securities \| Non-U.S. sovereign securities
Debt Securities, Available-for-sale [Abstract]
Available-for-sale Securities - Carrying Amount	2
Available-for-sale Securities - Estimated Fair Value	2
Available-for-sale Securities \| Corporate debt securities(1)
Debt Securities, Available-for-sale [Abstract]
Available-for-sale Securities - Carrying Amount	242
Available-for-sale Securities - Estimated Fair Value	242
Available-for-sale Securities \| Non-U.S. sovereign securities
Debt Securities, Available-for-sale [Abstract]
Available-for-sale Securities, Unrecognized Gain	0
Debt Securities, Available-for-sale and Held-to-maturity [Abstract]
Cash and Cash Equivalents	0
Marketable securities	2
Available-for-sale Securities \| Corporate debt securities(1)
Debt Securities, Available-for-sale [Abstract]
Available-for-sale Securities, Unrecognized Gain	0
Debt Securities, Available-for-sale and Held-to-maturity [Abstract]
Cash and Cash Equivalents	61
Marketable securities	181
Available-for-sale Securities \| U.S. Gov’t securities
Debt Securities, Available-for-sale [Abstract]
Available-for-sale Securities, Unrecognized Gain	0
Debt Securities, Available-for-sale and Held-to-maturity [Abstract]
Cash and Cash Equivalents	6,182
Marketable securities	403
Available-for-sale Securities \| U.S. Gov’t Agencies
Debt Securities, Available-for-sale [Abstract]
Available-for-sale Securities, Unrecognized Gain	0
Debt Securities, Available-for-sale and Held-to-maturity [Abstract]
Cash and Cash Equivalents	0
Marketable securities	$ 11

Fair Value Measurements - Sch_3

Fair Value Measurements - Schedule of Available for Sale Securities Maturities (Details) $ in Millions	Jun. 30, 2024 USD ($)
Cost Basis
Due within one year	$ 6,821
Due after one year through five years	19
Due after five years through ten years	0
Total debt securities	6,840
Fair Value
Due within one year	6,821
Due after one year through five years	19
Due after five years through ten years	0
Total debt securities	$ 6,840

Fair Value Measurements - Fin_2

Fair Value Measurements - Financial Liabilities not Measured at Fair Value (Details)	Jun. 30, 2024 USD ($)	Jun. 30, 2024 EUR (€)	Dec. 31, 2023 USD ($)
Financial Liabilities
Current Debt	$ 9,855,000,000		$ 3,451,000,000
Non-Current Debt
Non-Current Debt	31,636,000,000		$ 25,881,000,000
Unsecured Notes
Non-Current Debt
Debt instrument, face amount	6,700,000,000
Carrying Amount
Financial Liabilities
Current Debt	9,855,000,000
Non-Current Debt
Non-Current Debt	31,636,000,000
Estimated Fair Value
Financial Liabilities
Current Debt	9,835,000,000
Non-Current Debt
Non-Current Debt	$ 29,716,000,000
0.55% Notes due 2025
Non-Current Debt
Stated interest rate (as a percent)	0.55%	0.55%
0.55% Notes due 2025 \| Carrying Amount
Non-Current Debt
Non-Current Debt	$ 973,000,000
0.55% Notes due 2025 \| Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 950,000,000
2.46% Notes due 2026
Non-Current Debt
Stated interest rate (as a percent)	2.46%	2.46%
2.46% Notes due 2026 \| Carrying Amount
Non-Current Debt
Non-Current Debt	$ 1,998,000,000
2.46% Notes due 2026 \| Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 1,921,000,000
2.95% Notes due 2027
Non-Current Debt
Stated interest rate (as a percent)	2.95%	2.95%
2.95% Notes due 2027 \| Carrying Amount
Non-Current Debt
Non-Current Debt	$ 902,000,000
2.95% Notes due 2027 \| Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 955,000,000
0.95% Notes due 2027
Non-Current Debt
Stated interest rate (as a percent)	0.95%	0.95%
0.95% Notes due 2027 \| Carrying Amount
Non-Current Debt
Non-Current Debt	$ 1,430,000,000
0.95% Notes due 2027 \| Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 1,334,000,000
2.90% Notes due 2028
Non-Current Debt
Stated interest rate (as a percent)	2.90%	2.90%
2.90% Notes due 2028 \| Carrying Amount
Non-Current Debt
Non-Current Debt	$ 1,497,000,000
2.90% Notes due 2028 \| Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 1,418,000,000
1.150% Notes due 2028 (750MM Euro 1.0721)
Non-Current Debt
Stated interest rate (as a percent)	1.15%	1.15%
Debt instrument, face amount \| €		€ 750,000,000
Foreign exchange rate	1.0721	1.0721
1.150% Notes due 2028 (750MM Euro 1.0721) \| Carrying Amount
Non-Current Debt
Non-Current Debt	$ 801,000,000
1.150% Notes due 2028 (750MM Euro 1.0721) \| Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 744,000,000
4.80% Notes due 2029
Non-Current Debt
Stated interest rate (as a percent)	4.80%	4.80%
4.80% Notes due 2029 \| Carrying Amount
Non-Current Debt
Non-Current Debt	$ 1,145,000,000
4.80% Notes due 2029 \| Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 1,161,000,000
6.95% Notes due 2029
Non-Current Debt
Stated interest rate (as a percent)	6.95%	6.95%
6.95% Notes due 2029 \| Carrying Amount
Non-Current Debt
Non-Current Debt	$ 298,000,000
6.95% Notes due 2029 \| Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 332,000,000
1.30% Notes due 2030
Non-Current Debt
Stated interest rate (as a percent)	1.30%	1.30%
1.30% Notes due 2030 \| Carrying Amount
Non-Current Debt
Non-Current Debt	$ 1,626,000,000
1.30% Notes due 2030 \| Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 1,445,000,000
4.90% Notes due 2031
Non-Current Debt
Stated interest rate (as a percent)	4.90%	4.90%
4.90% Notes due 2031 \| Carrying Amount
Non-Current Debt
Non-Current Debt	$ 1,145,000,000
4.90% Notes due 2031 \| Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 1,161,000,000
3.20% Notes due 2032 (700MM Euro 1.0721)
Non-Current Debt
Stated interest rate (as a percent)	3.20%	3.20%
Debt instrument, face amount	$ 700,000,000
Foreign exchange rate	1.0721	1.0721
3.20% Notes due 2032 (700MM Euro 1.0721) \| Carrying Amount
Non-Current Debt
Non-Current Debt	$ 747,000,000
3.20% Notes due 2032 (700MM Euro 1.0721) \| Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 750,000,000
4.95% Notes due 2033
Non-Current Debt
Stated interest rate (as a percent)	4.95%	4.95%
4.95% Notes due 2033 \| Carrying Amount
Non-Current Debt
Non-Current Debt	$ 499,000,000
4.95% Notes due 2033 \| Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 513,000,000
4.375% Notes due 2033
Non-Current Debt
Stated interest rate (as a percent)	4.375%	4.375%
4.375% Notes due 2033 \| Carrying Amount
Non-Current Debt
Non-Current Debt	$ 854,000,000
4.375% Notes due 2033 \| Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 835,000,000
4.95% Notes due 2034
Non-Current Debt
Stated interest rate (as a percent)	4.95%	4.95%
4.95% Notes due 2034 \| Carrying Amount
Non-Current Debt
Non-Current Debt	$ 846,000,000
4.95% Notes due 2034 \| Estimated Fair Value
Non-Current Debt
Non-Current Debt	860,000,000
1.650% Notes due 2035 (1.5B Euro 1.0721) \| Carrying Amount
Non-Current Debt
Non-Current Debt	$ 1,597,000,000
Stated interest rate (as a percent)	1.65%	1.65%
Debt instrument, face amount	$ 1,500,000,000
Foreign exchange rate	1.0721	1.0721
1.650% Notes due 2035 (1.5B Euro 1.0721) \| Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 1,384,000,000
3.35% Notes Due 2036 (800MM Euro 1.0721)
Non-Current Debt
Stated interest rate (as a percent)	3.35%	3.35%
Debt instrument, face amount	$ 800,000,000
Foreign exchange rate	1.0721	1.0721
3.35% Notes Due 2036 (800MM Euro 1.0721) \| Carrying Amount
Non-Current Debt
Non-Current Debt	$ 852,000,000
3.35% Notes Due 2036 (800MM Euro 1.0721) \| Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 853,000,000
3.587% Notes due 2036
Non-Current Debt
Stated interest rate (as a percent)	3.587%	3.587%
3.587% Notes due 2036 \| Carrying Amount
Non-Current Debt
Non-Current Debt	$ 855,000,000
3.587% Notes due 2036 \| Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 876,000,000
5.95% Notes due 2037
Non-Current Debt
Stated interest rate (as a percent)	5.95%	5.95%
5.95% Notes due 2037 \| Carrying Amount
Non-Current Debt
Non-Current Debt	$ 994,000,000
5.95% Notes due 2037 \| Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 1,089,000,000
3.625% Notes due 2037
Non-Current Debt
Stated interest rate (as a percent)	3.625%	3.625%
3.625% Notes due 2037 \| Carrying Amount
Non-Current Debt
Non-Current Debt	$ 1,346,000,000
3.625% Notes due 2037 \| Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 1,310,000,000
3.40% Notes due 2038
Non-Current Debt
Stated interest rate (as a percent)	3.40%	3.40%
3.40% Notes due 2038 \| Carrying Amount
Non-Current Debt
Non-Current Debt	$ 993,000,000
3.40% Notes due 2038 \| Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 839,000,000
5.85% Notes due 2038
Non-Current Debt
Stated interest rate (as a percent)	5.85%	5.85%
5.85% Notes due 2038 \| Carrying Amount
Non-Current Debt
Non-Current Debt	$ 697,000,000
5.85% Notes due 2038 \| Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 756,000,000
4.50% Notes due 2040
Non-Current Debt
Stated interest rate (as a percent)	4.50%	4.50%
4.50% Notes due 2040 \| Carrying Amount
Non-Current Debt
Non-Current Debt	$ 541,000,000
4.50% Notes due 2040 \| Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 521,000,000
2.10% Notes due 2040
Non-Current Debt
Stated interest rate (as a percent)	2.10%	2.10%
2.10% Notes due 2040 \| Carrying Amount
Non-Current Debt
Non-Current Debt	$ 836,000,000
2.10% Notes due 2040 \| Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 670,000,000
4.85% Notes due 2041
Non-Current Debt
Stated interest rate (as a percent)	4.85%	4.85%
4.85% Notes due 2041 \| Carrying Amount
Non-Current Debt
Non-Current Debt	$ 297,000,000
4.85% Notes due 2041 \| Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 293,000,000
4.50% Notes due 2043
Non-Current Debt
Stated interest rate (as a percent)	4.50%	4.50%
4.50% Notes due 2043 \| Carrying Amount
Non-Current Debt
Non-Current Debt	$ 496,000,000
4.50% Notes due 2043 \| Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 470,000,000
3.55% Notes Due 2044 (1.0B Euro 1.0721)
Non-Current Debt
Stated interest rate (as a percent)	3.55%	3.55%
Debt instrument, face amount	$ 1,000,000,000
Foreign exchange rate	1.0721	1.0721
3.55% Notes Due 2044 (1.0B Euro 1.0721) \| Carrying Amount
Non-Current Debt
Non-Current Debt	$ 1,062,000,000
3.55% Notes Due 2044 (1.0B Euro 1.0721) \| Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 1,062,000,000
3.73% Notes due 2046
Non-Current Debt
Stated interest rate (as a percent)	3.73%	3.73%
3.73% Notes due 2046 \| Carrying Amount
Non-Current Debt
Non-Current Debt	$ 1,978,000,000
3.73% Notes due 2046 \| Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 1,609,000,000
3.75% Notes due 2047
Non-Current Debt
Stated interest rate (as a percent)	3.75%	3.75%
3.75% Notes due 2047 \| Carrying Amount
Non-Current Debt
Non-Current Debt	$ 816,000,000
3.75% Notes due 2047 \| Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 805,000,000
3.50% Notes due 2048
Non-Current Debt
Stated interest rate (as a percent)	3.50%	3.50%
3.50% Notes due 2048 \| Carrying Amount
Non-Current Debt
Non-Current Debt	$ 743,000,000
3.50% Notes due 2048 \| Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 579,000,000
2.25% Notes due 2050
Non-Current Debt
Stated interest rate (as a percent)	2.25%	2.25%
2.25% Notes due 2050 \| Carrying Amount
Non-Current Debt
Non-Current Debt	$ 807,000,000
2.25% Notes due 2050 \| Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 593,000,000
5.25% Notes due 2054
Non-Current Debt
Stated interest rate (as a percent)	5.25%	5.25%
5.25% Notes due 2054 \| Carrying Amount
Non-Current Debt
Non-Current Debt	$ 843,000,000
5.25% Notes due 2054 \| Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 854,000,000
2.45% Notes due 2060
Non-Current Debt
Stated interest rate (as a percent)	2.45%	2.45%
2.45% Notes due 2060 \| Carrying Amount
Non-Current Debt
Non-Current Debt	$ 1,055,000,000
2.45% Notes due 2060 \| Estimated Fair Value
Non-Current Debt
Non-Current Debt	707,000,000
Other \| Carrying Amount
Non-Current Debt
Non-Current Debt	67,000,000
Other \| Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 67,000,000

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Billions	6 Months Ended
Income Taxes (Details) - USD ($) $ in Billions	Jun. 30, 2024	Jul. 02, 2023
Income Tax Contingency
Worldwide effective income tax rate (as a percent)	16.10%	2.70%
Effective income tax rate reconciliation, tax settlement, percent	23%	23%
Unrecognized tax benefits	$ 2.5
Current unrecognized tax benefits and interest	0.4
Talc \| Consumer
Income Tax Contingency
Litigation expense	$ 3	$ 7

Pensions and Other Benefit Pl_3

Pensions and Other Benefit Plans - Components of Net Periodic Benefit Cost (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jul. 02, 2023	Jun. 30, 2024	Jul. 02, 2023
Retirement Plans
Components of net periodic benefit cost
Service cost	$ 222	$ 215	$ 446	$ 425
Interest cost	351	371	703	723
Expected return on plan assets	(639)	(694)	(1,281)	(1,362)
Amortization of prior service cost/‍(credit)	(46)	(46)	(92)	(92)
Recognized actuarial (gains)/losses	44	(50)	87	(100)
Curtailments and settlements	(8)	0	(8)	0
Net periodic benefit cost/(credit)	(76)	(204)	(145)	(406)
Other Benefit Plans
Components of net periodic benefit cost
Service cost	69	69	138	137
Interest cost	52	55	104	109
Expected return on plan assets	(1)	(2)	(3)	(3)
Amortization of prior service cost/‍(credit)	(1)	(1)	(1)	(1)
Recognized actuarial (gains)/losses	13	7	26	13
Curtailments and settlements	0	0	0	0
Net periodic benefit cost/(credit)	$ 132	$ 128	$ 264	$ 255

Pensions and Other Benefit Pl_4

Pensions and Other Benefit Plans (Details) $ in Millions	6 Months Ended
Pensions and Other Benefit Plans (Details) $ in Millions	Jun. 30, 2024 USD ($)
U.S.
Defined Benefit Plan Disclosure [Line Items]
Contribution to pension plans	$ 61
Foreign Plan
Defined Benefit Plan Disclosure [Line Items]
Contribution to pension plans	$ 7

Accumulated Other Comprehensi_3

Accumulated Other Comprehensive Income (Details) $ in Millions	6 Months Ended
	Jun. 30, 2024 USD ($)
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance	$ 68,774
Net change	1,274
Ending balance	71,538
Foreign Currency Translation
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance	(10,149)
Net change	1,734
Ending balance	(8,415)
Gain/ (Loss) On Securities
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance	(1)
Net change	1
Ending balance	0
Employee Benefit Plans
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance	(2,000)
Net change	61
Ending balance	(1,939)
Gain/ (Loss) On Derivatives & Hedges
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance	(377)
Net change	(522)
Ending balance	(899)
Total Accumulated Other Comprehensive Income/(Loss)
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance	(12,527)
Ending balance	$ (11,253)

Earnings Per Share (Details)

Earnings Per Share (Details) - $ / shares	3 Months Ended		6 Months Ended
Earnings Per Share (Details) - $ / shares	Jun. 30, 2024	Jul. 02, 2023	Jun. 30, 2024	Jul. 02, 2023
Reconciliation of basic net earnings per share to diluted net earnings per share
Continuing operations - basic (in dollars per share)	$ 1.95	$ 2.07	$ 3.30	$ 1.88
Discontinued operations - basic (in dollars per share)	0	(0.09)	0	0.07
Total net earnings per share - basic (in dollars per share)	$ 1.95	$ 1.98	$ 3.30	$ 1.95
Average shares outstanding — basic	2,406,800,000	2,598,400,000	2,407,500,000	2,601,900,000
Potential shares exercisable under stock option plans	62,600,000	95,200,000	79,300,000	96,900,000
Less: shares which could be repurchased under treasury stock method	(47,400,000)	(67,900,000)	(58,300,000)	(68,100,000)
Average shares outstanding — diluted	2,422,000,000	2,625,700,000	2,428,500,000	2,630,700,000
Continuing operations - diluted (in dollars per share)	$ 1.93	$ 2.05	$ 3.27	$ 1.86
Discontinued operations - diluted (in dollars per share)	0	(0.09)	0	0.07
Total net earnings per share - diluted (in dollars per share)	$ 1.93	$ 1.96	$ 3.27	$ 1.93
Antidilutive securities excluded from computation of earnings per share, amount	72.2	50.8	53.8	46.8

Segments of Business and Geog_3

Segments of Business and Geographic Areas - Narrative (Details)	6 Months Ended
	Jun. 30, 2024 segment
Segment Reporting [Abstract]
Number of operating segments	2

Segments of Business and Geog_4

Segments of Business and Geographic Areas - Sales By Segment Of Business (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jul. 02, 2023	Jun. 30, 2024	Jul. 02, 2023
Sales by segment of business
Sales to customers	$ 22,447	$ 21,519	$ 43,830	$ 42,413
Percent Change (as a percent)	4.30%		3.30%
U.S.
Sales by segment of business
Sales to customers	$ 12,569	11,657	$ 24,189	22,439
Percent Change (as a percent)	7.80%		7.80%
International
Sales by segment of business
Sales to customers	$ 9,878	9,862	$ 19,641	19,974
Percent Change (as a percent)	0.20%		(1.70%)
MEDTECH
Sales by segment of business
Sales to customers	$ 7,957	7,788	$ 15,778	15,269
Percent Change (as a percent)	2.20%		3.30%
MEDTECH \| U.S.
Sales by segment of business
Sales to customers	$ 4,059	3,839	$ 8,067	7,598
Percent Change (as a percent)	5.70%		6.20%
MEDTECH \| International
Sales by segment of business
Sales to customers	$ 3,898	3,949	$ 7,711	7,671
Percent Change (as a percent)	(1.30%)		0.50%
MEDTECH \| Cardiovascular(1)
Sales by segment of business
Sales to customers	$ 1,873	1,620	$ 3,679	3,123
Percent Change (as a percent)	15.60%		17.80%
MEDTECH \| Cardiovascular(1) \| U.S.
Sales by segment of business
Sales to customers	$ 1,119	908	$ 2,144	1,771
Percent Change (as a percent)	23.30%		21.10%
MEDTECH \| Cardiovascular(1) \| International
Sales by segment of business
Sales to customers	$ 753	712	$ 1,534	1,352
Percent Change (as a percent)	5.70%		13.40%
MEDTECH \| ELECTROPHYSIOLOGY
Sales by segment of business
Sales to customers	$ 1,323	1,196	$ 2,667	2,288
Percent Change (as a percent)	10.60%		16.50%
MEDTECH \| ELECTROPHYSIOLOGY \| U.S.
Sales by segment of business
Sales to customers	$ 705	609	$ 1,397	1,180
Percent Change (as a percent)	15.70%		18.40%
MEDTECH \| ELECTROPHYSIOLOGY \| International
Sales by segment of business
Sales to customers	$ 618	587	$ 1,270	1,109
Percent Change (as a percent)	5.40%		14.60%
MEDTECH \| ABIOMED
Sales by segment of business
Sales to customers	$ 379	331	$ 750	655
Percent Change (as a percent)	14.50%		14.50%
MEDTECH \| ABIOMED \| U.S.
Sales by segment of business
Sales to customers	$ 309	272	$ 612	536
Percent Change (as a percent)	13.20%		14.10%
MEDTECH \| ABIOMED \| International
Sales by segment of business
Sales to customers	$ 72	59	$ 139	119
Percent Change (as a percent)	20.70%		16.50%
MEDTECH \| Shockwave
Sales by segment of business
Sales to customers	$ 77	0	$ 77	0
MEDTECH \| Shockwave \| U.S.
Sales by segment of business
Sales to customers	77	0	77	0
MEDTECH \| Shockwave \| International
Sales by segment of business
Sales to customers	$ 0	0	$ 0	0
Percent Change (as a percent)	0%		0%
MEDTECH \| OTHER CARDIOVASCULAR(1)
Sales by segment of business
Sales to customers	$ 93	93	$ 185	180
Percent Change (as a percent)	0.30%		2.90%
MEDTECH \| OTHER CARDIOVASCULAR(1) \| U.S.
Sales by segment of business
Sales to customers	$ 29	27	$ 59	55
Percent Change (as a percent)	12.50%		7.70%
MEDTECH \| OTHER CARDIOVASCULAR(1) \| International
Sales by segment of business
Sales to customers	$ 64	67	$ 126	125
Percent Change (as a percent)	(4.50%)		0.80%
MEDTECH \| Orthopaedics
Sales by segment of business
Sales to customers	$ 2,312	2,265	$ 4,652	4,510
Percent Change (as a percent)	2.10%		3.20%
MEDTECH \| Orthopaedics \| U.S.
Sales by segment of business
Sales to customers	$ 1,422	1,388	$ 2,870	2,751
Percent Change (as a percent)	2.50%		4.30%
MEDTECH \| Orthopaedics \| International
Sales by segment of business
Sales to customers	$ 890	878	$ 1,782	1,759
Percent Change (as a percent)	1.40%		1.30%
MEDTECH \| Orthopaedics \| HIPS
Sales by segment of business
Sales to customers	$ 417	397	$ 839	787
Percent Change (as a percent)	4.90%		6.50%
MEDTECH \| Orthopaedics \| HIPS \| U.S.
Sales by segment of business
Sales to customers	$ 265	250	$ 535	491
Percent Change (as a percent)	5.80%		8.90%
MEDTECH \| Orthopaedics \| HIPS \| International
Sales by segment of business
Sales to customers	$ 152	147	$ 304	296
Percent Change (as a percent)	3.40%		2.60%
MEDTECH \| Orthopaedics \| KNEES
Sales by segment of business
Sales to customers	$ 394	363	$ 795	731
Percent Change (as a percent)	8.40%		8.70%
MEDTECH \| Orthopaedics \| KNEES \| U.S.
Sales by segment of business
Sales to customers	$ 230	221	$ 472	447
Percent Change (as a percent)	4.20%		5.50%
MEDTECH \| Orthopaedics \| KNEES \| International
Sales by segment of business
Sales to customers	$ 163	142	$ 323	284
Percent Change (as a percent)	14.90%		13.60%
MEDTECH \| Orthopaedics \| TRAUMA
Sales by segment of business
Sales to customers	$ 759	739	$ 1,524	1,496
Percent Change (as a percent)	2.80%		1.90%
MEDTECH \| Orthopaedics \| TRAUMA \| U.S.
Sales by segment of business
Sales to customers	$ 498	483	$ 1,002	974
Percent Change (as a percent)	3%		2.90%
MEDTECH \| Orthopaedics \| TRAUMA \| International
Sales by segment of business
Sales to customers	$ 260	255	$ 521	522
Percent Change (as a percent)	2.40%		0%
MEDTECH \| Orthopaedics \| SPINE, SPORTS & OTHER
Sales by segment of business
Sales to customers	$ 743	766	$ 1,495	1,495
Percent Change (as a percent)	(3.10%)		0%
MEDTECH \| Orthopaedics \| SPINE, SPORTS & OTHER \| U.S.
Sales by segment of business
Sales to customers	$ 430	433	$ 862	839
Percent Change (as a percent)	(0.80%)		2.70%
MEDTECH \| Orthopaedics \| SPINE, SPORTS & OTHER \| International
Sales by segment of business
Sales to customers	$ 314	334	$ 634	657
Percent Change (as a percent)	(6.10%)		(3.50%)
MEDTECH \| Surgery
Sales by segment of business
Sales to customers	$ 2,488	2,594	$ 4,904	5,028
Percent Change (as a percent)	(4.10%)		(2.50%)
MEDTECH \| Surgery \| U.S.
Sales by segment of business
Sales to customers	$ 995	1,015	$ 1,982	1,990
Percent Change (as a percent)	(2.00%)		(0.40%)
MEDTECH \| Surgery \| International
Sales by segment of business
Sales to customers	$ 1,493	1,580	$ 2,922	3,039
Percent Change (as a percent)	(5.50%)		(3.80%)
MEDTECH \| Surgery \| ADVANCED
Sales by segment of business
Sales to customers	$ 1,141	1,222	$ 2,228	2,340
Percent Change (as a percent)	(6.70%)		(4.80%)
MEDTECH \| Surgery \| ADVANCED \| U.S.
Sales by segment of business
Sales to customers	$ 466	466	$ 912	910
Percent Change (as a percent)	0.10%		0.20%
MEDTECH \| Surgery \| ADVANCED \| International
Sales by segment of business
Sales to customers	$ 675	757	$ 1,316	1,430
Percent Change (as a percent)	(10.80%)		(8.00%)
MEDTECH \| Surgery \| GENERAL
Sales by segment of business
Sales to customers	$ 1,346	1,372	$ 2,676	2,688
Percent Change (as a percent)	(1.90%)		(0.50%)
MEDTECH \| Surgery \| GENERAL \| U.S.
Sales by segment of business
Sales to customers	$ 528	548	$ 1,070	1,079
Percent Change (as a percent)	(3.70%)		(0.90%)
MEDTECH \| Surgery \| GENERAL \| International
Sales by segment of business
Sales to customers	$ 818	823	$ 1,606	1,608
Percent Change (as a percent)	(0.70%)		(0.20%)
MEDTECH \| Vision
Sales by segment of business
Sales to customers	$ 1,285	1,308	$ 2,543	2,608
Percent Change (as a percent)	(1.70%)		(2.50%)
MEDTECH \| Vision \| U.S.
Sales by segment of business
Sales to customers	$ 523	529	$ 1,070	1,087
Percent Change (as a percent)	(1.20%)		(1.50%)
MEDTECH \| Vision \| International
Sales by segment of business
Sales to customers	$ 763	778	$ 1,473	1,521
Percent Change (as a percent)	(2.00%)		(3.20%)
MEDTECH \| Vision \| CONTACT LENSES / OTHER
Sales by segment of business
Sales to customers	$ 918	939	$ 1,828	1,892
Percent Change (as a percent)	(2.20%)		(3.40%)
MEDTECH \| Vision \| CONTACT LENSES / OTHER \| U.S.
Sales by segment of business
Sales to customers	$ 409	409	$ 847	853
Percent Change (as a percent)	0.20%		(0.60%)
MEDTECH \| Vision \| CONTACT LENSES / OTHER \| International
Sales by segment of business
Sales to customers	$ 509	530	$ 981	1,039
Percent Change (as a percent)	(4.00%)		(5.60%)
MEDTECH \| Vision \| SURGICAL
Sales by segment of business
Sales to customers	$ 367	369	$ 715	716
Percent Change (as a percent)	(0.50%)		(0.10%)
MEDTECH \| Vision \| SURGICAL \| U.S.
Sales by segment of business
Sales to customers	$ 113	120	$ 223	234
Percent Change (as a percent)	(5.80%)		(4.80%)
MEDTECH \| Vision \| SURGICAL \| International
Sales by segment of business
Sales to customers	$ 254	249	$ 492	482
Percent Change (as a percent)	2.10%		2.10%
Innovative Medicine
Sales by segment of business
Sales to customers	$ 14,490	13,731	$ 28,052	27,144
Percent Change (as a percent)	5.50%		3.30%
Innovative Medicine \| U.S.
Sales by segment of business
Sales to customers	$ 8,510	7,818	$ 16,122	14,841
Percent Change (as a percent)	8.90%		8.60%
Innovative Medicine \| International
Sales by segment of business
Sales to customers	$ 5,980	5,913	$ 11,930	12,303
Percent Change (as a percent)	1.10%		(3.00%)
Innovative Medicine \| Immunology
Sales by segment of business
Sales to customers	$ 4,722	4,496	$ 8,969	8,608
Percent Change (as a percent)	5%		4.20%
Innovative Medicine \| Immunology \| U.S.
Sales by segment of business
Sales to customers	$ 2,978	2,865	$ 5,431	5,313
Percent Change (as a percent)	4%		2.20%
Innovative Medicine \| Immunology \| International
Sales by segment of business
Sales to customers	$ 1,744	1,631	$ 3,538	3,295
Percent Change (as a percent)	6.90%		7.40%
Innovative Medicine \| Immunology \| REMICADE
Sales by segment of business
Sales to customers	$ 393	462	$ 827	949
Percent Change (as a percent)	(14.90%)		(12.90%)
Innovative Medicine \| Immunology \| REMICADE \| U.S.
Sales by segment of business
Sales to customers	$ 231	277	$ 497	553
Percent Change (as a percent)	(16.70%)		(10.10%)
Innovative Medicine \| Immunology \| REMICADE \| U.S. Exports
Sales by segment of business
Sales to customers	$ 35	33	$ 62	74
Percent Change (as a percent)	7.90%		(15.40%)
Innovative Medicine \| Immunology \| REMICADE \| International
Sales by segment of business
Sales to customers	$ 127	152	$ 268	322
Percent Change (as a percent)	(16.60%)		(16.90%)
Innovative Medicine \| Immunology \| SIMPONI / SIMPONI ARIA
Sales by segment of business
Sales to customers	$ 537	529	$ 1,091	1,066
Percent Change (as a percent)	1.60%		2.30%
Innovative Medicine \| Immunology \| SIMPONI / SIMPONI ARIA \| U.S.
Sales by segment of business
Sales to customers	$ 267	285	$ 521	556
Percent Change (as a percent)	(6.30%)		(6.20%)
Innovative Medicine \| Immunology \| SIMPONI / SIMPONI ARIA \| International
Sales by segment of business
Sales to customers	$ 270	244	$ 569	510
Percent Change (as a percent)	10.90%		11.70%
Innovative Medicine \| Immunology \| STELARA
Sales by segment of business
Sales to customers	$ 2,885	2,797	$ 5,336	5,241
Percent Change (as a percent)	3.10%		1.80%
Innovative Medicine \| Immunology \| STELARA \| U.S.
Sales by segment of business
Sales to customers	$ 1,855	1,817	$ 3,251	3,268
Percent Change (as a percent)	2.10%		(0.50%)
Innovative Medicine \| Immunology \| STELARA \| International
Sales by segment of business
Sales to customers	$ 1,030	981	$ 2,085	1,974
Percent Change (as a percent)	5%		5.60%
Innovative Medicine \| Immunology \| TREMFYA
Sales by segment of business
Sales to customers	$ 906	706	$ 1,714	1,346
Percent Change (as a percent)	28.30%		27.30%
Innovative Medicine \| Immunology \| TREMFYA \| U.S.
Sales by segment of business
Sales to customers	$ 589	450	$ 1,098	856
Percent Change (as a percent)	30.80%		28.20%
Innovative Medicine \| Immunology \| TREMFYA \| International
Sales by segment of business
Sales to customers	$ 317	255	$ 616	489
Percent Change (as a percent)	23.90%		25.80%
Innovative Medicine \| Immunology \| OTHER IMMUNOLOGY
Sales by segment of business
Sales to customers	$ 2	4	$ 2	7
Percent Change (as a percent)	(51.50%)		(75.40%)
Innovative Medicine \| Immunology \| OTHER IMMUNOLOGY \| U.S.
Sales by segment of business
Sales to customers	$ 2	4	$ 2	7
Percent Change (as a percent)	(51.50%)		(75.40%)
Innovative Medicine \| Immunology \| OTHER IMMUNOLOGY \| International
Sales by segment of business
Sales to customers	$ 0	0	$ 0	0
Percent Change (as a percent)	0%		0%
Innovative Medicine \| Infectious Diseases
Sales by segment of business
Sales to customers	$ 965	1,121	$ 1,786	2,707
Percent Change (as a percent)	(13.90%)		(34.00%)
Innovative Medicine \| Infectious Diseases \| U.S.
Sales by segment of business
Sales to customers	$ 334	395	$ 658	787
Percent Change (as a percent)	(15.40%)		(16.40%)
Innovative Medicine \| Infectious Diseases \| International
Sales by segment of business
Sales to customers	$ 631	727	$ 1,128	1,920
Percent Change (as a percent)	(13.10%)		(41.30%)
Innovative Medicine \| Infectious Diseases \| COVID-19
Sales by segment of business
Sales to customers	$ 172	285	$ 197	1,032
Percent Change (as a percent)	(39.70%)		(80.90%)
Innovative Medicine \| Infectious Diseases \| COVID-19 \| U.S.
Sales by segment of business
Sales to customers	$ 0	0	$ 0	0
Percent Change (as a percent)	0%		0%
Innovative Medicine \| Infectious Diseases \| COVID-19 \| International
Sales by segment of business
Sales to customers	$ 172	285	$ 197	1,032
Percent Change (as a percent)	(39.70%)		(80.90%)
Innovative Medicine \| Infectious Diseases \| EDURANT / rilpivirine
Sales by segment of business
Sales to customers	$ 297	266	$ 620	546
Percent Change (as a percent)	11%		13.40%
Innovative Medicine \| Infectious Diseases \| EDURANT / rilpivirine \| U.S.
Sales by segment of business
Sales to customers	$ 8	8	$ 16	17
Percent Change (as a percent)	(2.80%)		(7.00%)
Innovative Medicine \| Infectious Diseases \| EDURANT / rilpivirine \| International
Sales by segment of business
Sales to customers	$ 288	258	$ 603	529
Percent Change (as a percent)	11.50%		14.10%
Innovative Medicine \| Infectious Diseases \| PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA
Sales by segment of business
Sales to customers	$ 438	491	$ 856	968
Percent Change (as a percent)	(11.00%)		(11.60%)
Innovative Medicine \| Infectious Diseases \| PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA \| U.S.
Sales by segment of business
Sales to customers	$ 321	382	$ 635	760
Percent Change (as a percent)	(16.00%)		(16.50%)
Innovative Medicine \| Infectious Diseases \| PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA \| International
Sales by segment of business
Sales to customers	$ 117	109	$ 221	208
Percent Change (as a percent)	6.50%		6%
Innovative Medicine \| Infectious Diseases \| OTHER INFECTIOUS DISEASES(
Sales by segment of business
Sales to customers	$ 61	79	$ 114	161
Percent Change (as a percent)	(23.10%)		(29.30%)
Innovative Medicine \| Infectious Diseases \| OTHER INFECTIOUS DISEASES( \| U.S.
Sales by segment of business
Sales to customers	$ 5	5	$ 7	10
Percent Change (as a percent)	18.50%		(29.40%)
Innovative Medicine \| Infectious Diseases \| OTHER INFECTIOUS DISEASES( \| International
Sales by segment of business
Sales to customers	$ 55	74	$ 107	151
Percent Change (as a percent)	(25.60%)		(29.30%)
Innovative Medicine \| Neuroscience
Sales by segment of business
Sales to customers	$ 1,782	1,793	$ 3,585	3,597
Percent Change (as a percent)	(0.60%)		(0.30%)
Innovative Medicine \| Neuroscience \| U.S.
Sales by segment of business
Sales to customers	$ 1,102	1,029	$ 2,156	2,007
Percent Change (as a percent)	7.10%		7.40%
Innovative Medicine \| Neuroscience \| International
Sales by segment of business
Sales to customers	$ 679	764	$ 1,428	1,590
Percent Change (as a percent)	(11.10%)		(10.20%)
Innovative Medicine \| Neuroscience \| CONCERTA / methylphenidate
Sales by segment of business
Sales to customers	$ 163	208	$ 340	414
Percent Change (as a percent)	(21.50%)		(17.80%)
Innovative Medicine \| Neuroscience \| CONCERTA / methylphenidate \| U.S.
Sales by segment of business
Sales to customers	$ 34	64	$ 75	134
Percent Change (as a percent)	(47.70%)		(44.30%)
Innovative Medicine \| Neuroscience \| CONCERTA / methylphenidate \| International
Sales by segment of business
Sales to customers	$ 129	143	$ 265	279
Percent Change (as a percent)	(9.80%)		(5.10%)
Innovative Medicine \| Neuroscience \| INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA
Sales by segment of business
Sales to customers	$ 1,054	1,031	$ 2,110	2,075
Percent Change (as a percent)	2.20%		1.70%
Innovative Medicine \| Neuroscience \| INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA \| U.S.
Sales by segment of business
Sales to customers	$ 784	721	$ 1,549	1,434
Percent Change (as a percent)	8.80%		8%
Innovative Medicine \| Neuroscience \| INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA \| International
Sales by segment of business
Sales to customers	$ 269	310	$ 561	641
Percent Change (as a percent)	(13.10%)		(12.40%)
Innovative Medicine \| Neuroscience \| SPRAVATO
Sales by segment of business
Sales to customers	$ 271	169	$ 496	300
Percent Change (as a percent)	60.20%		65.50%
Innovative Medicine \| Neuroscience \| SPRAVATO \| U.S.
Sales by segment of business
Sales to customers	$ 226	144	$ 417	255
Percent Change (as a percent)	57.90%		63.90%
Innovative Medicine \| Neuroscience \| SPRAVATO \| International
Sales by segment of business
Sales to customers	$ 44	25	$ 78	45
Percent Change (as a percent)	73.50%		74.60%
Innovative Medicine \| Neuroscience \| OTHER NEUROSCIENCE
Sales by segment of business
Sales to customers	$ 294	386	$ 639	809
Percent Change (as a percent)	(23.70%)		(21.00%)
Innovative Medicine \| Neuroscience \| OTHER NEUROSCIENCE \| U.S.
Sales by segment of business
Sales to customers	$ 57	100	$ 115	184
Percent Change (as a percent)	(42.50%)		(37.30%)
Innovative Medicine \| Neuroscience \| OTHER NEUROSCIENCE \| International
Sales by segment of business
Sales to customers	$ 237	286	$ 524	625
Percent Change (as a percent)	(17.00%)		(16.20%)
Innovative Medicine \| Oncology
Sales by segment of business
Sales to customers	$ 5,090	4,398	$ 9,904	8,510
Percent Change (as a percent)	15.70%		16.40%
Innovative Medicine \| Oncology \| U.S.
Sales by segment of business
Sales to customers	$ 2,636	2,069	$ 5,019	3,958
Percent Change (as a percent)	27.40%		26.80%
Innovative Medicine \| Oncology \| International
Sales by segment of business
Sales to customers	$ 2,455	2,329	$ 4,885	4,552
Percent Change (as a percent)	5.40%		7.30%
Innovative Medicine \| Oncology \| CARVYKTI
Sales by segment of business
Sales to customers	$ 186	117	$ 343	189
Percent Change (as a percent)	59.80%		81.50%
Innovative Medicine \| Oncology \| CARVYKTI \| U.S.
Sales by segment of business
Sales to customers	$ 167	114	$ 307	184
Percent Change (as a percent)	46.50%		66.80%
Innovative Medicine \| Oncology \| CARVYKTI \| International
Sales by segment of business
Sales to customers	$ 20	3	$ 36	5
Innovative Medicine \| Oncology \| DARZALEX
Sales by segment of business
Sales to customers	$ 2,878	2,431	$ 5,570	4,695
Percent Change (as a percent)	18.40%		18.60%
Innovative Medicine \| Oncology \| DARZALEX \| U.S.
Sales by segment of business
Sales to customers	$ 1,641	1,322	$ 3,105	2,513
Percent Change (as a percent)	24.20%		23.60%
Innovative Medicine \| Oncology \| DARZALEX \| International
Sales by segment of business
Sales to customers	$ 1,237	1,110	$ 2,465	2,182
Percent Change (as a percent)	11.50%		12.90%
Innovative Medicine \| Oncology \| ERLEADA
Sales by segment of business
Sales to customers	$ 736	567	$ 1,425	1,109
Percent Change (as a percent)	29.80%		28.40%
Innovative Medicine \| Oncology \| ERLEADA \| U.S.
Sales by segment of business
Sales to customers	$ 318	241	$ 603	490
Percent Change (as a percent)	32.20%		23%
Innovative Medicine \| Oncology \| ERLEADA \| International
Sales by segment of business
Sales to customers	$ 418	326	$ 822	619
Percent Change (as a percent)	28%		32.80%
Innovative Medicine \| Oncology \| IMBRUVICA
Sales by segment of business
Sales to customers	$ 770	841	$ 1,554	1,668
Percent Change (as a percent)	(8.50%)		(6.90%)
Innovative Medicine \| Oncology \| IMBRUVICA \| U.S.
Sales by segment of business
Sales to customers	$ 246	262	$ 511	532
Percent Change (as a percent)	(6.40%)		(3.90%)
Innovative Medicine \| Oncology \| IMBRUVICA \| International
Sales by segment of business
Sales to customers	$ 525	579	$ 1,043	1,136
Percent Change (as a percent)	(9.40%)		(8.30%)
Innovative Medicine \| Oncology \| ZYTIGA / abiraterone acetate
Sales by segment of business
Sales to customers	$ 165	227	$ 346	472
Percent Change (as a percent)	(27.70%)		(26.80%)
Innovative Medicine \| Oncology \| ZYTIGA / abiraterone acetate \| U.S.
Sales by segment of business
Sales to customers	$ 11	9	$ 20	25
Percent Change (as a percent)	21.60%		(19.70%)
Innovative Medicine \| Oncology \| ZYTIGA / abiraterone acetate \| International
Sales by segment of business
Sales to customers	$ 154	218	$ 326	447
Percent Change (as a percent)	(29.60%)		(27.20%)
Innovative Medicine \| Oncology \| OTHER ONCOLOGY
Sales by segment of business
Sales to customers	$ 221	120	$ 399	219
Percent Change (as a percent)	84.20%		82.40%
Innovative Medicine \| Oncology \| OTHER ONCOLOGY \| U.S.
Sales by segment of business
Sales to customers	$ 148	40	$ 267	75
Innovative Medicine \| Oncology \| OTHER ONCOLOGY \| International
Sales by segment of business
Sales to customers	$ 71	80	$ 131	144
Percent Change (as a percent)	(10.40%)		(8.50%)
Innovative Medicine \| Oncology \| Tecvayli
Sales by segment of business
Sales to customers	$ 135	94	$ 268	157
Percent Change (as a percent)	42.90%		70.20%
Innovative Medicine \| Oncology \| Tecvayli \| U.S.
Sales by segment of business
Sales to customers	$ 104	82	$ 205	139
Percent Change (as a percent)	27.50%		47.70%
Innovative Medicine \| Oncology \| Tecvayli \| International
Sales by segment of business
Sales to customers	$ 30	12	$ 63	18
Innovative Medicine \| Pulmonary Hypertension
Sales by segment of business
Sales to customers	$ 1,039	972	$ 2,088	1,844
Percent Change (as a percent)	6.90%		13.20%
Innovative Medicine \| Pulmonary Hypertension \| U.S.
Sales by segment of business
Sales to customers	$ 743	684	$ 1,509	1,284
Percent Change (as a percent)	8.70%		17.50%
Innovative Medicine \| Pulmonary Hypertension \| International
Sales by segment of business
Sales to customers	$ 296	289	$ 579	561
Percent Change (as a percent)	2.60%		3.40%
Innovative Medicine \| Pulmonary Hypertension \| OPSUMIT
Sales by segment of business
Sales to customers	$ 544	507	$ 1,068	947
Percent Change (as a percent)	7.10%		12.70%
Innovative Medicine \| Pulmonary Hypertension \| OPSUMIT \| U.S.
Sales by segment of business
Sales to customers	$ 373	328	$ 729	601
Percent Change (as a percent)	13.70%		21.30%
Innovative Medicine \| Pulmonary Hypertension \| OPSUMIT \| International
Sales by segment of business
Sales to customers	$ 170	179	$ 339	346
Percent Change (as a percent)	(5.00%)		(2.20%)
Innovative Medicine \| Pulmonary Hypertension \| UPTRAVI
Sales by segment of business
Sales to customers	$ 426	399	$ 894	761
Percent Change (as a percent)	6.60%		17.40%
Innovative Medicine \| Pulmonary Hypertension \| UPTRAVI \| U.S.
Sales by segment of business
Sales to customers	$ 349	338	$ 741	642
Percent Change (as a percent)	3.30%		15.50%
Innovative Medicine \| Pulmonary Hypertension \| UPTRAVI \| International
Sales by segment of business
Sales to customers	$ 76	61	$ 152	119
Percent Change (as a percent)	24.60%		27.60%
Innovative Medicine \| Pulmonary Hypertension \| Other
Sales by segment of business
Sales to customers	$ 71	66	$ 127	136
Percent Change (as a percent)	7.20%		(6.50%)
Innovative Medicine \| Pulmonary Hypertension \| Other \| U.S.
Sales by segment of business
Sales to customers	$ 20	18	$ 38	41
Percent Change (as a percent)	18.80%		(6.10%)
Innovative Medicine \| Pulmonary Hypertension \| Other \| International
Sales by segment of business
Sales to customers	$ 50	48	$ 89	95
Percent Change (as a percent)	3.10%		(6.70%)
Innovative Medicine \| Cardiovascular / Metabolism / Other
Sales by segment of business
Sales to customers	$ 892	950	$ 1,721	1,877
Percent Change (as a percent)	(6.20%)		(8.30%)
Innovative Medicine \| Cardiovascular / Metabolism / Other \| U.S.
Sales by segment of business
Sales to customers	$ 717	776	$ 1,348	1,491
Percent Change (as a percent)	(7.70%)		(9.60%)
Innovative Medicine \| Cardiovascular / Metabolism / Other \| International
Sales by segment of business
Sales to customers	$ 176	174	$ 373	386
Percent Change (as a percent)	0.60%		(3.60%)
Innovative Medicine \| Cardiovascular / Metabolism / Other \| Other
Sales by segment of business
Sales to customers	$ 305	313	$ 616	662
Percent Change (as a percent)	(2.50%)		(7.00%)
Innovative Medicine \| Cardiovascular / Metabolism / Other \| Other \| U.S.
Sales by segment of business
Sales to customers	$ 129	138	$ 243	275
Percent Change (as a percent)	(6.40%)		(11.80%)
Innovative Medicine \| Cardiovascular / Metabolism / Other \| Other \| International
Sales by segment of business
Sales to customers	$ 176	174	$ 373	386
Percent Change (as a percent)	0.60%		(3.60%)
Innovative Medicine \| Cardiovascular / Metabolism / Other \| XARELTO
Sales by segment of business
Sales to customers	$ 587	637	$ 1,105	1,215
Percent Change (as a percent)	(7.90%)		(9.10%)
Innovative Medicine \| Cardiovascular / Metabolism / Other \| XARELTO \| U.S.
Sales by segment of business
Sales to customers	$ 587	637	$ 1,105	1,215
Percent Change (as a percent)	(7.90%)		(9.10%)
Innovative Medicine \| Cardiovascular / Metabolism / Other \| XARELTO \| International
Sales by segment of business
Sales to customers	$ 0	$ 0	$ 0	$ 0
Percent Change (as a percent)	0%		0%

Segments of Business and Geog_5

Segments of Business and Geographic Areas - Operating Profit by Segment of Business (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jul. 02, 2023	Jun. 30, 2024	Jul. 02, 2023
Segment Reporting Information [Line Items]
Worldwide income (loss) before tax	$ 5,748	$ 6,306	$ 9,462	$ 5,019
Percent Change	(8.80%)		88.50%
Restructuring charges	$ (13)	145	$ 151	275
Loss on shares outstanding	400		400
Baby Powder \| Talc
Segment Reporting Information [Line Items]
Loss contingency, loss in period	300	200	3,000	7,100
Innovative Medicine
Segment Reporting Information [Line Items]
Restructuring charges		100	100	300
Restructuring income	100
Impairment of intangible assets	200		200
MedTech
Segment Reporting Information [Line Items]
Restructuring charges	100		100
Litigation settlement, gain		300		300
Acquisition related costs	600		600	100
Gain from divestiture of business	200		200
Operating Segments
Segment Reporting Information [Line Items]
Total segment operating income	$ 6,548	6,483	$ 13,037	12,294
Percent Change	1%		6%
Restructuring charges	$ (11)		$ 160
Operating Segments \| Innovative Medicine
Segment Reporting Information [Line Items]
Total segment operating income	$ 5,459	4,812	$ 10,428	9,214
Percent Change	13.40%		13.20%
Amortization	$ 700	700	$ 1,400	1,500
Restructuring charges	(63)		81
Other cost of operating revenue	100	200	100	600
Operating Segments \| MedTech
Segment Reporting Information [Line Items]
Total segment operating income	$ 1,089	1,671	$ 2,609	3,080
Percent Change	(34.80%)		(15.30%)
Amortization	$ 400	400	$ 800	800
Restructuring charges	52		79
Corporate, Non-Segment
Segment Reporting Information [Line Items]
Total segment operating income	$ 800	$ 177	$ 3,575	$ 7,275

Segments of Business and Geog_6

Segments of Business and Geographic Areas - Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jul. 02, 2023	Jun. 30, 2024	Jul. 02, 2023
Sales by geographic area
Sales	$ 22,447	$ 21,519	$ 43,830	$ 42,413
Percent Change	4.30%		3.30%
United States
Sales by geographic area
Sales	$ 12,569	11,657	$ 24,189	22,439
Percent Change	7.80%		7.80%
Europe
Sales by geographic area
Sales	$ 5,214	5,131	$ 10,377	10,721
Percent Change	1.60%		(3.20%)
Western Hemisphere, excluding U.S.
Sales by geographic area
Sales	$ 1,212	1,136	$ 2,406	2,212
Percent Change	6.70%		8.80%
Asia-Pacific, Africa
Sales by geographic area
Sales	$ 3,452	$ 3,595	$ 6,858	$ 7,041
Percent Change	(4.00%)		(2.60%)

Acquisitions and Divestitures_2

Acquisitions and Divestitures (Details) - USD ($) $ / shares in Units, $ in Millions				3 Months Ended		6 Months Ended
	Jul. 11, 2024	Jun. 20, 2024	May 31, 2024	Jun. 30, 2024	Mar. 31, 2024	Jun. 30, 2024	Jul. 02, 2023	Dec. 31, 2023
Business Acquisition [Line Items]
Payments to acquire businesses						$ 14,807	$ 0
Goodwill, related to acquisitions						8,057
Contingent consideration				$ 1,248		1,248		$ 1,092
Proceeds from sale of business				300	$ 200
Subsequent Event \| Yellow Jersey Therapeutics
Business Acquisition [Line Items]
Asset acquisition, consideration transferred	$ 1,250
Acquired in-process research and development	$ 1,250
Proteologix
Business Acquisition [Line Items]
Payments to acquire businesses		$ 800
Assets acquired		1,200
IPR&D		900
Goodwill, related to acquisitions		300
Liabilities assumed		300
Contingent consideration		$ 100
Discount rate		16%
Acquisition related costs				0
Proteologix \| Minimum
Business Acquisition [Line Items]
Probability of success factor		30%
Proteologix \| Maximum
Business Acquisition [Line Items]
Probability of success factor		45%
Shockwave Medical, Inc.
Business Acquisition [Line Items]
Assets acquired			$ 15,500
IPR&D			600
Liabilities assumed			$ 2,900
Discount rate			9%
Acquisition related costs				500
Acquisition related costs, equity awards				400
Share price (in dollars per share)			$ 335
Consideration transferred			$ 200
Weighted average useful life			14 years
Deferred taxes			$ 1,500
Shockwave Medical, Inc. \| Minimum
Business Acquisition [Line Items]
Probability of success factor			50%
Ambrx
Business Acquisition [Line Items]
Payments to acquire businesses				1,800
Assets acquired				2,300		2,300
IPR&D				1,900		1,900
Goodwill, related to acquisitions						300
Liabilities assumed				$ 500		$ 500
Discount rate				17%		17%
Share price (in dollars per share)				$ 28		$ 28
Consideration transferred				$ 2,000
Deferred taxes				$ 400		$ 400
Ambrx \| Minimum
Business Acquisition [Line Items]
Probability of success factor				40%		40%
Ambrx \| Maximum
Business Acquisition [Line Items]
Probability of success factor				70%		70%

Acquisitions and Divestitures -

Acquisitions and Divestitures - Schedule of Preliminary Amounts Recognized for Assets Acquired and Liabilities Assumed (Details) - USD ($) $ in Millions	3 Months Ended
	Jun. 30, 2024	May 31, 2024	Dec. 31, 2023
Assets acquired:
Goodwill (Note 3)	$ 44,250		$ 36,558
Shockwave Medical, Inc.
Assets acquired:
Cash		$ 1,100
Goodwill (Note 3)		7,500
Amortizable intangibles		5,300
IPR&D		600
Inventory		500
Other assets		500
Total assets acquired		15,500
Liabilities assumed:
Deferred taxes		1,500
Notes payable assumed		1,000
Accrued liabilities assumed		400
Total liabilities assumed		2,900
Net assets acquired	13,100	$ 12,600
Equity awards settled	600
Settlement of notes payable	$ 1,000

Legal Proceedings (Details)

Legal Proceedings (Details) $ in Millions		1 Months Ended						3 Months Ended
Legal Proceedings (Details) $ in Millions	May 01, 2024 USD ($)	Oct. 31, 2021 entity	Jun. 30, 2021 USD ($)	Jun. 30, 2020 USD ($)	Jan. 31, 2020 USD ($)	Oct. 31, 2019 USD ($)	Jul. 31, 2018 USD ($)	Jun. 30, 2024 USD ($) claimant claim	Apr. 03, 2022 USD ($)	Sep. 30, 2021 cases	May 31, 2021 cases claimant
Legal Proceeding (Textuals)
Number of new entities created \| entity		3
Judicial Ruling
Legal Proceeding (Textuals)
Damages awarded					$ 6.8	$ 8,000
Opioid
Legal Proceeding (Textuals)
Loss contingency accrual									$ 5,000
Number of pending claims \| claim								20
Product liability contingency, number of claimants \| claimant								3,500
Loss contingency accrual, payment percentage								70%
Pending claims, number, remaining \| claim								420
Loss contingency pending claims, number, additional \| claim								3
Physiomesh
Legal Proceeding (Textuals)
Product liability contingency, number of claimants \| claimant								170
Physiomesh \| Pending Litigation
Legal Proceeding (Textuals)
Number of pending claims \| cases											3,600
Product liability contingency, number of claimants \| claimant											4,300
Number of claims within settlement agreement \| cases										3,729
Ingham v. Johnson & Johnson
Legal Proceeding (Textuals)
Damages awarded				$ 2,100			$ 4,700
Damages paid			$ 2,500
DePuy ASR U.S. \| Settled Litigation
Legal Proceeding (Textuals)
Number of patients in settlement \| claimant								10,000
Talc
Legal Proceeding (Textuals)
Litigation contingency	$ 6,475
Payment period	25 years
Damages sought, nominal value	$ 8,000
Bankruptcy loss contingency, discount rate	4.40%
Total claims against company, percent	99.75%
Incremental charges								$ 3,000
Loss contingency accrual								10,600
Loss contingency accrual, nominal value								$ 12,800
Mesothelioma and State Claims
Legal Proceeding (Textuals)
Claims settled, percent	95%

Legal Proceedings - Product Lia

Legal Proceedings - Product Liability (Details)	Jun. 30, 2024 claimant
Talc
Loss Contingencies [Line Items]
Product liability contingency, number of claimants	62,370
ASR
Loss Contingencies [Line Items]
Product liability contingency, number of claimants	160
Pinnacle Acetabular Cup System
Loss Contingencies [Line Items]
Product liability contingency, number of claimants	910
Pelvic Meshes
Loss Contingencies [Line Items]
Product liability contingency, number of claimants	6,230
Physiomesh
Loss Contingencies [Line Items]
Product liability contingency, number of claimants	170
Risperdal
Loss Contingencies [Line Items]
Product liability contingency, number of claimants	20
Elmiron
Loss Contingencies [Line Items]
Product liability contingency, number of claimants	2,170

Kenvue Separation - Net Earning

Kenvue Separation - Net Earnings from Discontinued Operation (Details) - USD ($) $ in Millions	3 Months Ended	6 Months Ended
	Jul. 02, 2023	Jul. 02, 2023
Discontinued Operations and Disposal Groups [Abstract]
Sales to customers	$ 4,011	$ 7,863
Cost of products sold	1,750	3,458
Gross profit	2,261	4,405
Selling, marketing and administrative expenses	1,269	2,501
Research and development expense	126	234
Interest Income	(42)	(79)
Interest expense, net of portion capitalized	128	131
Other (income) expense, net	324	612
Earnings from Discontinued Operations Before Provision for Taxes on Income	456	1,006
Provision for taxes on income	688	815
Net (loss)/earnings from Discontinued Operations	$ (232)	$ 191

Kenvue Separation - Depreciatio

Kenvue Separation - Depreciation and Amortization of Discontinued Operation (Details) - USD ($) $ in Millions	3 Months Ended	6 Months Ended
	Jul. 02, 2023	Jul. 02, 2023
Discontinued Operations and Disposal Groups [Abstract]
Depreciation and Amortization	$ 149	$ 302
Capital expenditures	$ 92	$ 139

Restructuring - Narrative (Deta

Restructuring - Narrative (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
Restructuring - Narrative (Details) - USD ($) $ in Millions	Jun. 30, 2024	Jul. 02, 2023	Jun. 30, 2024	Jul. 02, 2023
Restructuring Cost and Reserve [Line Items]
Restructuring charges	$ (13)	$ 145	$ 151	$ 275
R&D Restructuring Plan
Restructuring Cost and Reserve [Line Items]
Restructuring income	100
Restructuring charges		$ 100	100	$ 300
Restructuring charges recorded to date	600		600
Orthopedics Restructuring Plan
Restructuring Cost and Reserve [Line Items]
Restructuring charges	100		100
Restructuring charges recorded to date	400		400
Orthopedics Restructuring Plan \| Minimum
Restructuring Cost and Reserve [Line Items]
Restructuring estimated cost	700		700
Orthopedics Restructuring Plan \| Maximum
Restructuring Cost and Reserve [Line Items]
Restructuring estimated cost	$ 800		$ 800

Restructuring - Schedule of Res

Restructuring - Schedule of Restructuring Reserve (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jul. 02, 2023	Jun. 30, 2024	Jul. 02, 2023
Restructuring Cost and Reserve [Line Items]
Restructuring charges	$ (13)	$ 145	$ 151	$ 275
Operating Segments
Restructuring Cost and Reserve [Line Items]
Restructuring charges	(11)		160
Innovative Medicine
Restructuring Cost and Reserve [Line Items]
Restructuring charges		$ 100	100	$ 300
Innovative Medicine \| Operating Segments
Restructuring Cost and Reserve [Line Items]
Restructuring charges	(63)		81
MEDTECH
Restructuring Cost and Reserve [Line Items]
Restructuring charges	100		100
MEDTECH \| Operating Segments
Restructuring Cost and Reserve [Line Items]
Restructuring charges	52		79
MEDTECH \| Restructuring Charges
Restructuring Cost and Reserve [Line Items]
Restructuring charges	50		70
MEDTECH \| Costs of Goods and Services Sold
Restructuring Cost and Reserve [Line Items]
Restructuring charges	$ 2		$ 9